[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYfnh1XGWauPveWVLDQAs2RkD7hzgauDOIEwoT1NsHaw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Medical College of Wisconsin",[4],535,false,163,25,524718,115,346,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Breast Cancer",15,{"name":18,"count":19},"Stroke",14,{"name":21,"count":22},"Multiple Myeloma",12,{"name":24,"count":25},"HIV",10,{"name":27,"count":25},"Cardiovascular Diseases",{"name":29,"count":30},"Lymphoma",9,{"name":32,"count":33},"Obesity",8,{"name":35,"count":33},"Prostate Cancer",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01972919","MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer","2023-12-13","Concurrent chemotherapy",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03571334","Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy","2023-12-31","IncobotulinumtoxinA",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04746209","Blinatumomab After TCR Alpha Beta\u002FCD19 Depleted HCT","2024-02-28","Blinatumomab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04319276","Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma","2025-02-13","Gallium maltolate",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04747145","Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma","2025-03-05","Concurrent Chemotherapy",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05270057","Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","2025-05-28","Etoposide",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04298034","Preeclampsia Postpartum Antihypertensive Treatment","2025-06-30","Labetalol, Nifedipine",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04243616","Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","2025-08-11","Cemiplimab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05687344","Intensive Postpartum Antihypertensive Treatment","2026-03","Nifedipine ER",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT03818763","Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A","2026-03-31","Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,144,172,199,217,235,253,271,289,307,325,350,382,405,608,661,687,713,756,787,825,911,953,975,997,1040,1067,1089,1122,1163,1185,1207,1225,1243,1261,1283,1301,1319,1337,1363,1388,1406,1432,1455,1482,1500,1523,1549,1574,1592,1610,1628,1646,1671,1689,1714,1738,1756,1782,1800,1818,1842,1877,1895,1913,1936,1954,1982,2060,2098,2155,2181,2209,2231,2253,2283,2301,2319,2337,2355,2373,2394,2424,2442,2469,2487,2505,2523,2541,2559,2585,2603,2627,2645,2663,2681,2707,2725,2747,2765,2790,2808,2836,2854,2872,2895,2919,2944,2962,2987,3011,3053,3076,3105,3123,3141,3187,3220,3262,3284,3302,3320,3356,3374,3392,3410,3428,3446,3471,3496,3523,3546,3569,3591,3615,3639,3669,3695,3739,3776,3798,3820,3842,3868,3892,3910,3938,3956,3982,4000,4018,4036,4054,4072,4090,4108,4126,4154,4172,4197,4215,4233,4260,4286,4310,4328,4353,4371,4398,4416,4441,4464,4490,4516,4554,4585,4607,4642,4682,4725,4743,4761,4779,4804,4827,4845,4872,4890,4908,4926,4944,4968,4992,5010,5035,5059,5090,5108,5126,5144,5162,5180,5198,5223,5247,5265,5290,5308,5326,5344,5362,5380,5398,5424,5442,5460,5478,5496,5514,5542,5560,5578,5596,5614,5632,5656,5674,5698,5716,5734,5757,5775,5799,5817,5835,5853,5875,5897,5937,5963,5981,5999,6017,6043,6061,6079,6097,6115,6133,6159,6177,6195,6213,6231,6249,6271,6295,6320,6338,6356,6374,6392,6410,6428,6446,6469,6495,6513,6539,6566,6584,6602,6625,6643,6661,6688,6706,6724,6747,6775,6793,6811,6829,6847,6882,6904,6929,6947,6965,6988,7034,7067,7096,7122,7147,7165,7191,7217,7235,7259,7289,7307,7325,7343,7361,7379,7397,7415,7438,7462,7487,7511,7529,7552,7570,7594,7620,7644,7670,7688,7706,7724,7742,7769,7787],{"intervention":96,"totalTrials":97,"cells":98},"Amoxicillin",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":142},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":141,"soonestReadout":128},[110,123],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NCT03404804","Oral Challenge in the Pediatric ED","COMPLETED",[92],"2020-12-04","2022-12-04","2017-12-04",116,[120,121],"Penicillin Allergy","Pediatric Emergency Medicine",[96],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT06494072","Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","RECRUITING",[92],"2028-05","2024-08-22",236,[132],"Community Acquired Pneumonia in Children",[134,135,96,136,137,138,139,140],"Ampicillin for","Ceftriaxone for","Ampicillin \u002F Sulbactam","Amoxicillin-clavulanate","Clindamycin","Cefprozil","Levofloxacin",1,{"trials":143,"activeCount":101},[],{"intervention":145,"totalTrials":141,"cells":146},"Human Papilloma Virus vaccine",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":170},{"trials":148,"activeCount":101},[],{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":101},[],{"trials":156,"activeCount":141,"soonestReadout":162},[157],{"nctId":158,"briefTitle":159,"status":160,"phases":161,"primaryCompletion":162,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":169},"NCT05557370","Immunogenicity of HPV Vaccine in Transplant Recipients.","ACTIVE_NOT_RECRUITING",[92],"2028-12-31","2035-12-31","2023-06-01",30,[167,168],"Chronic Kidney Diseases","Kidney Transplant",[145],{"trials":171,"activeCount":101},[],{"intervention":173,"totalTrials":141,"cells":174},"GLP-1 agonists",{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":197},{"trials":176,"activeCount":101},[],{"trials":178,"activeCount":101},[],{"trials":180,"activeCount":101},[],{"trials":182,"activeCount":101},[],{"trials":184,"activeCount":141,"soonestReadout":190},[185],{"nctId":186,"briefTitle":187,"status":188,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT07111494","Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial","NOT_YET_RECRUITING",[92],"2026-10-15","2028-10-15","2025-10-15",22,[195],"Psoriatic Arthritis (PsA)",[173],{"trials":198,"activeCount":101},[],{"intervention":134,"totalTrials":141,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":101},[],{"trials":204,"activeCount":101},[],{"trials":206,"activeCount":101},[],{"trials":208,"activeCount":101},[],{"trials":210,"activeCount":141,"soonestReadout":128},[211],{"nctId":124,"briefTitle":125,"status":126,"phases":212,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":213,"interventions":214},[92],[132],[134,135,96,136,137,138,139,140],{"trials":216,"activeCount":101},[],{"intervention":135,"totalTrials":141,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":233},{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":101},[],{"trials":224,"activeCount":101},[],{"trials":226,"activeCount":101},[],{"trials":228,"activeCount":141,"soonestReadout":128},[229],{"nctId":124,"briefTitle":125,"status":126,"phases":230,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":231,"interventions":232},[92],[132],[134,135,96,136,137,138,139,140],{"trials":234,"activeCount":101},[],{"intervention":136,"totalTrials":141,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":251},{"trials":238,"activeCount":101},[],{"trials":240,"activeCount":101},[],{"trials":242,"activeCount":101},[],{"trials":244,"activeCount":101},[],{"trials":246,"activeCount":141,"soonestReadout":128},[247],{"nctId":124,"briefTitle":125,"status":126,"phases":248,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":249,"interventions":250},[92],[132],[134,135,96,136,137,138,139,140],{"trials":252,"activeCount":101},[],{"intervention":137,"totalTrials":141,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":269},{"trials":256,"activeCount":101},[],{"trials":258,"activeCount":101},[],{"trials":260,"activeCount":101},[],{"trials":262,"activeCount":101},[],{"trials":264,"activeCount":141,"soonestReadout":128},[265],{"nctId":124,"briefTitle":125,"status":126,"phases":266,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":267,"interventions":268},[92],[132],[134,135,96,136,137,138,139,140],{"trials":270,"activeCount":101},[],{"intervention":138,"totalTrials":141,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":287},{"trials":274,"activeCount":101},[],{"trials":276,"activeCount":101},[],{"trials":278,"activeCount":101},[],{"trials":280,"activeCount":101},[],{"trials":282,"activeCount":141,"soonestReadout":128},[283],{"nctId":124,"briefTitle":125,"status":126,"phases":284,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":285,"interventions":286},[92],[132],[134,135,96,136,137,138,139,140],{"trials":288,"activeCount":101},[],{"intervention":139,"totalTrials":141,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":305},{"trials":292,"activeCount":101},[],{"trials":294,"activeCount":101},[],{"trials":296,"activeCount":101},[],{"trials":298,"activeCount":101},[],{"trials":300,"activeCount":141,"soonestReadout":128},[301],{"nctId":124,"briefTitle":125,"status":126,"phases":302,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":303,"interventions":304},[92],[132],[134,135,96,136,137,138,139,140],{"trials":306,"activeCount":101},[],{"intervention":140,"totalTrials":141,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":323},{"trials":310,"activeCount":101},[],{"trials":312,"activeCount":101},[],{"trials":314,"activeCount":101},[],{"trials":316,"activeCount":101},[],{"trials":318,"activeCount":141,"soonestReadout":128},[319],{"nctId":124,"briefTitle":125,"status":126,"phases":320,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":321,"interventions":322},[92],[132],[134,135,96,136,137,138,139,140],{"trials":324,"activeCount":101},[],{"intervention":326,"totalTrials":141,"cells":327},"Insulin",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":348},{"trials":329,"activeCount":101},[],{"trials":331,"activeCount":101},[],{"trials":333,"activeCount":101},[],{"trials":335,"activeCount":101},[],{"trials":337,"activeCount":141,"soonestReadout":85},[338],{"nctId":339,"briefTitle":340,"status":160,"phases":341,"primaryCompletion":85,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT03527537","Gestational Diabetes and Pharmacotherapy (GAP)",[92],"2026-10-01","2021-05-04",416,[346],"Gestational Diabetes",[326],{"trials":349,"activeCount":101},[],{"intervention":81,"totalTrials":97,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":367,"NA":369},{"trials":353,"activeCount":101},[],{"trials":355,"activeCount":101},[],{"trials":357,"activeCount":101},[],{"trials":359,"activeCount":141,"soonestReadout":80},[360],{"nctId":78,"briefTitle":79,"status":160,"phases":361,"primaryCompletion":80,"completion":80,"start":362,"enrollment":363,"conditions":364,"interventions":366},[91],"2023-09-01",60,[365],"Hypertensive Disorder of Pregnancy",[81],{"trials":368,"activeCount":101},[],{"trials":370,"activeCount":141,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":126,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT06220721","Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia",[93],"2029-03-31","2029-06-30","2024-10-23",618,[380],"Hypertension, Pregnancy-Induced",[81],{"intervention":71,"totalTrials":141,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":401,"NA":403},{"trials":385,"activeCount":101},[],{"trials":387,"activeCount":101},[],{"trials":389,"activeCount":101},[],{"trials":391,"activeCount":141,"soonestReadout":70},[392],{"nctId":68,"briefTitle":69,"status":160,"phases":393,"primaryCompletion":70,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":400},[91],"2025-12-30","2020-07-17",300,[398,399],"Preeclampsia","Hypertension in Pregnancy",[71],{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":101},[],{"intervention":406,"totalTrials":19,"cells":407},"Cyclophosphamide",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":442,"PHASE3":571,"PHASE4":604,"NA":606},{"trials":409,"activeCount":101},[],{"trials":411,"activeCount":97,"soonestReadout":65},[412,428],{"nctId":63,"briefTitle":64,"status":160,"phases":413,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":420},[89],"2027-10-11","2023-01-26",11,[418,419],"B-cell Lymphoma","Burkitt Lymphoma",[66,421,406,422,423,424,425,426,427],"Doxorubicin","Rituximab","Vincristine","Prednisone","Loncastuximab Tesirine 0.075 mg\u002Fkg by IV","Loncastuximab tesirine 0.12 mg\u002Fkg by IV","Loncastuximab tesirine 0.15 mg\u002Fkg by IV",{"nctId":429,"briefTitle":430,"status":188,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":438},"NCT07199413","Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases",[89],"2029-04-01","2026-03-01",20,[436,437],"Brain Metastases","Leptomeningeal Metastasis",[439,406,440,441],"SV-BR-1-GM Vaccine","Pembrolizumab","Interferon",{"trials":443,"activeCount":570,"soonestReadout":75},[444,457,469,483,496,509,520,530,543,556],{"nctId":445,"briefTitle":446,"status":188,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT06594939","Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",[90],"2028-06","2029-12","2026-06",31,[453],"Diffuse Large B Cell Lymphoma (DLBCL)",[455,456,406,421,424],"Polatuzumab Vedotin","Mosunetuzumab",{"nctId":458,"briefTitle":459,"status":113,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":141,"conditions":463,"interventions":465},"NCT01071239","Hematopoietic Stem Cell Transplant for Fanconi Anemia",[90],"2016-08-30","2009-04",[464],"Fanconi Anemia",[466,467,406,468],"Busulfan","Fludarabine","ATG",{"nctId":470,"briefTitle":471,"status":160,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT05622318","De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis",[90],"2026-07","2026-09","2023-08-29",56,[478],"Graft-versus-host Disease",[406,480,481,482],"Tacrolimus","Mycophenolate Mofetil","Ruxolitinib",{"nctId":484,"briefTitle":485,"status":126,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":492},"NCT04240054","Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency",[90],"2029-12-01","2030-12-01","2021-11-02",41,[21],[493,494,406,495],"Bortezomib","Isatuximab","Dexamethasone",{"nctId":497,"briefTitle":498,"status":113,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT02918292","Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)",[90],"2021-08-17","2017-07-03",32,[504],"Severe Aplastic Anemia",[506,467,406,480,507,508],"Antithymocyte Globulin","Mycophenolate mofetil","G-CSF",{"nctId":510,"briefTitle":511,"status":113,"phases":512,"primaryCompletion":129,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":517},"NCT05032820","Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma",[90],"2025-02-20","2022-01-05",40,[21],[518,519,406,467],"Lenalidomide","bb2121",{"nctId":73,"briefTitle":74,"status":160,"phases":521,"primaryCompletion":75,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":527},[90],"2030-08-12","2020-03-05",36,[526],"Invasive Breast Cancer",[76,528,529,421,406],"Paclitaxel","Carboplatin",{"nctId":531,"briefTitle":532,"status":533,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":541},"NCT02349178","Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT","TERMINATED",[90],"2017-03-16","2014-12-08",6,[539,540],"Leukemia, Acute Lymphoblastic","Acute Myeloid Leukemia",[542,406,66],"Clofarabine",{"nctId":544,"briefTitle":545,"status":546,"phases":547,"start":548,"enrollment":25,"conditions":549,"interventions":551},"NCT00003163","Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers","UNKNOWN",[90],"1997-09",[29,550],"Multiple Myeloma and Plasma Cell Neoplasm",[552,553,554,555],"filgrastim","sargramostim","cyclophosphamide","melphalan",{"nctId":557,"briefTitle":558,"status":113,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":565},"NCT03263559","Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)",[90],"2025-01-29","2017-10-03",95,[564],"Sickle Cell Disease",[566,567,568,467,406,569],"Hydroxyurea","Rabbit-ATG","Thiotepa","Mesna",4,{"trials":572,"activeCount":101},[573,591],{"nctId":574,"briefTitle":575,"status":113,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":587},"NCT00412360","Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)",[91],"2014-03","2014-10","2006-12",224,[582,583,584,585,586],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Myelodysplastic Syndrome","Natural Killer Cell Lymphoblastic Leukemia\u002FLymphoma",[588,589,406,467,590,481],"Single Umbilical Cord Blood Unit Transplant","Double Umbilical Cord Blood Unit Transplant","Cyclosporine A",{"nctId":592,"briefTitle":593,"status":113,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":602},"NCT03959241","TAC\u002FMTX vs. TAC\u002FMMF\u002FPTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703\u002F1801)",[91],"2022-09-19","2019-06-25",431,[599,600,601,29],"Acute Leukemia","Chronic Myelogenous Leukemia (CML)","Myelodysplasia",[480,603,480,481,406],"Methotrexate",{"trials":605,"activeCount":101},[],{"trials":607,"activeCount":101},[],{"intervention":495,"totalTrials":570,"cells":609},{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":630,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":611,"activeCount":101},[],{"trials":613,"activeCount":101},[614],{"nctId":615,"briefTitle":616,"status":617,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":101,"conditions":622,"interventions":625},"NCT04355039","INCB053914 and Pomalidomide With Dexamethasone for Relapsed and\u002For Refractory Multiple Myeloma","WITHDRAWN",[89],"2023-07-01","2024-07-01","2021-07-01",[623,624],"Refractory Multiple Myeloma","Relapse Multiple Myeloma",[626,495,627,628,629],"Pomalidomide","INCB053914 50 mg bis in die","INCB053914 65 mg BID","INCB053914 80 mg BID",{"trials":631,"activeCount":654,"soonestReadout":450},[632,639,643],{"nctId":633,"briefTitle":634,"status":160,"phases":635,"primaryCompletion":450,"completion":473,"start":636,"enrollment":165,"conditions":637,"interventions":638},"NCT05690984","Elimination of Minimal Residual Disease After Transplant",[90],"2023-06-26",[21],[495,494,518],{"nctId":484,"briefTitle":485,"status":126,"phases":640,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":641,"interventions":642},[90],[21],[493,494,406,495],{"nctId":644,"briefTitle":645,"status":160,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":652},"NCT04835129","Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and\u002For Refractory Multiple Myeloma",[90],"2027-04-01","2027-06-01","2022-01-10",28,[21],[494,494,626,653,495],"Elotuzumab",3,{"trials":656,"activeCount":101},[],{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":101},[],{"intervention":421,"totalTrials":654,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":671,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":664,"activeCount":101},[],{"trials":666,"activeCount":141,"soonestReadout":65},[667],{"nctId":63,"briefTitle":64,"status":160,"phases":668,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":669,"interventions":670},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":672,"activeCount":97,"soonestReadout":75},[673,677],{"nctId":445,"briefTitle":446,"status":188,"phases":674,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":675,"interventions":676},[90],[453],[455,456,406,421,424],{"nctId":73,"briefTitle":74,"status":160,"phases":678,"primaryCompletion":75,"completion":522,"start":523,"enrollment":524,"conditions":679,"interventions":680},[90],[526],[76,528,529,421,406],{"trials":682,"activeCount":101},[],{"trials":684,"activeCount":101},[],{"trials":686,"activeCount":101},[],{"intervention":494,"totalTrials":654,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":690,"activeCount":101},[],{"trials":692,"activeCount":101},[],{"trials":694,"activeCount":654,"soonestReadout":450},[695,699,703],{"nctId":633,"briefTitle":634,"status":160,"phases":696,"primaryCompletion":450,"completion":473,"start":636,"enrollment":165,"conditions":697,"interventions":698},[90],[21],[495,494,518],{"nctId":484,"briefTitle":485,"status":126,"phases":700,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":701,"interventions":702},[90],[21],[493,494,406,495],{"nctId":644,"briefTitle":645,"status":160,"phases":704,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":705,"interventions":706},[90],[21],[494,494,626,653,495],{"trials":708,"activeCount":101},[],{"trials":710,"activeCount":101},[],{"trials":712,"activeCount":101},[],{"intervention":424,"totalTrials":570,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":723,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":716,"activeCount":101},[],{"trials":718,"activeCount":141,"soonestReadout":65},[719],{"nctId":63,"briefTitle":64,"status":160,"phases":720,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":721,"interventions":722},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":724,"activeCount":141,"soonestReadout":448},[725,729,738],{"nctId":445,"briefTitle":446,"status":188,"phases":726,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":727,"interventions":728},[90],[453],[455,456,406,421,424],{"nctId":730,"briefTitle":731,"status":533,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":33,"conditions":735,"interventions":737},"NCT00555464","Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas",[90],"2012-12","2007-11",[736],"Hemangioma",[423,424],{"nctId":739,"briefTitle":740,"status":113,"phases":741,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT02806947","A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)",[90],"2018-08-17","2019-02-19","2016-10",127,[747],"Acute GVHD",[749,424],"Sirolimus",{"trials":751,"activeCount":101},[],{"trials":753,"activeCount":101},[],{"trials":755,"activeCount":101},[],{"intervention":41,"totalTrials":97,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":762,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":101},[],{"trials":763,"activeCount":97,"soonestReadout":40},[764,772],{"nctId":38,"briefTitle":39,"status":160,"phases":765,"primaryCompletion":40,"completion":766,"start":767,"enrollment":768,"conditions":769,"interventions":771},[90],"2026-11","2015-12-10",23,[770],"Unresectable Pancreatic Cancer",[41],{"nctId":58,"briefTitle":59,"status":160,"phases":773,"primaryCompletion":60,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},[90],"2027-09","2021-06-03",38,[778],"Glioblastoma",[61,780],"Adjuvant Chemotherapy",{"trials":782,"activeCount":101},[],{"trials":784,"activeCount":101},[],{"trials":786,"activeCount":101},[],{"intervention":788,"totalTrials":97,"cells":789},"Chemotherapy",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":791,"activeCount":101},[],{"trials":793,"activeCount":101},[],{"trials":795,"activeCount":141,"soonestReadout":800},[796],{"nctId":797,"briefTitle":798,"status":126,"phases":799,"primaryCompletion":800,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":808},"NCT06906887","PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer",[90],"2030-11-01","2032-06-01","2025-06-17",50,[805,806,807],"Esophageal Cancer","Oesophageal Cancer","GastroEsophageal Cancer",[809,788],"Induction Chemotherapy",{"trials":811,"activeCount":101},[],{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":141,"soonestReadout":820},[816],{"nctId":817,"briefTitle":818,"status":126,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":803,"conditions":822,"interventions":824},"NCT03896620","Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma",[],"2026-06-01","2019-06-18",[823],"Sarcoma",[788],{"intervention":480,"totalTrials":33,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":842,"PHASE3":877,"PHASE4":907,"NA":909},{"trials":828,"activeCount":101},[],{"trials":830,"activeCount":101},[831],{"nctId":832,"briefTitle":833,"status":617,"phases":834,"primaryCompletion":835,"completion":835,"start":836,"enrollment":101,"conditions":837,"interventions":839},"NCT02680717","Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea",[89],"2017-05","2016-03",[838],"Scleroderma",[840,841,480],"Clobetasol","Calcipotriene",{"trials":843,"activeCount":141,"soonestReadout":473},[844,848,852,865],{"nctId":470,"briefTitle":471,"status":160,"phases":845,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":846,"interventions":847},[90],[478],[406,480,481,482],{"nctId":497,"briefTitle":498,"status":113,"phases":849,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":850,"interventions":851},[90],[504],[506,467,406,480,507,508],{"nctId":853,"briefTitle":854,"status":113,"phases":855,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":859,"interventions":860},"NCT02766465","Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)",[90],"2023-05-02","2023-08-02",138,[564],[466,467,861,480,603,862,863,749,864,508],"r-ATG","Alemtuzumab","Total Body Irradiation","Melphalan",{"nctId":866,"briefTitle":867,"status":113,"phases":868,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":875},"NCT03699631","PROACTIVE: Preventing Acute\u002FChronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant",[90],"2022-03-02","2023-04-01","2018-11-06",29,[874],"Hematologic Malignancy",[480,603,876],"Tocilizumab",{"trials":878,"activeCount":101},[879,883,893],{"nctId":592,"briefTitle":593,"status":113,"phases":880,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":881,"interventions":882},[91],[599,600,601,29],[480,603,480,481,406],{"nctId":884,"briefTitle":885,"status":533,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":570,"conditions":889,"interventions":891},"NCT02954159","Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC",[91],"2019-01-31","2017-05-18",[890],"Ulcerative Colitis",[480,892],"Vedolizumab",{"nctId":894,"briefTitle":895,"status":113,"phases":896,"primaryCompletion":897,"completion":898,"start":899,"enrollment":900,"conditions":901,"interventions":906},"NCT00406393","Sirolimus\u002FTacrolimus Versus Tacrolimus\u002FMethotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)",[91],"2012-10","2015-10","2006-11",304,[902,903,904,905],"Leukemia, Myelocytic, Acute","Leukemia, Lymphocytic, Acute","Leukemia, Myeloid, Chronic","Myelodysplastic Syndromes",[480,603,749],{"trials":908,"activeCount":101},[],{"trials":910,"activeCount":101},[],{"intervention":481,"totalTrials":912,"cells":913},5,{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":928,"PHASE4":949,"NA":951},{"trials":915,"activeCount":101},[],{"trials":917,"activeCount":101},[],{"trials":919,"activeCount":141,"soonestReadout":473},[920,924],{"nctId":470,"briefTitle":471,"status":160,"phases":921,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":922,"interventions":923},[90],[478],[406,480,481,482],{"nctId":497,"briefTitle":498,"status":113,"phases":925,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":926,"interventions":927},[90],[504],[506,467,406,480,507,508],{"trials":929,"activeCount":101},[930,941,945],{"nctId":931,"briefTitle":932,"status":113,"phases":933,"primaryCompletion":934,"completion":935,"start":936,"enrollment":130,"conditions":937,"interventions":940},"NCT01002742","Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)",[91],"2012-01","2013-06","2010-01",[938,939],"Graft-versus-Host Disease","Immune System Disorders",[481],{"nctId":574,"briefTitle":575,"status":113,"phases":942,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":943,"interventions":944},[91],[582,583,584,585,586],[588,589,406,467,590,481],{"nctId":592,"briefTitle":593,"status":113,"phases":946,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":947,"interventions":948},[91],[599,600,601,29],[480,603,480,481,406],{"trials":950,"activeCount":101},[],{"trials":952,"activeCount":101},[],{"intervention":518,"totalTrials":97,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":956,"activeCount":101},[],{"trials":958,"activeCount":101},[],{"trials":960,"activeCount":141,"soonestReadout":450},[961,965],{"nctId":633,"briefTitle":634,"status":160,"phases":962,"primaryCompletion":450,"completion":473,"start":636,"enrollment":165,"conditions":963,"interventions":964},[90],[21],[495,494,518],{"nctId":510,"briefTitle":511,"status":113,"phases":966,"primaryCompletion":129,"completion":513,"start":514,"enrollment":515,"conditions":967,"interventions":968},[90],[21],[518,519,406,467],{"trials":970,"activeCount":101},[],{"trials":972,"activeCount":101},[],{"trials":974,"activeCount":101},[],{"intervention":626,"totalTrials":97,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":985,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":978,"activeCount":101},[],{"trials":980,"activeCount":101},[981],{"nctId":615,"briefTitle":616,"status":617,"phases":982,"primaryCompletion":619,"completion":620,"start":621,"enrollment":101,"conditions":983,"interventions":984},[89],[623,624],[626,495,627,628,629],{"trials":986,"activeCount":141,"soonestReadout":647},[987],{"nctId":644,"briefTitle":645,"status":160,"phases":988,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":989,"interventions":990},[90],[21],[494,494,626,653,495],{"trials":992,"activeCount":101},[],{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":101},[],{"intervention":998,"totalTrials":97,"cells":999},"Abemaciclib",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1021,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1001,"activeCount":101},[],{"trials":1003,"activeCount":101},[1004],{"nctId":1005,"briefTitle":1006,"status":617,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":1011,"interventions":1014},"NCT04316169","Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)\u002FHer 2 Negative Breast Cancer",[89],"2027-01","2028-01","2021-10-21",[1012,1013],"Solid Tumor","Advanced Breast Cancer",[998,1015,1016,1017,1018,1019,1020],"Hydroxychloroquine 200 mg","Faslodex","Anastrazole","Letrozole","Hydroxychloroquine 400 mg","Hydroxychloroquine 600 mg",{"trials":1022,"activeCount":141,"soonestReadout":648},[1023],{"nctId":1024,"briefTitle":1025,"status":126,"phases":1026,"primaryCompletion":648,"completion":648,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1033},"NCT04040205","Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",[90],"2019-10-07",44,[1030,1031,1032],"Chondrosarcoma","Osteosarcoma","Soft Tissue Sarcoma",[998],{"trials":1035,"activeCount":101},[],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":101},[],{"intervention":529,"totalTrials":97,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1043,"activeCount":101},[],{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":141,"soonestReadout":75},[1048,1057],{"nctId":1049,"briefTitle":1050,"status":113,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":744,"enrollment":872,"conditions":1054,"interventions":1056},"NCT02766582","Phase II: Pembrolizumab\u002FCarboplatin\u002FTaxol in Epithelial Ovary Cancer",[90],"2022-05","2023-12-30",[1055],"Ovarian Cancer",[440,529,528],{"nctId":73,"briefTitle":74,"status":160,"phases":1058,"primaryCompletion":75,"completion":522,"start":523,"enrollment":524,"conditions":1059,"interventions":1060},[90],[526],[76,528,529,421,406],{"trials":1062,"activeCount":101},[],{"trials":1064,"activeCount":101},[],{"trials":1066,"activeCount":101},[],{"intervention":528,"totalTrials":97,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1070,"activeCount":101},[],{"trials":1072,"activeCount":101},[],{"trials":1074,"activeCount":141,"soonestReadout":75},[1075,1079],{"nctId":1049,"briefTitle":1050,"status":113,"phases":1076,"primaryCompletion":1052,"completion":1053,"start":744,"enrollment":872,"conditions":1077,"interventions":1078},[90],[1055],[440,529,528],{"nctId":73,"briefTitle":74,"status":160,"phases":1080,"primaryCompletion":75,"completion":522,"start":523,"enrollment":524,"conditions":1081,"interventions":1082},[90],[526],[76,528,529,421,406],{"trials":1084,"activeCount":101},[],{"trials":1086,"activeCount":101},[],{"trials":1088,"activeCount":101},[],{"intervention":1090,"totalTrials":97,"cells":1091},"Pacritinib",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1093,"activeCount":101},[],{"trials":1095,"activeCount":101},[],{"trials":1097,"activeCount":141,"soonestReadout":1111},[1098,1107],{"nctId":1099,"briefTitle":1100,"status":533,"phases":1101,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":537,"conditions":1105,"interventions":1106},"NCT04635059","Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer",[90],"2023-11-30","2024-10-27","2021-06-01",[35],[1090],{"nctId":1108,"briefTitle":1109,"status":188,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":502,"conditions":1114,"interventions":1115},"NCT07226713","Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors",[90],"2029-03-01","2031-03-01","2026-07-01",[35],[1090],{"trials":1117,"activeCount":101},[],{"trials":1119,"activeCount":101},[],{"trials":1121,"activeCount":101},[],{"intervention":1123,"totalTrials":97,"cells":1124},"Imatinib",{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1126,"activeCount":101},[],{"trials":1128,"activeCount":101},[],{"trials":1130,"activeCount":141,"soonestReadout":448},[1131,1146],{"nctId":1132,"briefTitle":1133,"status":126,"phases":1134,"primaryCompletion":448,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT04838041","Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",[90],"2029-07","2021-11-11",51,[1139],"Chronic Phase Chronic Myelogenous Leukemia",[1141,1142,1143,1123,1144,1145],"Asciminib 40 MG","Asciminib 40 MG Twice Daily","Asciminib 80 MG daily","Nilotinib","Dasatinib",{"nctId":1147,"briefTitle":1148,"status":113,"phases":1149,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1155},"NCT02269267","The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)",[90],"2021-04-06","2022-04-06","2014-12-18",173,[904],[1123,1145,1144,1156],"Bosutinib",{"trials":1158,"activeCount":101},[],{"trials":1160,"activeCount":101},[],{"trials":1162,"activeCount":101},[],{"intervention":1144,"totalTrials":97,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1179,"PHASE4":1181,"NA":1183},{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":141,"soonestReadout":448},[1171,1175],{"nctId":1132,"briefTitle":1133,"status":126,"phases":1172,"primaryCompletion":448,"completion":1135,"start":1136,"enrollment":1137,"conditions":1173,"interventions":1174},[90],[1139],[1141,1142,1143,1123,1144,1145],{"nctId":1147,"briefTitle":1148,"status":113,"phases":1176,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1177,"interventions":1178},[90],[904],[1123,1145,1144,1156],{"trials":1180,"activeCount":101},[],{"trials":1182,"activeCount":101},[],{"trials":1184,"activeCount":101},[],{"intervention":1145,"totalTrials":97,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1188,"activeCount":101},[],{"trials":1190,"activeCount":101},[],{"trials":1192,"activeCount":141,"soonestReadout":448},[1193,1197],{"nctId":1132,"briefTitle":1133,"status":126,"phases":1194,"primaryCompletion":448,"completion":1135,"start":1136,"enrollment":1137,"conditions":1195,"interventions":1196},[90],[1139],[1141,1142,1143,1123,1144,1145],{"nctId":1147,"briefTitle":1148,"status":113,"phases":1198,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":1199,"interventions":1200},[90],[904],[1123,1145,1144,1156],{"trials":1202,"activeCount":101},[],{"trials":1204,"activeCount":101},[],{"trials":1206,"activeCount":101},[],{"intervention":455,"totalTrials":141,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":101},[],{"trials":1212,"activeCount":101},[],{"trials":1214,"activeCount":141,"soonestReadout":448},[1215],{"nctId":445,"briefTitle":446,"status":188,"phases":1216,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":1217,"interventions":1218},[90],[453],[455,456,406,421,424],{"trials":1220,"activeCount":101},[],{"trials":1222,"activeCount":101},[],{"trials":1224,"activeCount":101},[],{"intervention":456,"totalTrials":141,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":101},[],{"trials":1230,"activeCount":101},[],{"trials":1232,"activeCount":141,"soonestReadout":448},[1233],{"nctId":445,"briefTitle":446,"status":188,"phases":1234,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":1235,"interventions":1236},[90],[453],[455,456,406,421,424],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":101},[],{"trials":1242,"activeCount":101},[],{"intervention":809,"totalTrials":141,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1246,"activeCount":101},[],{"trials":1248,"activeCount":101},[],{"trials":1250,"activeCount":141,"soonestReadout":800},[1251],{"nctId":797,"briefTitle":798,"status":126,"phases":1252,"primaryCompletion":800,"completion":801,"start":802,"enrollment":803,"conditions":1253,"interventions":1254},[90],[805,806,807],[809,788],{"trials":1256,"activeCount":101},[],{"trials":1258,"activeCount":101},[],{"trials":1260,"activeCount":101},[],{"intervention":46,"totalTrials":141,"cells":1262},{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1264,"activeCount":101},[],{"trials":1266,"activeCount":101},[],{"trials":1268,"activeCount":141,"soonestReadout":45},[1269],{"nctId":43,"briefTitle":44,"status":126,"phases":1270,"primaryCompletion":45,"completion":1271,"start":1272,"enrollment":515,"conditions":1273,"interventions":1275},[90],"2024-12-31","2020-07-08",[1274],"Peripheral Neuropathy Due to Chemotherapy",[46,1276],"Normal saline",{"trials":1278,"activeCount":101},[],{"trials":1280,"activeCount":101},[],{"trials":1282,"activeCount":101},[],{"intervention":1276,"totalTrials":141,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1286,"activeCount":101},[],{"trials":1288,"activeCount":101},[],{"trials":1290,"activeCount":141,"soonestReadout":45},[1291],{"nctId":43,"briefTitle":44,"status":126,"phases":1292,"primaryCompletion":45,"completion":1271,"start":1272,"enrollment":515,"conditions":1293,"interventions":1294},[90],[1274],[46,1276],{"trials":1296,"activeCount":101},[],{"trials":1298,"activeCount":101},[],{"trials":1300,"activeCount":101},[],{"intervention":482,"totalTrials":141,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1304,"activeCount":101},[],{"trials":1306,"activeCount":101},[],{"trials":1308,"activeCount":141,"soonestReadout":473},[1309],{"nctId":470,"briefTitle":471,"status":160,"phases":1310,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":1311,"interventions":1312},[90],[478],[406,480,481,482],{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[],{"trials":1318,"activeCount":101},[],{"intervention":493,"totalTrials":141,"cells":1320},{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1322,"activeCount":101},[],{"trials":1324,"activeCount":101},[],{"trials":1326,"activeCount":141,"soonestReadout":487},[1327],{"nctId":484,"briefTitle":485,"status":126,"phases":1328,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":1329,"interventions":1330},[90],[21],[493,494,406,495],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":101},[],{"trials":1336,"activeCount":101},[],{"intervention":1338,"totalTrials":141,"cells":1339},"Maintenance Therapy",{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1341,"activeCount":101},[],{"trials":1343,"activeCount":101},[],{"trials":1345,"activeCount":141,"soonestReadout":1350},[1346],{"nctId":1347,"briefTitle":1348,"status":188,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1356},"NCT07572929","A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant",[90],"2034-02-01","2026-08-01",450,[1354,905,1355,540],"Myeloid Disorders","Myeloproliferative Neoplasm",[1338],{"trials":1358,"activeCount":101},[],{"trials":1360,"activeCount":101},[],{"trials":1362,"activeCount":101},[],{"intervention":1364,"totalTrials":141,"cells":1365},"First-line Chemotherapy",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":101},[],{"trials":1371,"activeCount":141,"soonestReadout":648},[1372],{"nctId":1373,"briefTitle":1374,"status":126,"phases":1375,"primaryCompletion":648,"completion":801,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1380},"NCT03322995","Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial",[90],"2018-06-21",125,[1379],"Pancreatic Cancer",[1364,1381],"Second-line Chemotherapy",{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":101},[],{"intervention":1381,"totalTrials":141,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1391,"activeCount":101},[],{"trials":1393,"activeCount":101},[],{"trials":1395,"activeCount":141,"soonestReadout":648},[1396],{"nctId":1373,"briefTitle":1374,"status":126,"phases":1397,"primaryCompletion":648,"completion":801,"start":1376,"enrollment":1377,"conditions":1398,"interventions":1399},[90],[1379],[1364,1381],{"trials":1401,"activeCount":101},[],{"trials":1403,"activeCount":101},[],{"trials":1405,"activeCount":101},[],{"intervention":1407,"totalTrials":141,"cells":1408},"Targeted TKI therapy",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1410,"activeCount":101},[],{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":141,"soonestReadout":1419},[1415],{"nctId":1416,"briefTitle":1417,"status":126,"phases":1418,"primaryCompletion":1419,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT06305715","Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)",[90],"2027-06-15","2028-06-15","2024-09-18",34,[1424],"Non Small Cell Lung Cancer",[1407],{"trials":1427,"activeCount":101},[],{"trials":1429,"activeCount":101},[],{"trials":1431,"activeCount":101},[],{"intervention":51,"totalTrials":141,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1435,"activeCount":101},[],{"trials":1437,"activeCount":101},[],{"trials":1439,"activeCount":141,"soonestReadout":50},[1440],{"nctId":48,"briefTitle":49,"status":126,"phases":1441,"primaryCompletion":50,"completion":1442,"start":1443,"enrollment":9,"conditions":1444,"interventions":1448},[90],"2029-12-31","2021-02-01",[1445,1446,1447],"B-cell Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","B-Cell ALL, Childhood",[51],{"trials":1450,"activeCount":101},[],{"trials":1452,"activeCount":101},[],{"trials":1454,"activeCount":101},[],{"intervention":1456,"totalTrials":141,"cells":1457},"Targeted agent",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1459,"activeCount":101},[],{"trials":1461,"activeCount":101},[],{"trials":1463,"activeCount":141,"soonestReadout":1468},[1464],{"nctId":1465,"briefTitle":1466,"status":126,"phases":1467,"primaryCompletion":1468,"completion":1469,"start":1470,"enrollment":1471,"conditions":1472,"interventions":1474},"NCT05674825","Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses",[89,90],"2027-06","2031-01","2022-12-21",400,[1473],"Cancer",[1456,1475],"Standard of care agent",{"trials":1477,"activeCount":101},[],{"trials":1479,"activeCount":101},[],{"trials":1481,"activeCount":101},[],{"intervention":1475,"totalTrials":141,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":101},[],{"trials":1487,"activeCount":101},[],{"trials":1489,"activeCount":141,"soonestReadout":1468},[1490],{"nctId":1465,"briefTitle":1466,"status":126,"phases":1491,"primaryCompletion":1468,"completion":1469,"start":1470,"enrollment":1471,"conditions":1492,"interventions":1493},[89,90],[1473],[1456,1475],{"trials":1495,"activeCount":101},[],{"trials":1497,"activeCount":101},[],{"trials":1499,"activeCount":101},[],{"intervention":1501,"totalTrials":141,"cells":1502},"Linvoseltamab",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1504,"activeCount":101},[],{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":141,"soonestReadout":1513},[1509],{"nctId":1510,"briefTitle":1511,"status":188,"phases":1512,"primaryCompletion":1513,"completion":1514,"start":1113,"enrollment":1422,"conditions":1515,"interventions":1516},"NCT07009899","BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)",[90],"2028-02-01","2029-02-01",[21],[1501],{"trials":1518,"activeCount":101},[],{"trials":1520,"activeCount":101},[],{"trials":1522,"activeCount":101},[],{"intervention":1524,"totalTrials":141,"cells":1525},"4.5mg daily dose of naltrexone",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1527,"activeCount":101},[],{"trials":1529,"activeCount":101},[],{"trials":1531,"activeCount":141,"soonestReadout":1536},[1532],{"nctId":1533,"briefTitle":1534,"status":160,"phases":1535,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":25,"conditions":1539,"interventions":1542},"NCT06723561","Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury",[90],"2026-06-30","2026-12-31","2025-02-01",[1540,1541],"Central Neuropathic Pain","Spinal Cord Injury",[1524],{"trials":1544,"activeCount":101},[],{"trials":1546,"activeCount":101},[],{"trials":1548,"activeCount":101},[],{"intervention":1550,"totalTrials":141,"cells":1551},"Fosamprenavir Calcium",{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1553,"activeCount":101},[],{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":141,"soonestReadout":648},[1558],{"nctId":1559,"briefTitle":1560,"status":188,"phases":1561,"primaryCompletion":648,"completion":1562,"start":1563,"enrollment":1564,"conditions":1565,"interventions":1567},"NCT04383262","Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction",[90],"2027-10-01","2026-05-15",104,[1566],"Laryngopharyngeal Reflux",[1550],{"trials":1569,"activeCount":101},[],{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"intervention":1141,"totalTrials":141,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":101},[],{"trials":1579,"activeCount":101},[],{"trials":1581,"activeCount":141,"soonestReadout":448},[1582],{"nctId":1132,"briefTitle":1133,"status":126,"phases":1583,"primaryCompletion":448,"completion":1135,"start":1136,"enrollment":1137,"conditions":1584,"interventions":1585},[90],[1139],[1141,1142,1143,1123,1144,1145],{"trials":1587,"activeCount":101},[],{"trials":1589,"activeCount":101},[],{"trials":1591,"activeCount":101},[],{"intervention":1142,"totalTrials":141,"cells":1593},{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1595,"activeCount":101},[],{"trials":1597,"activeCount":101},[],{"trials":1599,"activeCount":141,"soonestReadout":448},[1600],{"nctId":1132,"briefTitle":1133,"status":126,"phases":1601,"primaryCompletion":448,"completion":1135,"start":1136,"enrollment":1137,"conditions":1602,"interventions":1603},[90],[1139],[1141,1142,1143,1123,1144,1145],{"trials":1605,"activeCount":101},[],{"trials":1607,"activeCount":101},[],{"trials":1609,"activeCount":101},[],{"intervention":1143,"totalTrials":141,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1613,"activeCount":101},[],{"trials":1615,"activeCount":101},[],{"trials":1617,"activeCount":141,"soonestReadout":448},[1618],{"nctId":1132,"briefTitle":1133,"status":126,"phases":1619,"primaryCompletion":448,"completion":1135,"start":1136,"enrollment":1137,"conditions":1620,"interventions":1621},[90],[1139],[1141,1142,1143,1123,1144,1145],{"trials":1623,"activeCount":101},[],{"trials":1625,"activeCount":101},[],{"trials":1627,"activeCount":101},[],{"intervention":76,"totalTrials":141,"cells":1629},{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1631,"activeCount":101},[],{"trials":1633,"activeCount":101},[],{"trials":1635,"activeCount":141,"soonestReadout":75},[1636],{"nctId":73,"briefTitle":74,"status":160,"phases":1637,"primaryCompletion":75,"completion":522,"start":523,"enrollment":524,"conditions":1638,"interventions":1639},[90],[526],[76,528,529,421,406],{"trials":1641,"activeCount":101},[],{"trials":1643,"activeCount":101},[],{"trials":1645,"activeCount":101},[],{"intervention":1647,"totalTrials":141,"cells":1648},"mFOLFIRINOX Treatment Regimen",{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1650,"activeCount":101},[],{"trials":1652,"activeCount":101},[],{"trials":1654,"activeCount":141,"soonestReadout":1659},[1655],{"nctId":1656,"briefTitle":1657,"status":126,"phases":1658,"primaryCompletion":1659,"completion":162,"start":1660,"enrollment":1661,"conditions":1662,"interventions":1663},"NCT04683315","PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples",[90],"2027-12-31","2021-04-01",84,[1379],[1647,1664],"Gemcitabine\u002FNab-paclitaxel Treatment Regimen",{"trials":1666,"activeCount":101},[],{"trials":1668,"activeCount":101},[],{"trials":1670,"activeCount":101},[],{"intervention":1664,"totalTrials":141,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":101},[],{"trials":1676,"activeCount":101},[],{"trials":1678,"activeCount":141,"soonestReadout":1659},[1679],{"nctId":1656,"briefTitle":1657,"status":126,"phases":1680,"primaryCompletion":1659,"completion":162,"start":1660,"enrollment":1661,"conditions":1681,"interventions":1682},[90],[1379],[1647,1664],{"trials":1684,"activeCount":101},[],{"trials":1686,"activeCount":101},[],{"trials":1688,"activeCount":101},[],{"intervention":1690,"totalTrials":141,"cells":1691},"Fosamprenavir Calcium & Sodium Alginate",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1693,"activeCount":101},[],{"trials":1695,"activeCount":101},[],{"trials":1697,"activeCount":141,"soonestReadout":1702},[1698],{"nctId":1699,"briefTitle":1700,"status":188,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":433,"enrollment":363,"conditions":1704,"interventions":1707},"NCT06704100","Oral Fosamprenavir + Sodium Alginate for GERD",[90],"2028-02-28","2028-06-01",[1705,1706],"Refractory Gastroesophageal Reflux Disease","Gastroesophageal Reflux Disease",[1690],{"trials":1709,"activeCount":101},[],{"trials":1711,"activeCount":101},[],{"trials":1713,"activeCount":101},[],{"intervention":1715,"totalTrials":141,"cells":1716},"Haploidentical donor bone marrow transplant",{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1732,"PHASE4":1734,"NA":1736},{"trials":1718,"activeCount":101},[],{"trials":1720,"activeCount":101},[],{"trials":1722,"activeCount":141,"soonestReadout":1727},[1723],{"nctId":1724,"briefTitle":1725,"status":126,"phases":1726,"primaryCompletion":1727,"completion":1514,"start":1728,"enrollment":363,"conditions":1729,"interventions":1730},"NCT06517641","Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia",[90],"2028-08-01","2025-05-12",[504],[1715,1731],"Unrelated donor bone marrow transplant",{"trials":1733,"activeCount":101},[],{"trials":1735,"activeCount":101},[],{"trials":1737,"activeCount":101},[],{"intervention":1731,"totalTrials":141,"cells":1739},{"EARLY_PHASE1":1740,"PHASE1":1742,"PHASE2":1744,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1741,"activeCount":101},[],{"trials":1743,"activeCount":101},[],{"trials":1745,"activeCount":141,"soonestReadout":1727},[1746],{"nctId":1724,"briefTitle":1725,"status":126,"phases":1747,"primaryCompletion":1727,"completion":1514,"start":1728,"enrollment":363,"conditions":1748,"interventions":1749},[90],[504],[1715,1731],{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":101},[],{"trials":1755,"activeCount":101},[],{"intervention":1757,"totalTrials":141,"cells":1758},"Single Dose Theophylline",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1760,"activeCount":101},[],{"trials":1762,"activeCount":101},[],{"trials":1764,"activeCount":141,"soonestReadout":766},[1765],{"nctId":1766,"briefTitle":1767,"status":126,"phases":1768,"primaryCompletion":766,"completion":1769,"start":1770,"enrollment":165,"conditions":1771,"interventions":1774},"NCT05853601","Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage",[89,90],"2027-11","2023-10-17",[1772,1773],"Acute Kidney Injury","HIE",[1757,1775],"Repeat Dose Theophylline",{"trials":1777,"activeCount":101},[],{"trials":1779,"activeCount":101},[],{"trials":1781,"activeCount":101},[],{"intervention":1775,"totalTrials":141,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":101},[],{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":141,"soonestReadout":766},[1790],{"nctId":1766,"briefTitle":1767,"status":126,"phases":1791,"primaryCompletion":766,"completion":1769,"start":1770,"enrollment":165,"conditions":1792,"interventions":1793},[89,90],[1772,1773],[1757,1775],{"trials":1795,"activeCount":101},[],{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[],{"intervention":780,"totalTrials":141,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1812,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":141,"soonestReadout":60},[1808],{"nctId":58,"briefTitle":59,"status":160,"phases":1809,"primaryCompletion":60,"completion":774,"start":775,"enrollment":776,"conditions":1810,"interventions":1811},[90],[778],[61,780],{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":101},[],{"intervention":1819,"totalTrials":141,"cells":1820},"Memantine -Twice Daily or Extended Release",{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1822,"activeCount":101},[],{"trials":1824,"activeCount":101},[],{"trials":1826,"activeCount":141,"soonestReadout":128},[1827],{"nctId":1828,"briefTitle":1829,"status":126,"phases":1830,"primaryCompletion":128,"completion":1831,"start":1832,"enrollment":1833,"conditions":1834,"interventions":1835},"NCT05045950","Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique",[90],"2029-05","2021-11-17",53,[436],[1819],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":101},[],{"trials":1841,"activeCount":101},[],{"intervention":1843,"totalTrials":141,"cells":1844},"8\u002F12-Day Production of Car-T Cells",{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1871,"PHASE4":1873,"NA":1875},{"trials":1846,"activeCount":101},[],{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":141,"soonestReadout":1855},[1851],{"nctId":1852,"briefTitle":1853,"status":126,"phases":1854,"primaryCompletion":1855,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1868},"NCT04186520","CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",[89,90],"2027-02-28","2029-02-28","2020-05-18",100,[1860,1861,1862,1863,1864,1865,1866,1867],"Non Hodgkin Lymphoma (NHL)","Mantle Cell Lymphoma (MCL)","Chronic Lymphocytic Leukemia (CLL)","Follicular Lymphoma","Marginal Zone Lymphoma","Diffuse Large B Cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Central Nervous System Lymphoma",[1843,1869,1870],"8\u002F12-Day Production of Cryopreserved Car-T Cells","12-Day Production of Car-T Cells",{"trials":1872,"activeCount":101},[],{"trials":1874,"activeCount":101},[],{"trials":1876,"activeCount":101},[],{"intervention":1869,"totalTrials":141,"cells":1878},{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1889,"PHASE4":1891,"NA":1893},{"trials":1880,"activeCount":101},[],{"trials":1882,"activeCount":101},[],{"trials":1884,"activeCount":141,"soonestReadout":1855},[1885],{"nctId":1852,"briefTitle":1853,"status":126,"phases":1886,"primaryCompletion":1855,"completion":1856,"start":1857,"enrollment":1858,"conditions":1887,"interventions":1888},[89,90],[1860,1861,1862,1863,1864,1865,1866,1867],[1843,1869,1870],{"trials":1890,"activeCount":101},[],{"trials":1892,"activeCount":101},[],{"trials":1894,"activeCount":101},[],{"intervention":1870,"totalTrials":141,"cells":1896},{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1898,"activeCount":101},[],{"trials":1900,"activeCount":101},[],{"trials":1902,"activeCount":141,"soonestReadout":1855},[1903],{"nctId":1852,"briefTitle":1853,"status":126,"phases":1904,"primaryCompletion":1855,"completion":1856,"start":1857,"enrollment":1858,"conditions":1905,"interventions":1906},[89,90],[1860,1861,1862,1863,1864,1865,1866,1867],[1843,1869,1870],{"trials":1908,"activeCount":101},[],{"trials":1910,"activeCount":101},[],{"trials":1912,"activeCount":101},[],{"intervention":1914,"totalTrials":141,"cells":1915},"Aromatase inhibitors or tamoxifen",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1917,"activeCount":101},[],{"trials":1919,"activeCount":101},[],{"trials":1921,"activeCount":141,"soonestReadout":1926},[1922],{"nctId":1923,"briefTitle":1924,"status":126,"phases":1925,"primaryCompletion":1926,"completion":449,"start":1927,"enrollment":1858,"conditions":1928,"interventions":1929},"NCT06361940","Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer",[90],"2028-12","2024-09-30",[15],[1914],{"trials":1931,"activeCount":101},[],{"trials":1933,"activeCount":101},[],{"trials":1935,"activeCount":101},[],{"intervention":653,"totalTrials":141,"cells":1937},{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1942,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1939,"activeCount":101},[],{"trials":1941,"activeCount":101},[],{"trials":1943,"activeCount":141,"soonestReadout":647},[1944],{"nctId":644,"briefTitle":645,"status":160,"phases":1945,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":1946,"interventions":1947},[90],[21],[494,494,626,653,495],{"trials":1949,"activeCount":101},[],{"trials":1951,"activeCount":101},[],{"trials":1953,"activeCount":101},[],{"intervention":1955,"totalTrials":97,"cells":1956},"Gallium Maltolate",{"EARLY_PHASE1":1957,"PHASE1":1965,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1958,"activeCount":141,"soonestReadout":774},[1959],{"nctId":1960,"briefTitle":1961,"status":188,"phases":1962,"primaryCompletion":774,"completion":774,"start":450,"enrollment":33,"conditions":1963,"interventions":1964},"NCT07515924","Oral Gallium Maltolate for Recurrent Glioblastoma",[88],[778],[1955],{"trials":1966,"activeCount":141,"soonestReadout":55},[1967],{"nctId":53,"briefTitle":54,"status":160,"phases":1968,"primaryCompletion":55,"completion":1969,"start":1970,"enrollment":1971,"conditions":1972,"interventions":1973},[89],"2027-03-01","2022-11-11",26,[778],[56,56,56,56,56,56],{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[],{"intervention":467,"totalTrials":30,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":2002,"PHASE3":2050,"PHASE4":2056,"NA":2058},{"trials":1985,"activeCount":101},[],{"trials":1987,"activeCount":141,"soonestReadout":1008},[1988],{"nctId":1989,"briefTitle":1990,"status":126,"phases":1991,"primaryCompletion":1008,"completion":1008,"start":1992,"enrollment":515,"conditions":1993,"interventions":1996},"NCT05317403","Venetoclax to Augment Epigenetic Modification and Chemotherapy",[89],"2023-03-31",[1994,1995],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory",[1997,1998,1999,2000,467,2001],"Venetoclax","Azacitadine","Vorinostat","Cytarabine","Filgrastim",{"trials":2003,"activeCount":101},[2004,2008,2012,2024,2028,2032,2036],{"nctId":458,"briefTitle":459,"status":113,"phases":2005,"primaryCompletion":461,"completion":461,"start":462,"enrollment":141,"conditions":2006,"interventions":2007},[90],[464],[466,467,406,468],{"nctId":497,"briefTitle":498,"status":113,"phases":2009,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":2010,"interventions":2011},[90],[504],[506,467,406,480,507,508],{"nctId":2013,"briefTitle":2014,"status":113,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":2019,"conditions":2020,"interventions":2022},"NCT03159702","Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation",[90],"2024-11-12","2025-12-08","2017-12-08",43,[2021,21],"Hematological Malignancy",[2023,467],"Evomela",{"nctId":510,"briefTitle":511,"status":113,"phases":2025,"primaryCompletion":129,"completion":513,"start":514,"enrollment":515,"conditions":2026,"interventions":2027},[90],[21],[518,519,406,467],{"nctId":853,"briefTitle":854,"status":113,"phases":2029,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":2030,"interventions":2031},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"nctId":557,"briefTitle":558,"status":113,"phases":2033,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":2034,"interventions":2035},[90],[564],[566,567,568,467,406,569],{"nctId":2037,"briefTitle":2038,"status":113,"phases":2039,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":2044,"interventions":2046},"NCT00326417","Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)",[89,90],"2015-09","2016-01","2006-01",97,[2045],"Anemia, Aplastic",[467,2047,2048,2049],"Cyclophosphamide 150mg","Cyclophosphamide 100mg","Cyclophosphamide 50mg",{"trials":2051,"activeCount":101},[2052],{"nctId":574,"briefTitle":575,"status":113,"phases":2053,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":2054,"interventions":2055},[91],[582,583,584,585,586],[588,589,406,467,590,481],{"trials":2057,"activeCount":101},[],{"trials":2059,"activeCount":101},[],{"intervention":2001,"totalTrials":654,"cells":2061},{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2070,"PHASE3":2076,"PHASE4":2094,"NA":2096},{"trials":2063,"activeCount":101},[],{"trials":2065,"activeCount":141,"soonestReadout":1008},[2066],{"nctId":1989,"briefTitle":1990,"status":126,"phases":2067,"primaryCompletion":1008,"completion":1008,"start":1992,"enrollment":515,"conditions":2068,"interventions":2069},[89],[1994,1995],[1997,1998,1999,2000,467,2001],{"trials":2071,"activeCount":101},[2072],{"nctId":544,"briefTitle":545,"status":546,"phases":2073,"start":548,"enrollment":25,"conditions":2074,"interventions":2075},[90],[29,550],[552,553,554,555],{"trials":2077,"activeCount":101},[2078],{"nctId":2079,"briefTitle":2080,"status":533,"phases":2081,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":165,"conditions":2085,"interventions":2089},"NCT00096460","Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)",[90,91],"2006-03","2009-03","2004-08",[2086,2087,2088,1863],"Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma",[2090,2001,2091,2092,2093],"Cyclophosphamide and Rituximab","Non-myeloablative Conditioning regimen","Rituximab maintenance therapy","GVHD Prophylaxis",{"trials":2095,"activeCount":101},[],{"trials":2097,"activeCount":101},[],{"intervention":2000,"totalTrials":570,"cells":2099},{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2137,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":141,"soonestReadout":1008},[2104,2124,2133],{"nctId":2105,"briefTitle":2106,"status":617,"phases":2107,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":2111,"interventions":2114},"NCT06007911","Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[89],"2025-12","2027-04","2024-08-31",[2112,2113],"Relapsed Adult AML","Refractory AML",[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],"Navitoclax Dose Level -1","Navitoclax Dose Level 0","Navitoclax Dose Level 1","Navitoclax Dose Level 2","Venetoclax Dose Level -1","Venetoclax Dose Levels 0 to 2","Cladribine","Mitoxantrone","Granulocyte Colony-Stimulating Factor",{"nctId":2125,"briefTitle":2126,"status":113,"phases":2127,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1971,"conditions":2130,"interventions":2131},"NCT03441048","Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed\u002FRefractory Acute Myeloid Leukemia",[89],"2024-05-22","2018-05-22",[540],[2132,2121,2000,2122,508],"Lintuzumab-Ac-225",{"nctId":1989,"briefTitle":1990,"status":126,"phases":2134,"primaryCompletion":1008,"completion":1008,"start":1992,"enrollment":515,"conditions":2135,"interventions":2136},[89],[1994,1995],[1997,1998,1999,2000,467,2001],{"trials":2138,"activeCount":101},[2139],{"nctId":2140,"briefTitle":2141,"status":113,"phases":2142,"primaryCompletion":2143,"completion":2144,"start":2145,"enrollment":2019,"conditions":2146,"interventions":2147},"NCT01141712","Autologous Transplant in HIV Patients (BMT CTN 0803)",[90],"2015-05","2016-06","2010-04",[29,24],[2148,66,2000,864],"BCNU",{"trials":2150,"activeCount":101},[],{"trials":2152,"activeCount":101},[],{"trials":2154,"activeCount":101},[],{"intervention":66,"totalTrials":654,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2165,"PHASE3":2175,"PHASE4":2177,"NA":2179},{"trials":2158,"activeCount":101},[],{"trials":2160,"activeCount":141,"soonestReadout":65},[2161],{"nctId":63,"briefTitle":64,"status":160,"phases":2162,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":2163,"interventions":2164},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":2166,"activeCount":101},[2167,2171],{"nctId":531,"briefTitle":532,"status":533,"phases":2168,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":2169,"interventions":2170},[90],[539,540],[542,406,66],{"nctId":2140,"briefTitle":2141,"status":113,"phases":2172,"primaryCompletion":2143,"completion":2144,"start":2145,"enrollment":2019,"conditions":2173,"interventions":2174},[90],[29,24],[2148,66,2000,864],{"trials":2176,"activeCount":101},[],{"trials":2178,"activeCount":101},[],{"trials":2180,"activeCount":101},[],{"intervention":422,"totalTrials":97,"cells":2182},{"EARLY_PHASE1":2183,"PHASE1":2185,"PHASE2":2191,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2184,"activeCount":101},[],{"trials":2186,"activeCount":141,"soonestReadout":65},[2187],{"nctId":63,"briefTitle":64,"status":160,"phases":2188,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":2189,"interventions":2190},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":2192,"activeCount":101},[2193],{"nctId":2194,"briefTitle":2195,"status":617,"phases":2196,"primaryCompletion":2197,"completion":2197,"start":2198,"enrollment":101,"conditions":2199,"interventions":2201},"NCT02789397","Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency",[90],"2018-03-06","2016-05-02",[2200],"Granulomatous and Lymphocytic Interstitial Lung Disease",[422,2202],"Placebos",{"trials":2204,"activeCount":101},[],{"trials":2206,"activeCount":101},[],{"trials":2208,"activeCount":101},[],{"intervention":423,"totalTrials":97,"cells":2210},{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2219,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2212,"activeCount":101},[],{"trials":2214,"activeCount":141,"soonestReadout":65},[2215],{"nctId":63,"briefTitle":64,"status":160,"phases":2216,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":2217,"interventions":2218},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":2220,"activeCount":101},[2221],{"nctId":730,"briefTitle":731,"status":533,"phases":2222,"primaryCompletion":733,"completion":733,"start":734,"enrollment":33,"conditions":2223,"interventions":2224},[90],[736],[423,424],{"trials":2226,"activeCount":101},[],{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"intervention":440,"totalTrials":97,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2241,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2234,"activeCount":101},[],{"trials":2236,"activeCount":141,"soonestReadout":432},[2237],{"nctId":429,"briefTitle":430,"status":188,"phases":2238,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":2239,"interventions":2240},[89],[436,437],[439,406,440,441],{"trials":2242,"activeCount":101},[2243],{"nctId":1049,"briefTitle":1050,"status":113,"phases":2244,"primaryCompletion":1052,"completion":1053,"start":744,"enrollment":872,"conditions":2245,"interventions":2246},[90],[1055],[440,529,528],{"trials":2248,"activeCount":101},[],{"trials":2250,"activeCount":101},[],{"trials":2252,"activeCount":101},[],{"intervention":1997,"totalTrials":97,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2256,"activeCount":101},[],{"trials":2258,"activeCount":141,"soonestReadout":1008},[2259,2263],{"nctId":1989,"briefTitle":1990,"status":126,"phases":2260,"primaryCompletion":1008,"completion":1008,"start":1992,"enrollment":515,"conditions":2261,"interventions":2262},[89],[1994,1995],[1997,1998,1999,2000,467,2001],{"nctId":2264,"briefTitle":2265,"status":533,"phases":2266,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":2270,"conditions":2271,"interventions":2272},"NCT04172844","Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia",[89],"2021-12-12","2022-02-27","2020-01-13",16,[582],[2273,1997,2274],"Azacitidine","Pevonedistat",{"trials":2276,"activeCount":101},[],{"trials":2278,"activeCount":101},[],{"trials":2280,"activeCount":101},[],{"trials":2282,"activeCount":101},[],{"intervention":425,"totalTrials":141,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":101},[],{"trials":2288,"activeCount":141,"soonestReadout":65},[2289],{"nctId":63,"briefTitle":64,"status":160,"phases":2290,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":2291,"interventions":2292},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":2294,"activeCount":101},[],{"trials":2296,"activeCount":101},[],{"trials":2298,"activeCount":101},[],{"trials":2300,"activeCount":101},[],{"intervention":426,"totalTrials":141,"cells":2302},{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":141,"soonestReadout":65},[2307],{"nctId":63,"briefTitle":64,"status":160,"phases":2308,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":2309,"interventions":2310},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[],{"trials":2316,"activeCount":101},[],{"trials":2318,"activeCount":101},[],{"intervention":427,"totalTrials":141,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":141,"soonestReadout":65},[2325],{"nctId":63,"briefTitle":64,"status":160,"phases":2326,"primaryCompletion":65,"completion":414,"start":415,"enrollment":416,"conditions":2327,"interventions":2328},[89],[418,419],[66,421,406,422,423,424,425,426,427],{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":101},[],{"trials":2334,"activeCount":101},[],{"trials":2336,"activeCount":101},[],{"intervention":439,"totalTrials":141,"cells":2338},{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":141,"soonestReadout":432},[2343],{"nctId":429,"briefTitle":430,"status":188,"phases":2344,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":2345,"interventions":2346},[89],[436,437],[439,406,440,441],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[],{"trials":2352,"activeCount":101},[],{"trials":2354,"activeCount":101},[],{"intervention":441,"totalTrials":141,"cells":2356},{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2358,"activeCount":101},[],{"trials":2360,"activeCount":141,"soonestReadout":432},[2361],{"nctId":429,"briefTitle":430,"status":188,"phases":2362,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":2363,"interventions":2364},[89],[436,437],[439,406,440,441],{"trials":2366,"activeCount":101},[],{"trials":2368,"activeCount":101},[],{"trials":2370,"activeCount":101},[],{"trials":2372,"activeCount":101},[],{"intervention":86,"totalTrials":141,"cells":2374},{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2376,"activeCount":101},[],{"trials":2378,"activeCount":141,"soonestReadout":85},[2379],{"nctId":83,"briefTitle":84,"status":160,"phases":2380,"primaryCompletion":85,"completion":2381,"start":2382,"enrollment":912,"conditions":2383,"interventions":2385},[89],"2033-05-01","2020-04-29",[2384],"Hemophilia A",[86],{"trials":2387,"activeCount":101},[],{"trials":2389,"activeCount":101},[],{"trials":2391,"activeCount":101},[],{"trials":2393,"activeCount":101},[],{"intervention":2395,"totalTrials":141,"cells":2396},"anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells",{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2398,"activeCount":101},[],{"trials":2400,"activeCount":141,"soonestReadout":1009},[2401],{"nctId":2402,"briefTitle":2403,"status":126,"phases":2404,"primaryCompletion":1009,"completion":1135,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2414},"NCT05544968","Anti-CD30 biAb-AATC in Patients With Relapsed\u002FRefractory CD30 Positive Hematopoietic Malignancies",[89],"2026-03-04",42,[2408,2409,2410,2411,2412,2413,29],"Hodgkin Disease","CD30-Positive Diffuse Large B-Cell Lymphoma","CD30+ Anaplastic Large Cell Lymphoma","CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma","CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma","Leukemia",[2395,2415],"GM-CSF",{"trials":2417,"activeCount":101},[],{"trials":2419,"activeCount":101},[],{"trials":2421,"activeCount":101},[],{"trials":2423,"activeCount":101},[],{"intervention":2415,"totalTrials":141,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2434,"PHASE3":2436,"PHASE4":2438,"NA":2440},{"trials":2427,"activeCount":101},[],{"trials":2429,"activeCount":141,"soonestReadout":1009},[2430],{"nctId":2402,"briefTitle":2403,"status":126,"phases":2431,"primaryCompletion":1009,"completion":1135,"start":2405,"enrollment":2406,"conditions":2432,"interventions":2433},[89],[2408,2409,2410,2411,2412,2413,29],[2395,2415],{"trials":2435,"activeCount":101},[],{"trials":2437,"activeCount":101},[],{"trials":2439,"activeCount":101},[],{"trials":2441,"activeCount":101},[],{"intervention":2443,"totalTrials":141,"cells":2444},"Azacitidine Level -1",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2461,"PHASE3":2463,"PHASE4":2465,"NA":2467},{"trials":2446,"activeCount":101},[],{"trials":2448,"activeCount":141,"soonestReadout":1537},[2449],{"nctId":2450,"briefTitle":2451,"status":126,"phases":2452,"primaryCompletion":1537,"completion":1659,"start":2453,"enrollment":22,"conditions":2454,"interventions":2455},"NCT06502145","Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome",[89],"2025-01-10",[905],[2443,2456,2457,2458,2459,2460],"Azacitidine Level 0","Azacitidine Level 1","Iadademstat Level -1","Iadademstat Level 0","Iadademstat Level 1",{"trials":2462,"activeCount":101},[],{"trials":2464,"activeCount":101},[],{"trials":2466,"activeCount":101},[],{"trials":2468,"activeCount":101},[],{"intervention":2456,"totalTrials":141,"cells":2470},{"EARLY_PHASE1":2471,"PHASE1":2473,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2472,"activeCount":101},[],{"trials":2474,"activeCount":141,"soonestReadout":1537},[2475],{"nctId":2450,"briefTitle":2451,"status":126,"phases":2476,"primaryCompletion":1537,"completion":1659,"start":2453,"enrollment":22,"conditions":2477,"interventions":2478},[89],[905],[2443,2456,2457,2458,2459,2460],{"trials":2480,"activeCount":101},[],{"trials":2482,"activeCount":101},[],{"trials":2484,"activeCount":101},[],{"trials":2486,"activeCount":101},[],{"intervention":2457,"totalTrials":141,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2490,"activeCount":101},[],{"trials":2492,"activeCount":141,"soonestReadout":1537},[2493],{"nctId":2450,"briefTitle":2451,"status":126,"phases":2494,"primaryCompletion":1537,"completion":1659,"start":2453,"enrollment":22,"conditions":2495,"interventions":2496},[89],[905],[2443,2456,2457,2458,2459,2460],{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[],{"trials":2502,"activeCount":101},[],{"trials":2504,"activeCount":101},[],{"intervention":2458,"totalTrials":141,"cells":2506},{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2508,"activeCount":101},[],{"trials":2510,"activeCount":141,"soonestReadout":1537},[2511],{"nctId":2450,"briefTitle":2451,"status":126,"phases":2512,"primaryCompletion":1537,"completion":1659,"start":2453,"enrollment":22,"conditions":2513,"interventions":2514},[89],[905],[2443,2456,2457,2458,2459,2460],{"trials":2516,"activeCount":101},[],{"trials":2518,"activeCount":101},[],{"trials":2520,"activeCount":101},[],{"trials":2522,"activeCount":101},[],{"intervention":2459,"totalTrials":141,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2533,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":101},[],{"trials":2528,"activeCount":141,"soonestReadout":1537},[2529],{"nctId":2450,"briefTitle":2451,"status":126,"phases":2530,"primaryCompletion":1537,"completion":1659,"start":2453,"enrollment":22,"conditions":2531,"interventions":2532},[89],[905],[2443,2456,2457,2458,2459,2460],{"trials":2534,"activeCount":101},[],{"trials":2536,"activeCount":101},[],{"trials":2538,"activeCount":101},[],{"trials":2540,"activeCount":101},[],{"intervention":2460,"totalTrials":141,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2551,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2544,"activeCount":101},[],{"trials":2546,"activeCount":141,"soonestReadout":1537},[2547],{"nctId":2450,"briefTitle":2451,"status":126,"phases":2548,"primaryCompletion":1537,"completion":1659,"start":2453,"enrollment":22,"conditions":2549,"interventions":2550},[89],[905],[2443,2456,2457,2458,2459,2460],{"trials":2552,"activeCount":101},[],{"trials":2554,"activeCount":101},[],{"trials":2556,"activeCount":101},[],{"trials":2558,"activeCount":101},[],{"intervention":2560,"totalTrials":141,"cells":2561},"Pirtobrutinib",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2577,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2563,"activeCount":101},[],{"trials":2565,"activeCount":141,"soonestReadout":473},[2566],{"nctId":2567,"briefTitle":2568,"status":126,"phases":2569,"primaryCompletion":473,"completion":2570,"start":2571,"enrollment":22,"conditions":2572,"interventions":2575},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[89],"2027-07","2025-02-06",[2573,1865,1863,1864,2574,419],"Non Hodgkin Lymphoma","Mantle Cell Lymphoma",[2560,2576],"LV20.19 CAR T cells",{"trials":2578,"activeCount":101},[],{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[],{"trials":2584,"activeCount":101},[],{"intervention":2576,"totalTrials":141,"cells":2586},{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2595,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2588,"activeCount":101},[],{"trials":2590,"activeCount":141,"soonestReadout":473},[2591],{"nctId":2567,"briefTitle":2568,"status":126,"phases":2592,"primaryCompletion":473,"completion":2570,"start":2571,"enrollment":22,"conditions":2593,"interventions":2594},[89],[2573,1865,1863,1864,2574,419],[2560,2576],{"trials":2596,"activeCount":101},[],{"trials":2598,"activeCount":101},[],{"trials":2600,"activeCount":101},[],{"trials":2602,"activeCount":101},[],{"intervention":2604,"totalTrials":141,"cells":2605},"FT836 CAR T cells",{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2625},{"trials":2607,"activeCount":101},[],{"trials":2609,"activeCount":141,"soonestReadout":2614},[2610],{"nctId":2611,"briefTitle":2612,"status":188,"phases":2613,"primaryCompletion":2614,"completion":2615,"start":473,"enrollment":22,"conditions":2616,"interventions":2617},"NCT07221032","FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[89],"2028-03","2030-03",[624,623],[2604,2604,2604,2618],"Daratumumab 16 mg\u002Fkg",{"trials":2620,"activeCount":101},[],{"trials":2622,"activeCount":101},[],{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[],{"intervention":2618,"totalTrials":141,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2637,"PHASE3":2639,"PHASE4":2641,"NA":2643},{"trials":2630,"activeCount":101},[],{"trials":2632,"activeCount":141,"soonestReadout":2614},[2633],{"nctId":2611,"briefTitle":2612,"status":188,"phases":2634,"primaryCompletion":2614,"completion":2615,"start":473,"enrollment":22,"conditions":2635,"interventions":2636},[89],[624,623],[2604,2604,2604,2618],{"trials":2638,"activeCount":101},[],{"trials":2640,"activeCount":101},[],{"trials":2642,"activeCount":101},[],{"trials":2644,"activeCount":101},[],{"intervention":1998,"totalTrials":141,"cells":2646},{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2655,"PHASE3":2657,"PHASE4":2659,"NA":2661},{"trials":2648,"activeCount":101},[],{"trials":2650,"activeCount":141,"soonestReadout":1008},[2651],{"nctId":1989,"briefTitle":1990,"status":126,"phases":2652,"primaryCompletion":1008,"completion":1008,"start":1992,"enrollment":515,"conditions":2653,"interventions":2654},[89],[1994,1995],[1997,1998,1999,2000,467,2001],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":101},[],{"trials":2660,"activeCount":101},[],{"trials":2662,"activeCount":101},[],{"intervention":1999,"totalTrials":141,"cells":2664},{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2673,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2666,"activeCount":101},[],{"trials":2668,"activeCount":141,"soonestReadout":1008},[2669],{"nctId":1989,"briefTitle":1990,"status":126,"phases":2670,"primaryCompletion":1008,"completion":1008,"start":1992,"enrollment":515,"conditions":2671,"interventions":2672},[89],[1994,1995],[1997,1998,1999,2000,467,2001],{"trials":2674,"activeCount":101},[],{"trials":2676,"activeCount":101},[],{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"intervention":2682,"totalTrials":141,"cells":2683},"Capecitabine",{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2699,"PHASE3":2701,"PHASE4":2703,"NA":2705},{"trials":2685,"activeCount":101},[],{"trials":2687,"activeCount":141,"soonestReadout":2692},[2688],{"nctId":2689,"briefTitle":2690,"status":126,"phases":2691,"primaryCompletion":2692,"completion":2693,"start":2694,"enrollment":193,"conditions":2695,"interventions":2697},"NCT04808323","MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer",[89],"2027-04-14","2029-01-20","2021-06-17",[2696],"Rectal Adenocarcinoma",[2682,2698],"FOLFOX",{"trials":2700,"activeCount":101},[],{"trials":2702,"activeCount":101},[],{"trials":2704,"activeCount":101},[],{"trials":2706,"activeCount":101},[],{"intervention":2698,"totalTrials":141,"cells":2708},{"EARLY_PHASE1":2709,"PHASE1":2711,"PHASE2":2717,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2710,"activeCount":101},[],{"trials":2712,"activeCount":141,"soonestReadout":2692},[2713],{"nctId":2689,"briefTitle":2690,"status":126,"phases":2714,"primaryCompletion":2692,"completion":2693,"start":2694,"enrollment":193,"conditions":2715,"interventions":2716},[89],[2696],[2682,2698],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[],{"trials":2722,"activeCount":101},[],{"trials":2724,"activeCount":101},[],{"intervention":2726,"totalTrials":141,"cells":2727},"BCMA-TGFβ CAR-T cells",{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2729,"activeCount":101},[],{"trials":2731,"activeCount":141,"soonestReadout":128},[2732],{"nctId":2733,"briefTitle":2734,"status":188,"phases":2735,"primaryCompletion":128,"completion":1831,"start":1113,"enrollment":165,"conditions":2736,"interventions":2737},"NCT05976555","Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma",[89],[21],[2726,2726,2726,2726,2738],"Maximum tolerated dose",{"trials":2740,"activeCount":101},[],{"trials":2742,"activeCount":101},[],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[],{"intervention":2738,"totalTrials":141,"cells":2748},{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2750,"activeCount":101},[],{"trials":2752,"activeCount":141,"soonestReadout":128},[2753],{"nctId":2733,"briefTitle":2734,"status":188,"phases":2754,"primaryCompletion":128,"completion":1831,"start":1113,"enrollment":165,"conditions":2755,"interventions":2756},[89],[21],[2726,2726,2726,2726,2738],{"trials":2758,"activeCount":101},[],{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"intervention":2766,"totalTrials":141,"cells":2767},"Talquetamab",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2769,"activeCount":101},[],{"trials":2771,"activeCount":141,"soonestReadout":2776},[2772],{"nctId":2773,"briefTitle":2774,"status":126,"phases":2775,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":451,"conditions":2779,"interventions":2780},"NCT07093554","Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed\u002FRefractory Multiple Myeloma",[89],"2027-07-01","2028-01-01","2025-12-02",[624,623],[2766,2781],"Ciltacabtagene Autoleucel",{"trials":2783,"activeCount":101},[],{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"intervention":2781,"totalTrials":141,"cells":2791},{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2800,"PHASE3":2802,"PHASE4":2804,"NA":2806},{"trials":2793,"activeCount":101},[],{"trials":2795,"activeCount":141,"soonestReadout":2776},[2796],{"nctId":2773,"briefTitle":2774,"status":126,"phases":2797,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":451,"conditions":2798,"interventions":2799},[89],[624,623],[2766,2781],{"trials":2801,"activeCount":101},[],{"trials":2803,"activeCount":101},[],{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[],{"intervention":2809,"totalTrials":141,"cells":2810},"1 X 10^6 cells\u002Fkg",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":141,"soonestReadout":2819},[2815],{"nctId":2816,"briefTitle":2817,"status":188,"phases":2818,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2823,"interventions":2825},"NCT07335328","Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and\u002For Refractory B Cell Malignancies",[89],"2027-05-01","2031-05-01","2026-05-01",24,[2824],"B-cell Non Hodgkin Lymphoma",[2809,2826,2827],"2.5 X 10^6 cells\u002Fkg","Dose expansion: The maximum tolerated dose of CAR-T cells",{"trials":2829,"activeCount":101},[],{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"trials":2835,"activeCount":101},[],{"intervention":2826,"totalTrials":141,"cells":2837},{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2839,"activeCount":101},[],{"trials":2841,"activeCount":141,"soonestReadout":2819},[2842],{"nctId":2816,"briefTitle":2817,"status":188,"phases":2843,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2844,"interventions":2845},[89],[2824],[2809,2826,2827],{"trials":2847,"activeCount":101},[],{"trials":2849,"activeCount":101},[],{"trials":2851,"activeCount":101},[],{"trials":2853,"activeCount":101},[],{"intervention":2827,"totalTrials":141,"cells":2855},{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2864,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":141,"soonestReadout":2819},[2860],{"nctId":2816,"briefTitle":2817,"status":188,"phases":2861,"primaryCompletion":2819,"completion":2820,"start":2821,"enrollment":2822,"conditions":2862,"interventions":2863},[89],[2824],[2809,2826,2827],{"trials":2865,"activeCount":101},[],{"trials":2867,"activeCount":101},[],{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"intervention":2873,"totalTrials":141,"cells":2874},"Ursodiol 500 MG",{"EARLY_PHASE1":2875,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2876,"activeCount":141,"soonestReadout":2819},[2877],{"nctId":2878,"briefTitle":2879,"status":188,"phases":2880,"primaryCompletion":2819,"completion":2881,"start":2821,"enrollment":165,"conditions":2882,"interventions":2884},"NCT06884748","Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy",[88],"2028-05-01",[2883],"Clostridioides Difficile Infection",[2873],{"trials":2886,"activeCount":101},[],{"trials":2888,"activeCount":101},[],{"trials":2890,"activeCount":101},[],{"trials":2892,"activeCount":101},[],{"trials":2894,"activeCount":101},[],{"intervention":2896,"totalTrials":141,"cells":2897},"Trehalose",{"EARLY_PHASE1":2898,"PHASE1":2909,"PHASE2":2911,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2899,"activeCount":141,"soonestReadout":162},[2900],{"nctId":2901,"briefTitle":2902,"status":126,"phases":2903,"primaryCompletion":162,"completion":1442,"start":2904,"enrollment":363,"conditions":2905,"interventions":2908},"NCT05593549","Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction",[88],"2023-01-01",[2906,2907],"Type 2 Diabetes","Healthy Aging",[2896],{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[],{"trials":2914,"activeCount":101},[],{"trials":2916,"activeCount":101},[],{"trials":2918,"activeCount":101},[],{"intervention":2920,"totalTrials":141,"cells":2921},"Regional Anesthesia",{"EARLY_PHASE1":2922,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2940,"NA":2942},{"trials":2923,"activeCount":141,"soonestReadout":2928},[2924],{"nctId":2925,"briefTitle":2926,"status":126,"phases":2927,"primaryCompletion":2928,"completion":1926,"start":2929,"enrollment":434,"conditions":2930,"interventions":2932},"NCT06617949","Evaluating Pain Control Strategies in Postpartum Patients on Opioid Use Disorder Medications.",[88],"2027-12","2025-01-16",[2931],"Substance Use Disorder (SUD)",[2920,2933],"Hydromorphone Patient Controlled Analgelsic",{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[],{"trials":2939,"activeCount":101},[],{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"intervention":2933,"totalTrials":141,"cells":2945},{"EARLY_PHASE1":2946,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2947,"activeCount":141,"soonestReadout":2928},[2948],{"nctId":2925,"briefTitle":2926,"status":126,"phases":2949,"primaryCompletion":2928,"completion":1926,"start":2929,"enrollment":434,"conditions":2950,"interventions":2951},[88],[2931],[2920,2933],{"trials":2953,"activeCount":101},[],{"trials":2955,"activeCount":101},[],{"trials":2957,"activeCount":101},[],{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[],{"intervention":2963,"totalTrials":141,"cells":2964},"Metformin",{"EARLY_PHASE1":2965,"PHASE1":2977,"PHASE2":2979,"PHASE3":2981,"PHASE4":2983,"NA":2985},{"trials":2966,"activeCount":141,"soonestReadout":2971},[2967],{"nctId":2968,"briefTitle":2969,"status":126,"phases":2970,"primaryCompletion":2971,"completion":2972,"start":2973,"enrollment":515,"conditions":2974,"interventions":2976},"NCT07120971","Metformin for Premature Infants With Bronchopulmonary Dysplasia",[88],"2028-09-01","2030-09-01","2025-12-19",[2975],"Bronchopulmonary Dysplasia (BPD)",[2963,2963,2963,2963,2963,2963,2963,2963,2963],{"trials":2978,"activeCount":101},[],{"trials":2980,"activeCount":101},[],{"trials":2982,"activeCount":101},[],{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"intervention":2988,"totalTrials":141,"cells":2989},"gene variations",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2991,"activeCount":101},[],{"trials":2993,"activeCount":101},[],{"trials":2995,"activeCount":101},[],{"trials":2997,"activeCount":101},[],{"trials":2999,"activeCount":101},[],{"trials":3001,"activeCount":141,"soonestReadout":1468},[3002],{"nctId":3003,"briefTitle":3004,"status":126,"phases":3005,"primaryCompletion":1468,"completion":448,"start":3006,"enrollment":3007,"conditions":3008,"interventions":3010},"NCT00710112","Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants",[],"2006-06",1100,[3009],"Chronic Lung Disease",[2988],{"intervention":3012,"totalTrials":141,"cells":3013},"Substudy only: Maternal\u002FInfant Pharmacogenomic assessment postnatally",{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":101},[],{"trials":3019,"activeCount":101},[],{"trials":3021,"activeCount":101},[],{"trials":3023,"activeCount":101},[],{"trials":3025,"activeCount":141,"soonestReadout":3030},[3026],{"nctId":3027,"briefTitle":3028,"status":126,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":165,"conditions":3032,"interventions":3052},"NCT03775954","Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise",[],"2028-11-30","2018-07-01",[3033,3034,3035,3036,3037,3038,3039,3040,3041,3042,3043,3044,3045,3046,3047,3048,3049,3050,3051],"High Risk Pregnancy","Congenital Heart Disease","Fetal Hydrops","Twin Monochorionic Monoamniotic Placenta","Gastroschisis","Fetal Demise","Stillbirth","Fetal Arrhythmia","Long QT Syndrome","Intrauterine Fetal Death","Sudden Infant Death","Pregnancy Loss","Twin Twin Transfusion Syndrome","Birth Defect","Fetal Cardiac Anomaly","Fetal Cardiac Disorder","Fetal Death","Brugada Syndrome","Fetal Tachycardia",[3012],{"intervention":3054,"totalTrials":141,"cells":3055},"GLP-1 receptor agonist",{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3057,"activeCount":101},[],{"trials":3059,"activeCount":101},[],{"trials":3061,"activeCount":101},[],{"trials":3063,"activeCount":101},[],{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":141,"soonestReadout":1926},[3068],{"nctId":3069,"briefTitle":3070,"status":188,"phases":3071,"primaryCompletion":1926,"completion":1926,"start":473,"enrollment":165,"conditions":3072,"interventions":3075},"NCT06982378","GLP-1 RA on Liver OMICS in MASLD",[],[3073,3074,32],"NAFLD","Diabetes",[3054],{"intervention":3077,"totalTrials":141,"cells":3078},"Nω-nitro-L-arginine methyl ester",{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3085,"PHASE4":3087,"NA":3089},{"trials":3080,"activeCount":101},[],{"trials":3082,"activeCount":101},[],{"trials":3084,"activeCount":101},[],{"trials":3086,"activeCount":101},[],{"trials":3088,"activeCount":101},[],{"trials":3090,"activeCount":141,"soonestReadout":3095},[3091],{"nctId":3092,"briefTitle":3093,"status":160,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3097,"conditions":3098,"interventions":3102},"NCT06043310","Estrogen and Microvascular Function",[],"2031-12","2023-10-12",45,[3099,27,3100,3101],"Estrogen","Microvasculature","Oral Contraceptive Use",[3077,3103,3104],"Acetylcholine","Sodium Nitroprusside",{"intervention":3103,"totalTrials":141,"cells":3106},{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3117},{"trials":3108,"activeCount":101},[],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":141,"soonestReadout":3095},[3119],{"nctId":3092,"briefTitle":3093,"status":160,"phases":3120,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3097,"conditions":3121,"interventions":3122},[],[3099,27,3100,3101],[3077,3103,3104],{"intervention":3104,"totalTrials":141,"cells":3124},{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3131,"PHASE4":3133,"NA":3135},{"trials":3126,"activeCount":101},[],{"trials":3128,"activeCount":101},[],{"trials":3130,"activeCount":101},[],{"trials":3132,"activeCount":101},[],{"trials":3134,"activeCount":101},[],{"trials":3136,"activeCount":141,"soonestReadout":3095},[3137],{"nctId":3092,"briefTitle":3093,"status":160,"phases":3138,"primaryCompletion":3095,"completion":3095,"start":3096,"enrollment":3097,"conditions":3139,"interventions":3140},[],[3099,27,3100,3101],[3077,3103,3104],{"intervention":3142,"totalTrials":654,"cells":3143},"Vancomycin Oral",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3158,"PHASE3":3171,"PHASE4":3173,"NA":3185},{"trials":3145,"activeCount":101},[],{"trials":3147,"activeCount":101},[3148],{"nctId":3149,"briefTitle":3150,"status":113,"phases":3151,"primaryCompletion":1104,"completion":3152,"start":3153,"enrollment":3154,"conditions":3155,"interventions":3157},"NCT03827447","Vancomycin for the Treatment of NAAT(+)\u002FToxin(-) C. Difficile",[89],"2021-06-30","2019-07-17",7,[3156],"Clostridium Difficile Infection",[3142],{"trials":3159,"activeCount":101},[3160],{"nctId":3161,"briefTitle":3162,"status":113,"phases":3163,"primaryCompletion":3164,"completion":3164,"start":3165,"enrollment":30,"conditions":3166,"interventions":3170},"NCT03030248","Vancomycin for C Difficile NAAT+\u002FEIA- Hematology Oncology Patients",[90],"2020-06-30","2018-06-01",[3156,3167,3168,3169],"Hematologic Diseases","Bone Marrow Transplant","Oncologic Disorders",[3142],{"trials":3172,"activeCount":101},[],{"trials":3174,"activeCount":101},[3175],{"nctId":3176,"briefTitle":3177,"status":113,"phases":3178,"primaryCompletion":3179,"completion":3179,"start":935,"enrollment":3180,"conditions":3181,"interventions":3183},"NCT01952834","Effect of Probiotic Supplementation on Endothelial Function",[92],"2015-03",21,[3182],"Coronary Artery Disease",[3184],"Vancomycin",{"trials":3186,"activeCount":101},[],{"intervention":3188,"totalTrials":97,"cells":3189},"Cyproheptadine",{"EARLY_PHASE1":3190,"PHASE1":3201,"PHASE2":3203,"PHASE3":3205,"PHASE4":3207,"NA":3218},{"trials":3191,"activeCount":101},[3192],{"nctId":3193,"briefTitle":3194,"status":113,"phases":3195,"primaryCompletion":2143,"completion":2143,"start":3196,"enrollment":3197,"conditions":3198,"interventions":3199},"NCT01688570","Mechanisms of Neuromuscular Fatigue Post Stroke",[88],"2011-08",27,[18],[3200,3188],"duloxetine",{"trials":3202,"activeCount":101},[],{"trials":3204,"activeCount":101},[],{"trials":3206,"activeCount":101},[],{"trials":3208,"activeCount":101},[3209],{"nctId":3210,"briefTitle":3211,"status":533,"phases":3212,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":570,"conditions":3215,"interventions":3217},"NCT02568007","Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders",[92],"2016-08","2015-12",[3216],"Feeding Behaviors",[3188],{"trials":3219,"activeCount":101},[],{"intervention":3221,"totalTrials":97,"cells":3222},"Acetaminophen",{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3227,"PHASE3":3229,"PHASE4":3231,"NA":3260},{"trials":3224,"activeCount":101},[],{"trials":3226,"activeCount":101},[],{"trials":3228,"activeCount":101},[],{"trials":3230,"activeCount":101},[],{"trials":3232,"activeCount":101},[3233,3248],{"nctId":3234,"briefTitle":3235,"status":113,"phases":3236,"primaryCompletion":3237,"completion":3237,"start":2040,"enrollment":3238,"conditions":3239,"interventions":3242},"NCT02432456","Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients",[92],"2018-08",153,[3240,3241],"Wounds and Injuries","Rib Fractures",[3243,3221,3244,3245,3246,3247],"Ketamine","Ibuprofen","Pantoprazole","Methocarbamol","Opioid",{"nctId":3249,"briefTitle":3250,"status":617,"phases":3251,"primaryCompletion":3252,"completion":3237,"start":3253,"enrollment":101,"conditions":3254,"interventions":3258},"NCT02785003","Ketamine in Colorectal Surgery",[92],"2017-08","2016-07",[3255,3256,3257],"Acute Pain","Pain, Postoperative","Colorectal Surgery",[3243,3221,3247,3259],"Alvimopan",{"trials":3261,"activeCount":101},[],{"intervention":3247,"totalTrials":97,"cells":3263},{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3270,"PHASE4":3272,"NA":3282},{"trials":3265,"activeCount":101},[],{"trials":3267,"activeCount":101},[],{"trials":3269,"activeCount":101},[],{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":101},[3274,3278],{"nctId":3234,"briefTitle":3235,"status":113,"phases":3275,"primaryCompletion":3237,"completion":3237,"start":2040,"enrollment":3238,"conditions":3276,"interventions":3277},[92],[3240,3241],[3243,3221,3244,3245,3246,3247],{"nctId":3249,"briefTitle":3250,"status":617,"phases":3279,"primaryCompletion":3252,"completion":3237,"start":3253,"enrollment":101,"conditions":3280,"interventions":3281},[92],[3255,3256,3257],[3243,3221,3247,3259],{"trials":3283,"activeCount":101},[],{"intervention":3245,"totalTrials":141,"cells":3285},{"EARLY_PHASE1":3286,"PHASE1":3288,"PHASE2":3290,"PHASE3":3292,"PHASE4":3294,"NA":3300},{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":101},[],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[3296],{"nctId":3234,"briefTitle":3235,"status":113,"phases":3297,"primaryCompletion":3237,"completion":3237,"start":2040,"enrollment":3238,"conditions":3298,"interventions":3299},[92],[3240,3241],[3243,3221,3244,3245,3246,3247],{"trials":3301,"activeCount":101},[],{"intervention":3246,"totalTrials":141,"cells":3303},{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3310,"PHASE4":3312,"NA":3318},{"trials":3305,"activeCount":101},[],{"trials":3307,"activeCount":101},[],{"trials":3309,"activeCount":101},[],{"trials":3311,"activeCount":101},[],{"trials":3313,"activeCount":101},[3314],{"nctId":3234,"briefTitle":3235,"status":113,"phases":3315,"primaryCompletion":3237,"completion":3237,"start":2040,"enrollment":3238,"conditions":3316,"interventions":3317},[92],[3240,3241],[3243,3221,3244,3245,3246,3247],{"trials":3319,"activeCount":101},[],{"intervention":3321,"totalTrials":141,"cells":3322},"propofol",{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3329,"PHASE4":3331,"NA":3354},{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[],{"trials":3330,"activeCount":101},[],{"trials":3332,"activeCount":101},[3333],{"nctId":3334,"briefTitle":3335,"status":113,"phases":3336,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":515,"conditions":3340,"interventions":3348},"NCT03513757","Dexmedetomidine and Propofol for Pediatric MRI Sedation",[92],"2018-08-21","2018-10-21","2018-03-04",[3341,3342,3343,3344,3345,3346,3347],"Headache","Tumor","Seizure Disorder","Neurofibromatoses","Hydrocephalus","Abdominal Neoplasm","Spine Deformity",[3321,3349,3350,3351,3352,3353],"Dexmedetomidine","Glycopyrrolate","Lidocaine 1% Injectable Solution","Nitrous Oxide","Sevoflurane",{"trials":3355,"activeCount":101},[],{"intervention":3349,"totalTrials":141,"cells":3357},{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3362,"PHASE3":3364,"PHASE4":3366,"NA":3372},{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[3368],{"nctId":3334,"briefTitle":3335,"status":113,"phases":3369,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":515,"conditions":3370,"interventions":3371},[92],[3341,3342,3343,3344,3345,3346,3347],[3321,3349,3350,3351,3352,3353],{"trials":3373,"activeCount":101},[],{"intervention":3350,"totalTrials":141,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3382,"PHASE4":3384,"NA":3390},{"trials":3377,"activeCount":101},[],{"trials":3379,"activeCount":101},[],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[3386],{"nctId":3334,"briefTitle":3335,"status":113,"phases":3387,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":515,"conditions":3388,"interventions":3389},[92],[3341,3342,3343,3344,3345,3346,3347],[3321,3349,3350,3351,3352,3353],{"trials":3391,"activeCount":101},[],{"intervention":3351,"totalTrials":141,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3400,"PHASE4":3402,"NA":3408},{"trials":3395,"activeCount":101},[],{"trials":3397,"activeCount":101},[],{"trials":3399,"activeCount":101},[],{"trials":3401,"activeCount":101},[],{"trials":3403,"activeCount":101},[3404],{"nctId":3334,"briefTitle":3335,"status":113,"phases":3405,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":515,"conditions":3406,"interventions":3407},[92],[3341,3342,3343,3344,3345,3346,3347],[3321,3349,3350,3351,3352,3353],{"trials":3409,"activeCount":101},[],{"intervention":3352,"totalTrials":141,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3418,"PHASE4":3420,"NA":3426},{"trials":3413,"activeCount":101},[],{"trials":3415,"activeCount":101},[],{"trials":3417,"activeCount":101},[],{"trials":3419,"activeCount":101},[],{"trials":3421,"activeCount":101},[3422],{"nctId":3334,"briefTitle":3335,"status":113,"phases":3423,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":515,"conditions":3424,"interventions":3425},[92],[3341,3342,3343,3344,3345,3346,3347],[3321,3349,3350,3351,3352,3353],{"trials":3427,"activeCount":101},[],{"intervention":3353,"totalTrials":141,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3444},{"trials":3431,"activeCount":101},[],{"trials":3433,"activeCount":101},[],{"trials":3435,"activeCount":101},[],{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[3440],{"nctId":3334,"briefTitle":3335,"status":113,"phases":3441,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":515,"conditions":3442,"interventions":3443},[92],[3341,3342,3343,3344,3345,3346,3347],[3321,3349,3350,3351,3352,3353],{"trials":3445,"activeCount":101},[],{"intervention":3447,"totalTrials":141,"cells":3448},"CPX-351",{"EARLY_PHASE1":3449,"PHASE1":3451,"PHASE2":3453,"PHASE3":3455,"PHASE4":3457,"NA":3469},{"trials":3450,"activeCount":101},[],{"trials":3452,"activeCount":101},[],{"trials":3454,"activeCount":101},[],{"trials":3456,"activeCount":101},[],{"trials":3458,"activeCount":101},[3459],{"nctId":3460,"briefTitle":3461,"status":533,"phases":3462,"primaryCompletion":3463,"completion":3464,"start":3465,"enrollment":654,"conditions":3466,"interventions":3468},"NCT03988205","Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia",[92],"2021-12-01","2022-04-01","2019-08-28",[3467],"Leukemia, Myeloid, Acute",[3447],{"trials":3470,"activeCount":101},[],{"intervention":3472,"totalTrials":141,"cells":3473},"Patient-controlled analgesia",{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3494},{"trials":3475,"activeCount":101},[],{"trials":3477,"activeCount":101},[],{"trials":3479,"activeCount":101},[],{"trials":3481,"activeCount":101},[],{"trials":3483,"activeCount":101},[3484],{"nctId":3485,"briefTitle":3486,"status":113,"phases":3487,"primaryCompletion":3488,"completion":1271,"start":3489,"enrollment":3490,"conditions":3491,"interventions":3493},"NCT05144828","Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection",[92],"2024-10-04","2022-02-15",33,[3256,3492],"Lung Diseases",[3472],{"trials":3495,"activeCount":101},[],{"intervention":3497,"totalTrials":141,"cells":3498},"Ziprasidone",{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3507,"NA":3521},{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":101},[],{"trials":3504,"activeCount":101},[],{"trials":3506,"activeCount":101},[],{"trials":3508,"activeCount":101},[3509],{"nctId":3510,"briefTitle":3511,"status":113,"phases":3512,"completion":3513,"start":3514,"enrollment":434,"conditions":3515,"interventions":3520},"NCT00199940","Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness",[92],"2007-04","2003-12",[3516,3517,3518,3519],"Schizophrenia","Affective Disorders","Psychotic Disorder","Psychotic Mood Disorder",[3497],{"trials":3522,"activeCount":101},[],{"intervention":3524,"totalTrials":141,"cells":3525},"4% Lidocaine Patch",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3532,"PHASE4":3534,"NA":3544},{"trials":3527,"activeCount":101},[],{"trials":3529,"activeCount":101},[],{"trials":3531,"activeCount":101},[],{"trials":3533,"activeCount":101},[],{"trials":3535,"activeCount":101},[3536],{"nctId":3537,"briefTitle":3538,"status":533,"phases":3539,"primaryCompletion":3540,"completion":3540,"start":3541,"enrollment":912,"conditions":3542,"interventions":3543},"NCT05714631","Lidocaine Patches in Elderly Patients With Traumatic Rib Fractures",[92],"2024-08-01","2023-10-01",[3241],[3524],{"trials":3545,"activeCount":101},[],{"intervention":3547,"totalTrials":141,"cells":3548},"Divalproex sodium extended release",{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3567},{"trials":3550,"activeCount":101},[],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[],{"trials":3556,"activeCount":101},[],{"trials":3558,"activeCount":101},[3559],{"nctId":3560,"briefTitle":3561,"status":113,"phases":3562,"completion":3563,"start":3514,"enrollment":165,"conditions":3564,"interventions":3566},"NCT00199966","Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder",[92],"2005-11",[3565],"Bipolar Disorder",[3547],{"trials":3568,"activeCount":101},[],{"intervention":3570,"totalTrials":141,"cells":3571},"sitagliptin",{"EARLY_PHASE1":3572,"PHASE1":3574,"PHASE2":3576,"PHASE3":3578,"PHASE4":3580,"NA":3589},{"trials":3573,"activeCount":101},[],{"trials":3575,"activeCount":101},[],{"trials":3577,"activeCount":101},[],{"trials":3579,"activeCount":101},[],{"trials":3581,"activeCount":101},[3582],{"nctId":3583,"briefTitle":3584,"status":113,"phases":3585,"primaryCompletion":2041,"completion":3253,"start":935,"enrollment":776,"conditions":3586,"interventions":3588},"NCT01859793","Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy",[92],[3074,3587],"Atherosclerosis",[3570],{"trials":3590,"activeCount":101},[],{"intervention":3592,"totalTrials":141,"cells":3593},"Betamethasone",{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3600,"PHASE4":3602,"NA":3613},{"trials":3595,"activeCount":101},[],{"trials":3597,"activeCount":101},[],{"trials":3599,"activeCount":101},[],{"trials":3601,"activeCount":101},[],{"trials":3603,"activeCount":101},[3604],{"nctId":3605,"briefTitle":3606,"status":533,"phases":3607,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":2270,"conditions":3610,"interventions":3612},"NCT02038634","Ultrasound-guided Injection for DeQuervain's",[92],"2021-03-15","2014-08-05",[3611],"DeQuervain's Tenosynovitis",[3592],{"trials":3614,"activeCount":101},[],{"intervention":3616,"totalTrials":141,"cells":3617},"F18 Florbetapir (amyvid) cardiac PET\u002FCT imaging",{"EARLY_PHASE1":3618,"PHASE1":3620,"PHASE2":3622,"PHASE3":3624,"PHASE4":3626,"NA":3637},{"trials":3619,"activeCount":101},[],{"trials":3621,"activeCount":101},[],{"trials":3623,"activeCount":101},[],{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[3628],{"nctId":3629,"briefTitle":3630,"status":533,"phases":3631,"primaryCompletion":3632,"completion":3632,"start":3633,"enrollment":654,"conditions":3634,"interventions":3636},"NCT03333551","Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy",[92],"2023-05-08","2020-10-01",[3635],"Cardiac Amyloidosis",[3616],{"trials":3638,"activeCount":101},[],{"intervention":603,"totalTrials":570,"cells":3640},{"EARLY_PHASE1":3641,"PHASE1":3643,"PHASE2":3645,"PHASE3":3655,"PHASE4":3665,"NA":3667},{"trials":3642,"activeCount":101},[],{"trials":3644,"activeCount":101},[],{"trials":3646,"activeCount":101},[3647,3651],{"nctId":853,"briefTitle":854,"status":113,"phases":3648,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":3649,"interventions":3650},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"nctId":866,"briefTitle":867,"status":113,"phases":3652,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":3653,"interventions":3654},[90],[874],[480,603,876],{"trials":3656,"activeCount":101},[3657,3661],{"nctId":592,"briefTitle":593,"status":113,"phases":3658,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":3659,"interventions":3660},[91],[599,600,601,29],[480,603,480,481,406],{"nctId":894,"briefTitle":895,"status":113,"phases":3662,"primaryCompletion":897,"completion":898,"start":899,"enrollment":900,"conditions":3663,"interventions":3664},[91],[902,903,904,905],[480,603,749],{"trials":3666,"activeCount":101},[],{"trials":3668,"activeCount":101},[],{"intervention":749,"totalTrials":654,"cells":3670},{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3685,"PHASE4":3691,"NA":3693},{"trials":3672,"activeCount":101},[],{"trials":3674,"activeCount":101},[],{"trials":3676,"activeCount":101},[3677,3681],{"nctId":853,"briefTitle":854,"status":113,"phases":3678,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":3679,"interventions":3680},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"nctId":739,"briefTitle":740,"status":113,"phases":3682,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":3683,"interventions":3684},[90],[747],[749,424],{"trials":3686,"activeCount":101},[3687],{"nctId":894,"briefTitle":895,"status":113,"phases":3688,"primaryCompletion":897,"completion":898,"start":899,"enrollment":900,"conditions":3689,"interventions":3690},[91],[902,903,904,905],[480,603,749],{"trials":3692,"activeCount":101},[],{"trials":3694,"activeCount":101},[],{"intervention":3696,"totalTrials":654,"cells":3697},"GVHD prophylaxis",{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3729,"PHASE4":3735,"NA":3737},{"trials":3699,"activeCount":101},[],{"trials":3701,"activeCount":101},[],{"trials":3703,"activeCount":101},[3704,3719],{"nctId":3705,"briefTitle":3706,"status":113,"phases":3707,"primaryCompletion":3708,"completion":3709,"start":3710,"enrollment":3711,"conditions":3712,"interventions":3717},"NCT00849147","Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)",[90],"2011-06","2013-11","2008-10",55,[3713,3467,419,3714,3715,3716],"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","Lymphoma, B-Cell","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse",[3718,3696],"Haploidentical Bone Marrow Transplantation",{"nctId":3720,"briefTitle":3721,"status":113,"phases":3722,"primaryCompletion":3723,"completion":3709,"start":3724,"enrollment":3725,"conditions":3726,"interventions":3727},"NCT00864227","Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)",[90],"2011-04","2008-12",54,[3713,3467,419,3714,3715,3716],[3728,3696],"Hematopoietic Umbilical Cord Blood Stem Cell Transplantation",{"trials":3730,"activeCount":101},[3731],{"nctId":2079,"briefTitle":2080,"status":533,"phases":3732,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":165,"conditions":3733,"interventions":3734},[90,91],[2086,2087,2088,1863],[2090,2001,2091,2092,2093],{"trials":3736,"activeCount":101},[],{"trials":3738,"activeCount":101},[],{"intervention":3740,"totalTrials":97,"cells":3741},"Fludarabine and Busulfan",{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3760,"PHASE4":3772,"NA":3774},{"trials":3743,"activeCount":101},[],{"trials":3745,"activeCount":101},[],{"trials":3747,"activeCount":101},[3748],{"nctId":3749,"briefTitle":3750,"status":113,"phases":3751,"primaryCompletion":3752,"completion":3753,"start":3754,"enrollment":434,"conditions":3755,"interventions":3756},"NCT01410344","Allogeneic Transplant in HIV Patients (BMT CTN 0903)",[90],"2016-11","2018-06","2011-09",[2413,29,24],[3740,3757,3758,3759],"Fludarabine and Melphalan","Busulfan and Fludarabine","Cyclophosphamide and Total Body Irradiation",{"trials":3761,"activeCount":101},[3762],{"nctId":3763,"briefTitle":3764,"status":533,"phases":3765,"primaryCompletion":3766,"completion":3767,"start":3708,"enrollment":3768,"conditions":3769,"interventions":3770},"NCT01339910","Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)",[91],"2017-01-16","2017-10-16",272,[902],[3740,3757,3758,3771,3759],"Busulfan and Cyclophosphamide",{"trials":3773,"activeCount":101},[],{"trials":3775,"activeCount":101},[],{"intervention":3757,"totalTrials":97,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3788,"PHASE4":3794,"NA":3796},{"trials":3779,"activeCount":101},[],{"trials":3781,"activeCount":101},[],{"trials":3783,"activeCount":101},[3784],{"nctId":3749,"briefTitle":3750,"status":113,"phases":3785,"primaryCompletion":3752,"completion":3753,"start":3754,"enrollment":434,"conditions":3786,"interventions":3787},[90],[2413,29,24],[3740,3757,3758,3759],{"trials":3789,"activeCount":101},[3790],{"nctId":3763,"briefTitle":3764,"status":533,"phases":3791,"primaryCompletion":3766,"completion":3767,"start":3708,"enrollment":3768,"conditions":3792,"interventions":3793},[91],[902],[3740,3757,3758,3771,3759],{"trials":3795,"activeCount":101},[],{"trials":3797,"activeCount":101},[],{"intervention":3758,"totalTrials":97,"cells":3799},{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3804,"PHASE3":3810,"PHASE4":3816,"NA":3818},{"trials":3801,"activeCount":101},[],{"trials":3803,"activeCount":101},[],{"trials":3805,"activeCount":101},[3806],{"nctId":3749,"briefTitle":3750,"status":113,"phases":3807,"primaryCompletion":3752,"completion":3753,"start":3754,"enrollment":434,"conditions":3808,"interventions":3809},[90],[2413,29,24],[3740,3757,3758,3759],{"trials":3811,"activeCount":101},[3812],{"nctId":3763,"briefTitle":3764,"status":533,"phases":3813,"primaryCompletion":3766,"completion":3767,"start":3708,"enrollment":3768,"conditions":3814,"interventions":3815},[91],[902],[3740,3757,3758,3771,3759],{"trials":3817,"activeCount":101},[],{"trials":3819,"activeCount":101},[],{"intervention":3759,"totalTrials":97,"cells":3821},{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3826,"PHASE3":3832,"PHASE4":3838,"NA":3840},{"trials":3823,"activeCount":101},[],{"trials":3825,"activeCount":101},[],{"trials":3827,"activeCount":101},[3828],{"nctId":3749,"briefTitle":3750,"status":113,"phases":3829,"primaryCompletion":3752,"completion":3753,"start":3754,"enrollment":434,"conditions":3830,"interventions":3831},[90],[2413,29,24],[3740,3757,3758,3759],{"trials":3833,"activeCount":101},[3834],{"nctId":3763,"briefTitle":3764,"status":533,"phases":3835,"primaryCompletion":3766,"completion":3767,"start":3708,"enrollment":3768,"conditions":3836,"interventions":3837},[91],[902],[3740,3757,3758,3771,3759],{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":101},[],{"intervention":3843,"totalTrials":141,"cells":3844},"Vasopressin, Arginine",{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3849,"PHASE3":3851,"PHASE4":3864,"NA":3866},{"trials":3846,"activeCount":101},[],{"trials":3848,"activeCount":101},[],{"trials":3850,"activeCount":101},[],{"trials":3852,"activeCount":101},[3853],{"nctId":3854,"briefTitle":3855,"status":113,"phases":3856,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":434,"conditions":3860,"interventions":3863},"NCT03088345","Early Use of Vasopressin in Post-Fontan Management",[90,91],"2018-11-01","2019-01-28","2017-03-06",[3861,3034,3862],"Circulatory Perfusion Disorder","Single-ventricle",[3843],{"trials":3865,"activeCount":101},[],{"trials":3867,"activeCount":101},[],{"intervention":3869,"totalTrials":141,"cells":3870},"Caphosol",{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3875,"PHASE3":3877,"PHASE4":3888,"NA":3890},{"trials":3872,"activeCount":101},[],{"trials":3874,"activeCount":101},[],{"trials":3876,"activeCount":101},[],{"trials":3878,"activeCount":101},[3879],{"nctId":3880,"briefTitle":3881,"status":533,"phases":3882,"primaryCompletion":3883,"completion":3883,"start":744,"enrollment":141,"conditions":3884,"interventions":3886},"NCT02539342","Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy",[91],"2017-03-02",[3885],"Oral Mucositis",[3869,3887],"Biotene",{"trials":3889,"activeCount":101},[],{"trials":3891,"activeCount":101},[],{"intervention":3887,"totalTrials":141,"cells":3893},{"EARLY_PHASE1":3894,"PHASE1":3896,"PHASE2":3898,"PHASE3":3900,"PHASE4":3906,"NA":3908},{"trials":3895,"activeCount":101},[],{"trials":3897,"activeCount":101},[],{"trials":3899,"activeCount":101},[],{"trials":3901,"activeCount":101},[3902],{"nctId":3880,"briefTitle":3881,"status":533,"phases":3903,"primaryCompletion":3883,"completion":3883,"start":744,"enrollment":141,"conditions":3904,"interventions":3905},[91],[3885],[3869,3887],{"trials":3907,"activeCount":101},[],{"trials":3909,"activeCount":101},[],{"intervention":3911,"totalTrials":141,"cells":3912},"Haploidentical Bone Marrow Transplant",{"EARLY_PHASE1":3913,"PHASE1":3915,"PHASE2":3917,"PHASE3":3919,"PHASE4":3934,"NA":3936},{"trials":3914,"activeCount":101},[],{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[],{"trials":3920,"activeCount":101},[3921],{"nctId":3922,"briefTitle":3923,"status":113,"phases":3924,"primaryCompletion":3925,"completion":3925,"start":3926,"enrollment":3927,"conditions":3928,"interventions":3932},"NCT01597778","Double Cord Versus Haploidentical (BMT CTN 1101)",[91],"2020-09-11","2012-06",368,[583,582,3929,1863,3930,2574,3931],"Burkitt's Lymphoma","Hodgkin Lymphoma","Non-Hodgkin Lymphoma",[3911,3933],"Double Umbilical Cord Blood Transplant",{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[],{"intervention":3933,"totalTrials":141,"cells":3939},{"EARLY_PHASE1":3940,"PHASE1":3942,"PHASE2":3944,"PHASE3":3946,"PHASE4":3952,"NA":3954},{"trials":3941,"activeCount":101},[],{"trials":3943,"activeCount":101},[],{"trials":3945,"activeCount":101},[],{"trials":3947,"activeCount":101},[3948],{"nctId":3922,"briefTitle":3923,"status":113,"phases":3949,"primaryCompletion":3925,"completion":3925,"start":3926,"enrollment":3927,"conditions":3950,"interventions":3951},[91],[583,582,3929,1863,3930,2574,3931],[3911,3933],{"trials":3953,"activeCount":101},[],{"trials":3955,"activeCount":101},[],{"intervention":3957,"totalTrials":141,"cells":3958},"Fenoldopam",{"EARLY_PHASE1":3959,"PHASE1":3961,"PHASE2":3963,"PHASE3":3965,"PHASE4":3978,"NA":3980},{"trials":3960,"activeCount":101},[],{"trials":3962,"activeCount":101},[],{"trials":3964,"activeCount":101},[],{"trials":3966,"activeCount":101},[3967],{"nctId":3968,"briefTitle":3969,"status":533,"phases":3970,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":141,"conditions":3973,"interventions":3976},"NCT02620761","Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants",[90,91],"2020-01-31","2019-02-06",[3974,3975],"Patent Ductus Arteriosus (PDA)","Acute Kidney Injury (AKI)",[3957,3977],"0.9%NS",{"trials":3979,"activeCount":101},[],{"trials":3981,"activeCount":101},[],{"intervention":3977,"totalTrials":141,"cells":3983},{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":3988,"PHASE3":3990,"PHASE4":3996,"NA":3998},{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[3992],{"nctId":3968,"briefTitle":3969,"status":533,"phases":3993,"primaryCompletion":3971,"completion":3971,"start":3972,"enrollment":141,"conditions":3994,"interventions":3995},[90,91],[3974,3975],[3957,3977],{"trials":3997,"activeCount":101},[],{"trials":3999,"activeCount":101},[],{"intervention":3771,"totalTrials":141,"cells":4001},{"EARLY_PHASE1":4002,"PHASE1":4004,"PHASE2":4006,"PHASE3":4008,"PHASE4":4014,"NA":4016},{"trials":4003,"activeCount":101},[],{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[4010],{"nctId":3763,"briefTitle":3764,"status":533,"phases":4011,"primaryCompletion":3766,"completion":3767,"start":3708,"enrollment":3768,"conditions":4012,"interventions":4013},[91],[902],[3740,3757,3758,3771,3759],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[],{"intervention":588,"totalTrials":141,"cells":4019},{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4032,"NA":4034},{"trials":4021,"activeCount":101},[],{"trials":4023,"activeCount":101},[],{"trials":4025,"activeCount":101},[],{"trials":4027,"activeCount":101},[4028],{"nctId":574,"briefTitle":575,"status":113,"phases":4029,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":4030,"interventions":4031},[91],[582,583,584,585,586],[588,589,406,467,590,481],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"intervention":589,"totalTrials":141,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4044,"PHASE4":4050,"NA":4052},{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[],{"trials":4043,"activeCount":101},[],{"trials":4045,"activeCount":101},[4046],{"nctId":574,"briefTitle":575,"status":113,"phases":4047,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":4048,"interventions":4049},[91],[582,583,584,585,586],[588,589,406,467,590,481],{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":101},[],{"intervention":590,"totalTrials":141,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4062,"PHASE4":4068,"NA":4070},{"trials":4057,"activeCount":101},[],{"trials":4059,"activeCount":101},[],{"trials":4061,"activeCount":101},[],{"trials":4063,"activeCount":101},[4064],{"nctId":574,"briefTitle":575,"status":113,"phases":4065,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":4066,"interventions":4067},[91],[582,583,584,585,586],[588,589,406,467,590,481],{"trials":4069,"activeCount":101},[],{"trials":4071,"activeCount":101},[],{"intervention":2090,"totalTrials":141,"cells":4073},{"EARLY_PHASE1":4074,"PHASE1":4076,"PHASE2":4078,"PHASE3":4080,"PHASE4":4086,"NA":4088},{"trials":4075,"activeCount":101},[],{"trials":4077,"activeCount":101},[],{"trials":4079,"activeCount":101},[],{"trials":4081,"activeCount":101},[4082],{"nctId":2079,"briefTitle":2080,"status":533,"phases":4083,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":165,"conditions":4084,"interventions":4085},[90,91],[2086,2087,2088,1863],[2090,2001,2091,2092,2093],{"trials":4087,"activeCount":101},[],{"trials":4089,"activeCount":101},[],{"intervention":2091,"totalTrials":141,"cells":4091},{"EARLY_PHASE1":4092,"PHASE1":4094,"PHASE2":4096,"PHASE3":4098,"PHASE4":4104,"NA":4106},{"trials":4093,"activeCount":101},[],{"trials":4095,"activeCount":101},[],{"trials":4097,"activeCount":101},[],{"trials":4099,"activeCount":101},[4100],{"nctId":2079,"briefTitle":2080,"status":533,"phases":4101,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":165,"conditions":4102,"interventions":4103},[90,91],[2086,2087,2088,1863],[2090,2001,2091,2092,2093],{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[],{"intervention":2092,"totalTrials":141,"cells":4109},{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4114,"PHASE3":4116,"PHASE4":4122,"NA":4124},{"trials":4111,"activeCount":101},[],{"trials":4113,"activeCount":101},[],{"trials":4115,"activeCount":101},[],{"trials":4117,"activeCount":101},[4118],{"nctId":2079,"briefTitle":2080,"status":533,"phases":4119,"primaryCompletion":2082,"completion":2083,"start":2084,"enrollment":165,"conditions":4120,"interventions":4121},[90,91],[2086,2087,2088,1863],[2090,2001,2091,2092,2093],{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"intervention":4127,"totalTrials":141,"cells":4128},"Allogeneic bone marrow transplantation",{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4135,"PHASE4":4150,"NA":4152},{"trials":4130,"activeCount":101},[],{"trials":4132,"activeCount":101},[],{"trials":4134,"activeCount":101},[],{"trials":4136,"activeCount":101},[4137],{"nctId":4138,"briefTitle":4139,"status":113,"phases":4140,"primaryCompletion":4141,"completion":4142,"start":4143,"enrollment":4144,"conditions":4145,"interventions":4148},"NCT00075816","Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)",[91],"2013-04","2014-04","2004-01",551,[2413,4146,4147],"Myeloproliferative Disorders","Myelodysplastic-Myeloproliferative Diseases",[4127,4149],"Peripheral blood stem cell transplantation",{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":101},[],{"intervention":4149,"totalTrials":141,"cells":4155},{"EARLY_PHASE1":4156,"PHASE1":4158,"PHASE2":4160,"PHASE3":4162,"PHASE4":4168,"NA":4170},{"trials":4157,"activeCount":101},[],{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[4164],{"nctId":4138,"briefTitle":4139,"status":113,"phases":4165,"primaryCompletion":4141,"completion":4142,"start":4143,"enrollment":4144,"conditions":4166,"interventions":4167},[91],[2413,4146,4147],[4127,4149],{"trials":4169,"activeCount":101},[],{"trials":4171,"activeCount":101},[],{"intervention":4173,"totalTrials":141,"cells":4174},"Sirolimus + calcineurin inhibitor + prednisone",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4193,"NA":4195},{"trials":4176,"activeCount":101},[],{"trials":4178,"activeCount":101},[],{"trials":4180,"activeCount":101},[],{"trials":4182,"activeCount":101},[4183],{"nctId":4184,"briefTitle":4185,"status":113,"phases":4186,"primaryCompletion":4187,"completion":3753,"start":2145,"enrollment":4188,"conditions":4189,"interventions":4191},"NCT01106833","Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)",[90,91],"2017-02-14",151,[4190],"Chronic GVHD",[4173,4192],"Sirolimus + prednisone",{"trials":4194,"activeCount":101},[],{"trials":4196,"activeCount":101},[],{"intervention":4192,"totalTrials":141,"cells":4198},{"EARLY_PHASE1":4199,"PHASE1":4201,"PHASE2":4203,"PHASE3":4205,"PHASE4":4211,"NA":4213},{"trials":4200,"activeCount":101},[],{"trials":4202,"activeCount":101},[],{"trials":4204,"activeCount":101},[],{"trials":4206,"activeCount":101},[4207],{"nctId":4184,"briefTitle":4185,"status":113,"phases":4208,"primaryCompletion":4187,"completion":3753,"start":2145,"enrollment":4188,"conditions":4209,"interventions":4210},[90,91],[4190],[4173,4192],{"trials":4212,"activeCount":101},[],{"trials":4214,"activeCount":101},[],{"intervention":892,"totalTrials":141,"cells":4216},{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4221,"PHASE3":4223,"PHASE4":4229,"NA":4231},{"trials":4218,"activeCount":101},[],{"trials":4220,"activeCount":101},[],{"trials":4222,"activeCount":101},[],{"trials":4224,"activeCount":101},[4225],{"nctId":884,"briefTitle":885,"status":533,"phases":4226,"primaryCompletion":887,"completion":887,"start":888,"enrollment":570,"conditions":4227,"interventions":4228},[91],[890],[480,892],{"trials":4230,"activeCount":101},[],{"trials":4232,"activeCount":101},[],{"intervention":4234,"totalTrials":141,"cells":4235},"Methadone",{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4240,"PHASE3":4242,"PHASE4":4256,"NA":4258},{"trials":4237,"activeCount":101},[],{"trials":4239,"activeCount":101},[],{"trials":4241,"activeCount":101},[],{"trials":4243,"activeCount":101},[4244],{"nctId":4245,"briefTitle":4246,"status":113,"phases":4247,"primaryCompletion":4248,"completion":2904,"start":4249,"enrollment":4250,"conditions":4251,"interventions":4254},"NCT02558010","Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients",[91],"2022-01-01","2016-02-01",58,[4252,4253],"Scoliosis","Pain",[4234,4255],"Morphine",{"trials":4257,"activeCount":101},[],{"trials":4259,"activeCount":101},[],{"intervention":4261,"totalTrials":141,"cells":4262},"Nitric Oxide",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4282,"NA":4284},{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[],{"trials":4268,"activeCount":101},[],{"trials":4270,"activeCount":101},[4271],{"nctId":4272,"briefTitle":4273,"status":113,"phases":4274,"primaryCompletion":4275,"completion":4276,"start":4277,"enrollment":515,"conditions":4278,"interventions":4281},"NCT03455218","Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation",[90,91],"2019-04-20","2019-05-05","2018-04-25",[4279,4280],"Inflammation","Platelet Dysfunction",[4261],{"trials":4283,"activeCount":101},[],{"trials":4285,"activeCount":101},[],{"intervention":4287,"totalTrials":141,"cells":4288},"Intravenous Magnesium Sulfate",{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4293,"PHASE3":4295,"PHASE4":4306,"NA":4308},{"trials":4290,"activeCount":101},[],{"trials":4292,"activeCount":101},[],{"trials":4294,"activeCount":101},[],{"trials":4296,"activeCount":101},[4297],{"nctId":4298,"briefTitle":4299,"status":113,"phases":4300,"primaryCompletion":577,"completion":577,"start":4301,"enrollment":4302,"conditions":4303,"interventions":4304},"NCT01197417","Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis",[90,91],"2010-12",208,[564],[4287,4305],"Normal Saline Placebo",{"trials":4307,"activeCount":101},[],{"trials":4309,"activeCount":101},[],{"intervention":4305,"totalTrials":141,"cells":4311},{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4318,"PHASE4":4324,"NA":4326},{"trials":4313,"activeCount":101},[],{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[],{"trials":4319,"activeCount":101},[4320],{"nctId":4298,"briefTitle":4299,"status":113,"phases":4321,"primaryCompletion":577,"completion":577,"start":4301,"enrollment":4302,"conditions":4322,"interventions":4323},[90,91],[564],[4287,4305],{"trials":4325,"activeCount":101},[],{"trials":4327,"activeCount":101},[],{"intervention":4329,"totalTrials":141,"cells":4330},"Montelukast",{"EARLY_PHASE1":4331,"PHASE1":4333,"PHASE2":4335,"PHASE3":4337,"PHASE4":4349,"NA":4351},{"trials":4332,"activeCount":101},[],{"trials":4334,"activeCount":101},[],{"trials":4336,"activeCount":101},[],{"trials":4338,"activeCount":101},[4339],{"nctId":4340,"briefTitle":4341,"status":617,"phases":4342,"primaryCompletion":4343,"completion":4343,"start":934,"enrollment":101,"conditions":4344,"interventions":4347},"NCT01702701","Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone",[91],"2017-07-20",[4345,4346],"Eosinophilic Esophagitis","Dysphagia",[4329,4348],"Fluticasone",{"trials":4350,"activeCount":101},[],{"trials":4352,"activeCount":101},[],{"intervention":4348,"totalTrials":141,"cells":4354},{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4361,"PHASE4":4367,"NA":4369},{"trials":4356,"activeCount":101},[],{"trials":4358,"activeCount":101},[],{"trials":4360,"activeCount":101},[],{"trials":4362,"activeCount":101},[4363],{"nctId":4340,"briefTitle":4341,"status":617,"phases":4364,"primaryCompletion":4343,"completion":4343,"start":934,"enrollment":101,"conditions":4365,"interventions":4366},[91],[4345,4346],[4329,4348],{"trials":4368,"activeCount":101},[],{"trials":4370,"activeCount":101},[],{"intervention":4372,"totalTrials":141,"cells":4373},"Fluconazole",{"EARLY_PHASE1":4374,"PHASE1":4376,"PHASE2":4378,"PHASE3":4380,"PHASE4":4394,"NA":4396},{"trials":4375,"activeCount":101},[],{"trials":4377,"activeCount":101},[],{"trials":4379,"activeCount":101},[],{"trials":4381,"activeCount":101},[4382],{"nctId":4383,"briefTitle":4384,"status":113,"phases":4385,"primaryCompletion":4386,"completion":4387,"start":4388,"enrollment":4389,"conditions":4390,"interventions":4392},"NCT00075803","Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)",[91],"2006-09","2007-09","2003-11",600,[29,4391,2413],"Infection",[4372,4393],"Voriconazole",{"trials":4395,"activeCount":101},[],{"trials":4397,"activeCount":101},[],{"intervention":4393,"totalTrials":141,"cells":4399},{"EARLY_PHASE1":4400,"PHASE1":4402,"PHASE2":4404,"PHASE3":4406,"PHASE4":4412,"NA":4414},{"trials":4401,"activeCount":101},[],{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[4408],{"nctId":4383,"briefTitle":4384,"status":113,"phases":4409,"primaryCompletion":4386,"completion":4387,"start":4388,"enrollment":4389,"conditions":4410,"interventions":4411},[91],[29,4391,2413],[4372,4393],{"trials":4413,"activeCount":101},[],{"trials":4415,"activeCount":101},[],{"intervention":4417,"totalTrials":141,"cells":4418},"Quetiapine",{"EARLY_PHASE1":4419,"PHASE1":4421,"PHASE2":4423,"PHASE3":4425,"PHASE4":4437,"NA":4439},{"trials":4420,"activeCount":101},[],{"trials":4422,"activeCount":101},[],{"trials":4424,"activeCount":101},[],{"trials":4426,"activeCount":101},[4427],{"nctId":4428,"briefTitle":4429,"status":617,"phases":4430,"primaryCompletion":4431,"completion":4432,"start":4433,"enrollment":101,"conditions":4434,"interventions":4436},"NCT03572257","Quetiapine Treatment for Pediatric Delirium",[90,91],"2020-02-27","2020-03-02","2019-04-15",[4435],"Delirium",[4417],{"trials":4438,"activeCount":101},[],{"trials":4440,"activeCount":101},[],{"intervention":4442,"totalTrials":141,"cells":4443},"Erythropoietin administration",{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4460,"NA":4462},{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":101},[],{"trials":4451,"activeCount":101},[4452],{"nctId":4453,"briefTitle":4454,"status":617,"phases":4455,"primaryCompletion":936,"completion":936,"start":4456,"enrollment":101,"conditions":4457,"interventions":4459},"NCT00260052","Erythropoietin Effects After Traumatic Brain Injury",[90,91],"2003-07",[4458],"Traumatic Brain Injury",[4442],{"trials":4461,"activeCount":101},[],{"trials":4463,"activeCount":101},[],{"intervention":508,"totalTrials":654,"cells":4465},{"EARLY_PHASE1":4466,"PHASE1":4468,"PHASE2":4474,"PHASE3":4484,"PHASE4":4486,"NA":4488},{"trials":4467,"activeCount":101},[],{"trials":4469,"activeCount":101},[4470],{"nctId":2125,"briefTitle":2126,"status":113,"phases":4471,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1971,"conditions":4472,"interventions":4473},[89],[540],[2132,2121,2000,2122,508],{"trials":4475,"activeCount":101},[4476,4480],{"nctId":497,"briefTitle":498,"status":113,"phases":4477,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":4478,"interventions":4479},[90],[504],[506,467,406,480,507,508],{"nctId":853,"briefTitle":854,"status":113,"phases":4481,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":4482,"interventions":4483},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"trials":4485,"activeCount":101},[],{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"intervention":864,"totalTrials":654,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4493,"activeCount":101},[],{"trials":4495,"activeCount":101},[],{"trials":4497,"activeCount":101},[4498,4502,4506],{"nctId":853,"briefTitle":854,"status":113,"phases":4499,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":4500,"interventions":4501},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"nctId":544,"briefTitle":545,"status":546,"phases":4503,"start":548,"enrollment":25,"conditions":4504,"interventions":4505},[90],[29,550],[552,553,554,555],{"nctId":2140,"briefTitle":2141,"status":113,"phases":4507,"primaryCompletion":2143,"completion":2144,"start":2145,"enrollment":2019,"conditions":4508,"interventions":4509},[90],[29,24],[2148,66,2000,864],{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":101},[],{"intervention":876,"totalTrials":654,"cells":4517},{"EARLY_PHASE1":4518,"PHASE1":4520,"PHASE2":4532,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4519,"activeCount":101},[],{"trials":4521,"activeCount":101},[4522],{"nctId":4523,"briefTitle":4524,"status":533,"phases":4525,"primaryCompletion":4526,"completion":4526,"start":4527,"enrollment":97,"conditions":4528,"interventions":4530},"NCT03588936","Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant",[89],"2020-07-15","2018-09-14",[599,4529,29,905],"Chronic Leukemia",[4531,876,4531],"Nivolumab",{"trials":4533,"activeCount":101},[4534,4544],{"nctId":4535,"briefTitle":4536,"status":533,"phases":4537,"primaryCompletion":4538,"completion":4539,"start":4540,"enrollment":19,"conditions":4541,"interventions":4543},"NCT01475162","Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease",[89,90],"2016-02-17","2018-09-29","2011-08-08",[4542],"Acute Graft Versus Host Disease",[876],{"nctId":866,"briefTitle":867,"status":113,"phases":4545,"primaryCompletion":869,"completion":870,"start":871,"enrollment":872,"conditions":4546,"interventions":4547},[90],[874],[480,603,876],{"trials":4549,"activeCount":101},[],{"trials":4551,"activeCount":101},[],{"trials":4553,"activeCount":101},[],{"intervention":1018,"totalTrials":97,"cells":4555},{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4564,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4557,"activeCount":101},[],{"trials":4559,"activeCount":101},[4560],{"nctId":1005,"briefTitle":1006,"status":617,"phases":4561,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":4562,"interventions":4563},[89],[1012,1013],[998,1015,1016,1017,1018,1019,1020],{"trials":4565,"activeCount":101},[4566],{"nctId":4567,"briefTitle":4568,"status":113,"phases":4569,"primaryCompletion":4570,"completion":4571,"start":4572,"enrollment":4573,"conditions":4574,"interventions":4575},"NCT03219476","Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer",[90],"2020-02-04","2025-03-20","2017-02-05",37,[15,526],[4576,1018,4577,4578],"Anastrozole","Exemestane","Tamoxifen",{"trials":4580,"activeCount":101},[],{"trials":4582,"activeCount":101},[],{"trials":4584,"activeCount":101},[],{"intervention":466,"totalTrials":97,"cells":4586},{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4601,"PHASE4":4603,"NA":4605},{"trials":4588,"activeCount":101},[],{"trials":4590,"activeCount":101},[],{"trials":4592,"activeCount":101},[4593,4597],{"nctId":458,"briefTitle":459,"status":113,"phases":4594,"primaryCompletion":461,"completion":461,"start":462,"enrollment":141,"conditions":4595,"interventions":4596},[90],[464],[466,467,406,468],{"nctId":853,"briefTitle":854,"status":113,"phases":4598,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":4599,"interventions":4600},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"trials":4602,"activeCount":101},[],{"trials":4604,"activeCount":101},[],{"trials":4606,"activeCount":101},[],{"intervention":4608,"totalTrials":97,"cells":4609},"Doxycycline",{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4614,"PHASE3":4636,"PHASE4":4638,"NA":4640},{"trials":4611,"activeCount":101},[],{"trials":4613,"activeCount":101},[],{"trials":4615,"activeCount":101},[4616,4626],{"nctId":4617,"briefTitle":4618,"status":113,"phases":4619,"primaryCompletion":4620,"completion":4621,"start":4622,"enrollment":22,"conditions":4623,"interventions":4625},"NCT02775695","Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer",[90],"2018-09-25","2022-05-26","2017-04-03",[4624],"Resectable Pancreatic Cancer",[4608],{"nctId":4627,"briefTitle":4628,"status":113,"phases":4629,"primaryCompletion":4630,"completion":4631,"start":4632,"enrollment":502,"conditions":4633,"interventions":4635},"NCT02207556","Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial",[90],"2017-07-31","2020-05-19","2014-10-01",[4634],"Primary Systemic Amyloidosis",[4608],{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[],{"intervention":4643,"totalTrials":97,"cells":4644},"Hematopoietic Stem Cell Transplant",{"EARLY_PHASE1":4645,"PHASE1":4647,"PHASE2":4649,"PHASE3":4676,"PHASE4":4678,"NA":4680},{"trials":4646,"activeCount":101},[],{"trials":4648,"activeCount":101},[],{"trials":4650,"activeCount":101},[4651,4667],{"nctId":4652,"briefTitle":4653,"status":113,"phases":4654,"primaryCompletion":4655,"completion":4656,"start":4657,"enrollment":4658,"conditions":4659,"interventions":4666},"NCT01998633","Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)",[90],"2016-09-23","2016-12","2013-12",47,[4660,4661,4662,4663,4664,4665],"Hemophagocytic Lymphohistiocytosis","Chronic Active Epstein-Barr Virus Infection","Chronic Granulomatous Disease","HIGM-1","Leukocyte Adhesion Deficiency","IPEX",[4643],{"nctId":4668,"briefTitle":4669,"status":113,"phases":4670,"primaryCompletion":4671,"completion":3213,"start":462,"enrollment":4672,"conditions":4673,"interventions":4675},"NCT00912223","Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)",[90],"2014-11",65,[4674],"Lymphoma, Non-Hodgkin",[4643],{"trials":4677,"activeCount":101},[],{"trials":4679,"activeCount":101},[],{"trials":4681,"activeCount":101},[],{"intervention":4683,"totalTrials":97,"cells":4684},"Gemcitabine",{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4700,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4686,"activeCount":101},[],{"trials":4688,"activeCount":101},[4689],{"nctId":4690,"briefTitle":4691,"status":533,"phases":4692,"primaryCompletion":4693,"completion":4693,"start":4694,"enrollment":33,"conditions":4695,"interventions":4697},"NCT05325281","CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma",[89],"2025-07-08","2022-10-31",[4696],"Pancreas Adenocarcinoma",[4698,4698,4698,4698,4699,4683],"CPI-613®","CPI-613® Maximum Tolerated Dose",{"trials":4701,"activeCount":101},[4702],{"nctId":4703,"briefTitle":4704,"status":617,"phases":4705,"primaryCompletion":4706,"completion":4707,"start":4708,"enrollment":101,"conditions":4709,"interventions":4715},"NCT03908333","High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer",[89,90],"2022-05-01","2023-05-01","2019-05-01",[4710,1379,4711,4712,4713,4714],"Metastatic Pancreatic Cancer","Pancreas Cancer","Pancreatic Adenocarcinoma Resectable","Pancreatic Ductal Adenocarcinoma","Pancreatic Metastasis",[4716,4717,4718,4683],"Ascorbic Acid","Paclitaxel protein-bound","Cisplatin",{"trials":4720,"activeCount":101},[],{"trials":4722,"activeCount":101},[],{"trials":4724,"activeCount":101},[],{"intervention":468,"totalTrials":141,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4731,"PHASE3":4737,"PHASE4":4739,"NA":4741},{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[],{"trials":4732,"activeCount":101},[4733],{"nctId":458,"briefTitle":459,"status":113,"phases":4734,"primaryCompletion":461,"completion":461,"start":462,"enrollment":141,"conditions":4735,"interventions":4736},[90],[464],[466,467,406,468],{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":101},[],{"trials":4742,"activeCount":101},[],{"intervention":506,"totalTrials":141,"cells":4744},{"EARLY_PHASE1":4745,"PHASE1":4747,"PHASE2":4749,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4746,"activeCount":101},[],{"trials":4748,"activeCount":101},[],{"trials":4750,"activeCount":101},[4751],{"nctId":497,"briefTitle":498,"status":113,"phases":4752,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":4753,"interventions":4754},[90],[504],[506,467,406,480,507,508],{"trials":4756,"activeCount":101},[],{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[],{"intervention":2023,"totalTrials":141,"cells":4762},{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4767,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4764,"activeCount":101},[],{"trials":4766,"activeCount":101},[],{"trials":4768,"activeCount":101},[4769],{"nctId":2013,"briefTitle":2014,"status":113,"phases":4770,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":2019,"conditions":4771,"interventions":4772},[90],[2021,21],[2023,467],{"trials":4774,"activeCount":101},[],{"trials":4776,"activeCount":101},[],{"trials":4778,"activeCount":101},[],{"intervention":4780,"totalTrials":141,"cells":4781},"anti-SARS-CoV-2 convalescent plasma",{"EARLY_PHASE1":4782,"PHASE1":4784,"PHASE2":4786,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4783,"activeCount":101},[],{"trials":4785,"activeCount":101},[],{"trials":4787,"activeCount":101},[4788],{"nctId":4789,"briefTitle":4790,"status":113,"phases":4791,"primaryCompletion":4792,"completion":4792,"start":4793,"enrollment":4794,"conditions":4795,"interventions":4797},"NCT04354831","Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients",[90],"2021-02-10","2020-05-11",131,[4796],"COVID-19",[4780],{"trials":4799,"activeCount":101},[],{"trials":4801,"activeCount":101},[],{"trials":4803,"activeCount":101},[],{"intervention":4805,"totalTrials":141,"cells":4806},"Belantamab mafodotin",{"EARLY_PHASE1":4807,"PHASE1":4809,"PHASE2":4811,"PHASE3":4821,"PHASE4":4823,"NA":4825},{"trials":4808,"activeCount":101},[],{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[4813],{"nctId":4814,"briefTitle":4815,"status":533,"phases":4816,"primaryCompletion":4817,"completion":4817,"start":4818,"enrollment":141,"conditions":4819,"interventions":4820},"NCT05117008","Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[90],"2024-01-15","2022-07-19",[623,624],[4805],{"trials":4822,"activeCount":101},[],{"trials":4824,"activeCount":101},[],{"trials":4826,"activeCount":101},[],{"intervention":519,"totalTrials":141,"cells":4828},{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4833,"PHASE3":4839,"PHASE4":4841,"NA":4843},{"trials":4830,"activeCount":101},[],{"trials":4832,"activeCount":101},[],{"trials":4834,"activeCount":101},[4835],{"nctId":510,"briefTitle":511,"status":113,"phases":4836,"primaryCompletion":129,"completion":513,"start":514,"enrollment":515,"conditions":4837,"interventions":4838},[90],[21],[518,519,406,467],{"trials":4840,"activeCount":101},[],{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":101},[],{"intervention":4846,"totalTrials":141,"cells":4847},"Oxaliplatin",{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4852,"PHASE3":4866,"PHASE4":4868,"NA":4870},{"trials":4849,"activeCount":101},[],{"trials":4851,"activeCount":101},[],{"trials":4853,"activeCount":101},[4854],{"nctId":4855,"briefTitle":4856,"status":617,"phases":4857,"primaryCompletion":4858,"completion":4858,"start":4859,"enrollment":101,"conditions":4860,"interventions":4864},"NCT00244348","Hepatic Artery Infusion With Oxaliplatin",[89,90],"2015-08","2005-10",[4861,4862,4863],"Colorectal Cancer","Metastasis","Liver Cancer",[4846,4865],"5 Fluorouracil",{"trials":4867,"activeCount":101},[],{"trials":4869,"activeCount":101},[],{"trials":4871,"activeCount":101},[],{"intervention":4865,"totalTrials":141,"cells":4873},{"EARLY_PHASE1":4874,"PHASE1":4876,"PHASE2":4878,"PHASE3":4884,"PHASE4":4886,"NA":4888},{"trials":4875,"activeCount":101},[],{"trials":4877,"activeCount":101},[],{"trials":4879,"activeCount":101},[4880],{"nctId":4855,"briefTitle":4856,"status":617,"phases":4881,"primaryCompletion":4858,"completion":4858,"start":4859,"enrollment":101,"conditions":4882,"interventions":4883},[89,90],[4861,4862,4863],[4846,4865],{"trials":4885,"activeCount":101},[],{"trials":4887,"activeCount":101},[],{"trials":4889,"activeCount":101},[],{"intervention":861,"totalTrials":141,"cells":4891},{"EARLY_PHASE1":4892,"PHASE1":4894,"PHASE2":4896,"PHASE3":4902,"PHASE4":4904,"NA":4906},{"trials":4893,"activeCount":101},[],{"trials":4895,"activeCount":101},[],{"trials":4897,"activeCount":101},[4898],{"nctId":853,"briefTitle":854,"status":113,"phases":4899,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":4900,"interventions":4901},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"trials":4903,"activeCount":101},[],{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[],{"intervention":862,"totalTrials":141,"cells":4909},{"EARLY_PHASE1":4910,"PHASE1":4912,"PHASE2":4914,"PHASE3":4920,"PHASE4":4922,"NA":4924},{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[],{"trials":4915,"activeCount":101},[4916],{"nctId":853,"briefTitle":854,"status":113,"phases":4917,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":4918,"interventions":4919},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"trials":4921,"activeCount":101},[],{"trials":4923,"activeCount":101},[],{"trials":4925,"activeCount":101},[],{"intervention":863,"totalTrials":141,"cells":4927},{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4938,"PHASE4":4940,"NA":4942},{"trials":4929,"activeCount":101},[],{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":101},[4934],{"nctId":853,"briefTitle":854,"status":113,"phases":4935,"primaryCompletion":856,"completion":857,"start":535,"enrollment":858,"conditions":4936,"interventions":4937},[90],[564],[466,467,861,480,603,862,863,749,864,508],{"trials":4939,"activeCount":101},[],{"trials":4941,"activeCount":101},[],{"trials":4943,"activeCount":101},[],{"intervention":4945,"totalTrials":141,"cells":4946},"Hematopoietic Stem Cell Transplantation",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4948,"activeCount":101},[],{"trials":4950,"activeCount":101},[],{"trials":4952,"activeCount":101},[4953],{"nctId":4954,"briefTitle":4955,"status":113,"phases":4956,"primaryCompletion":4957,"completion":4958,"start":4959,"enrollment":165,"conditions":4960,"interventions":4961},"NCT00745420","Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)",[90],"2015-07","2016-09","2008-08",[564],[4945],{"trials":4963,"activeCount":101},[],{"trials":4965,"activeCount":101},[],{"trials":4967,"activeCount":101},[],{"intervention":4969,"totalTrials":141,"cells":4970},"Standard of care ADT +",{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4975,"PHASE3":4986,"PHASE4":4988,"NA":4990},{"trials":4972,"activeCount":101},[],{"trials":4974,"activeCount":101},[],{"trials":4976,"activeCount":101},[4977],{"nctId":4978,"briefTitle":4979,"status":113,"phases":4980,"primaryCompletion":4981,"completion":4982,"start":577,"enrollment":4983,"conditions":4984,"interventions":4985},"NCT01607879","Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation",[90],"2018-07","2021-02-16",48,[35],[4969],{"trials":4987,"activeCount":101},[],{"trials":4989,"activeCount":101},[],{"trials":4991,"activeCount":101},[],{"intervention":2202,"totalTrials":141,"cells":4993},{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5004,"PHASE4":5006,"NA":5008},{"trials":4995,"activeCount":101},[],{"trials":4997,"activeCount":101},[],{"trials":4999,"activeCount":101},[5000],{"nctId":2194,"briefTitle":2195,"status":617,"phases":5001,"primaryCompletion":2197,"completion":2197,"start":2198,"enrollment":101,"conditions":5002,"interventions":5003},[90],[2200],[422,2202],{"trials":5005,"activeCount":101},[],{"trials":5007,"activeCount":101},[],{"trials":5009,"activeCount":101},[],{"intervention":5011,"totalTrials":141,"cells":5012},"Haploidentical\u002Fcord transplant",{"EARLY_PHASE1":5013,"PHASE1":5015,"PHASE2":5017,"PHASE3":5029,"PHASE4":5031,"NA":5033},{"trials":5014,"activeCount":101},[],{"trials":5016,"activeCount":101},[],{"trials":5018,"activeCount":101},[5019],{"nctId":5020,"briefTitle":5021,"status":533,"phases":5022,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":141,"conditions":5025,"interventions":5028},"NCT01050946","Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit",[90],"2013-03","2009-07",[903,5026,902,904,4674,5027],"Leukemia, Lymphocytic, Chronic","Lymphoma, Hodgkins",[5011],{"trials":5030,"activeCount":101},[],{"trials":5032,"activeCount":101},[],{"trials":5034,"activeCount":101},[],{"intervention":5036,"totalTrials":141,"cells":5037},"Hydroxocobalamin",{"EARLY_PHASE1":5038,"PHASE1":5040,"PHASE2":5042,"PHASE3":5053,"PHASE4":5055,"NA":5057},{"trials":5039,"activeCount":101},[],{"trials":5041,"activeCount":101},[],{"trials":5043,"activeCount":101},[5044],{"nctId":5045,"briefTitle":5046,"status":113,"phases":5047,"primaryCompletion":5048,"completion":5048,"start":5049,"enrollment":434,"conditions":5050,"interventions":5052},"NCT03783091","A Trial of Vitamin B12 in Septic Shock",[90],"2023-02-23","2019-08-05",[5051],"Septic Shock",[5036],{"trials":5054,"activeCount":101},[],{"trials":5056,"activeCount":101},[],{"trials":5058,"activeCount":101},[],{"intervention":5060,"totalTrials":141,"cells":5061},"Milestone 1: Targeted chemotherapy prior to surgery",{"EARLY_PHASE1":5062,"PHASE1":5064,"PHASE2":5066,"PHASE3":5084,"PHASE4":5086,"NA":5088},{"trials":5063,"activeCount":101},[],{"trials":5065,"activeCount":101},[],{"trials":5067,"activeCount":101},[5068],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5071,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5075,"interventions":5077},"NCT01726582","Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (\"Personalized Medicine\")",[90],"2022-04-11","2011-11",229,[5076],"Pancreatic Adenocarcinoma",[5060,5078,5079,5080,5081,5082,5083],"Milestone 3: Targeted chemotherapy prior to surgery","Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery","Milestone 5: Targeted chemotherapy after surgery","Milestone 6: Gemcitabine after surgery","Milestone 8: Targeted chemotherapy after surgery","Milestone 9: Gemcitabine after surgery",{"trials":5085,"activeCount":101},[],{"trials":5087,"activeCount":101},[],{"trials":5089,"activeCount":101},[],{"intervention":5078,"totalTrials":141,"cells":5091},{"EARLY_PHASE1":5092,"PHASE1":5094,"PHASE2":5096,"PHASE3":5102,"PHASE4":5104,"NA":5106},{"trials":5093,"activeCount":101},[],{"trials":5095,"activeCount":101},[],{"trials":5097,"activeCount":101},[5098],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5099,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5100,"interventions":5101},[90],[5076],[5060,5078,5079,5080,5081,5082,5083],{"trials":5103,"activeCount":101},[],{"trials":5105,"activeCount":101},[],{"trials":5107,"activeCount":101},[],{"intervention":5079,"totalTrials":141,"cells":5109},{"EARLY_PHASE1":5110,"PHASE1":5112,"PHASE2":5114,"PHASE3":5120,"PHASE4":5122,"NA":5124},{"trials":5111,"activeCount":101},[],{"trials":5113,"activeCount":101},[],{"trials":5115,"activeCount":101},[5116],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5117,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5118,"interventions":5119},[90],[5076],[5060,5078,5079,5080,5081,5082,5083],{"trials":5121,"activeCount":101},[],{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":101},[],{"intervention":5080,"totalTrials":141,"cells":5127},{"EARLY_PHASE1":5128,"PHASE1":5130,"PHASE2":5132,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5129,"activeCount":101},[],{"trials":5131,"activeCount":101},[],{"trials":5133,"activeCount":101},[5134],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5135,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5136,"interventions":5137},[90],[5076],[5060,5078,5079,5080,5081,5082,5083],{"trials":5139,"activeCount":101},[],{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":101},[],{"intervention":5081,"totalTrials":141,"cells":5145},{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5156,"PHASE4":5158,"NA":5160},{"trials":5147,"activeCount":101},[],{"trials":5149,"activeCount":101},[],{"trials":5151,"activeCount":101},[5152],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5153,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5154,"interventions":5155},[90],[5076],[5060,5078,5079,5080,5081,5082,5083],{"trials":5157,"activeCount":101},[],{"trials":5159,"activeCount":101},[],{"trials":5161,"activeCount":101},[],{"intervention":5082,"totalTrials":141,"cells":5163},{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5168,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5165,"activeCount":101},[],{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[5170],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5171,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5172,"interventions":5173},[90],[5076],[5060,5078,5079,5080,5081,5082,5083],{"trials":5175,"activeCount":101},[],{"trials":5177,"activeCount":101},[],{"trials":5179,"activeCount":101},[],{"intervention":5083,"totalTrials":141,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5192,"PHASE4":5194,"NA":5196},{"trials":5183,"activeCount":101},[],{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":101},[5188],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5189,"primaryCompletion":3753,"completion":5072,"start":5073,"enrollment":5074,"conditions":5190,"interventions":5191},[90],[5076],[5060,5078,5079,5080,5081,5082,5083],{"trials":5193,"activeCount":101},[],{"trials":5195,"activeCount":101},[],{"trials":5197,"activeCount":101},[],{"intervention":5199,"totalTrials":141,"cells":5200},"Tildrakizumab",{"EARLY_PHASE1":5201,"PHASE1":5203,"PHASE2":5205,"PHASE3":5217,"PHASE4":5219,"NA":5221},{"trials":5202,"activeCount":101},[],{"trials":5204,"activeCount":101},[],{"trials":5206,"activeCount":101},[5207],{"nctId":5208,"briefTitle":5209,"status":113,"phases":5210,"primaryCompletion":5211,"completion":5212,"start":5213,"enrollment":1137,"conditions":5214,"interventions":5216},"NCT04112810","Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease",[90],"2024-06-01","2024-06-17","2020-03-01",[5215],"Hematologic Malignancies",[5199],{"trials":5218,"activeCount":101},[],{"trials":5220,"activeCount":101},[],{"trials":5222,"activeCount":101},[],{"intervention":5224,"totalTrials":141,"cells":5225},"Melphalan HCl for",{"EARLY_PHASE1":5226,"PHASE1":5228,"PHASE2":5230,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5227,"activeCount":101},[],{"trials":5229,"activeCount":101},[],{"trials":5231,"activeCount":101},[5232],{"nctId":5233,"briefTitle":5234,"status":113,"phases":5235,"primaryCompletion":5236,"completion":5237,"start":5238,"enrollment":2822,"conditions":5239,"interventions":5240},"NCT02669615","Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation",[90],"2017-06-09","2017-07-19","2016-11-01",[21],[5224],{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[],{"trials":5246,"activeCount":101},[],{"intervention":542,"totalTrials":141,"cells":5248},{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5259,"PHASE4":5261,"NA":5263},{"trials":5250,"activeCount":101},[],{"trials":5252,"activeCount":101},[],{"trials":5254,"activeCount":101},[5255],{"nctId":531,"briefTitle":532,"status":533,"phases":5256,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":5257,"interventions":5258},[90],[539,540],[542,406,66],{"trials":5260,"activeCount":101},[],{"trials":5262,"activeCount":101},[],{"trials":5264,"activeCount":101},[],{"intervention":5266,"totalTrials":141,"cells":5267},"Buprenorphine",{"EARLY_PHASE1":5268,"PHASE1":5270,"PHASE2":5272,"PHASE3":5284,"PHASE4":5286,"NA":5288},{"trials":5269,"activeCount":101},[],{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[5274],{"nctId":5275,"briefTitle":5276,"status":113,"phases":5277,"primaryCompletion":5278,"completion":5278,"start":5279,"enrollment":434,"conditions":5280,"interventions":5282},"NCT04752384","Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients",[90],"2024-04-04","2021-07-08",[5281],"Head and Neck Squamous Cell Carcinoma",[5266,5283],"Tramadol",{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"trials":5289,"activeCount":101},[],{"intervention":5283,"totalTrials":141,"cells":5291},{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[],{"trials":5297,"activeCount":101},[5298],{"nctId":5275,"briefTitle":5276,"status":113,"phases":5299,"primaryCompletion":5278,"completion":5278,"start":5279,"enrollment":434,"conditions":5300,"interventions":5301},[90],[5281],[5266,5283],{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[],{"trials":5307,"activeCount":101},[],{"intervention":553,"totalTrials":141,"cells":5309},{"EARLY_PHASE1":5310,"PHASE1":5312,"PHASE2":5314,"PHASE3":5320,"PHASE4":5322,"NA":5324},{"trials":5311,"activeCount":101},[],{"trials":5313,"activeCount":101},[],{"trials":5315,"activeCount":101},[5316],{"nctId":544,"briefTitle":545,"status":546,"phases":5317,"start":548,"enrollment":25,"conditions":5318,"interventions":5319},[90],[29,550],[552,553,554,555],{"trials":5321,"activeCount":101},[],{"trials":5323,"activeCount":101},[],{"trials":5325,"activeCount":101},[],{"intervention":4576,"totalTrials":141,"cells":5327},{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5338,"PHASE4":5340,"NA":5342},{"trials":5329,"activeCount":101},[],{"trials":5331,"activeCount":101},[],{"trials":5333,"activeCount":101},[5334],{"nctId":4567,"briefTitle":4568,"status":113,"phases":5335,"primaryCompletion":4570,"completion":4571,"start":4572,"enrollment":4573,"conditions":5336,"interventions":5337},[90],[15,526],[4576,1018,4577,4578],{"trials":5339,"activeCount":101},[],{"trials":5341,"activeCount":101},[],{"trials":5343,"activeCount":101},[],{"intervention":4577,"totalTrials":141,"cells":5345},{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5356,"PHASE4":5358,"NA":5360},{"trials":5347,"activeCount":101},[],{"trials":5349,"activeCount":101},[],{"trials":5351,"activeCount":101},[5352],{"nctId":4567,"briefTitle":4568,"status":113,"phases":5353,"primaryCompletion":4570,"completion":4571,"start":4572,"enrollment":4573,"conditions":5354,"interventions":5355},[90],[15,526],[4576,1018,4577,4578],{"trials":5357,"activeCount":101},[],{"trials":5359,"activeCount":101},[],{"trials":5361,"activeCount":101},[],{"intervention":4578,"totalTrials":141,"cells":5363},{"EARLY_PHASE1":5364,"PHASE1":5366,"PHASE2":5368,"PHASE3":5374,"PHASE4":5376,"NA":5378},{"trials":5365,"activeCount":101},[],{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[5370],{"nctId":4567,"briefTitle":4568,"status":113,"phases":5371,"primaryCompletion":4570,"completion":4571,"start":4572,"enrollment":4573,"conditions":5372,"interventions":5373},[90],[15,526],[4576,1018,4577,4578],{"trials":5375,"activeCount":101},[],{"trials":5377,"activeCount":101},[],{"trials":5379,"activeCount":101},[],{"intervention":1156,"totalTrials":141,"cells":5381},{"EARLY_PHASE1":5382,"PHASE1":5384,"PHASE2":5386,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5383,"activeCount":101},[],{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[5388],{"nctId":1147,"briefTitle":1148,"status":113,"phases":5389,"primaryCompletion":1150,"completion":1151,"start":1152,"enrollment":1153,"conditions":5390,"interventions":5391},[90],[904],[1123,1145,1144,1156],{"trials":5393,"activeCount":101},[],{"trials":5395,"activeCount":101},[],{"trials":5397,"activeCount":101},[],{"intervention":5399,"totalTrials":141,"cells":5400},"alteplase",{"EARLY_PHASE1":5401,"PHASE1":5403,"PHASE2":5405,"PHASE3":5418,"PHASE4":5420,"NA":5422},{"trials":5402,"activeCount":101},[],{"trials":5404,"activeCount":101},[],{"trials":5406,"activeCount":101},[5407],{"nctId":5408,"briefTitle":5409,"status":113,"phases":5410,"primaryCompletion":5411,"completion":5411,"start":5412,"enrollment":434,"conditions":5413,"interventions":5416},"NCT03672006","t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection",[90],"2019-12-15","2019-04-22",[5414,5415],"Central Venous Catheter Thrombosis","Central Venous Catheter Associated Bloodstream Infection",[5399,5417],"Heparin",{"trials":5419,"activeCount":101},[],{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[],{"intervention":5417,"totalTrials":141,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5430,"PHASE3":5436,"PHASE4":5438,"NA":5440},{"trials":5427,"activeCount":101},[],{"trials":5429,"activeCount":101},[],{"trials":5431,"activeCount":101},[5432],{"nctId":5408,"briefTitle":5409,"status":113,"phases":5433,"primaryCompletion":5411,"completion":5411,"start":5412,"enrollment":434,"conditions":5434,"interventions":5435},[90],[5414,5415],[5399,5417],{"trials":5437,"activeCount":101},[],{"trials":5439,"activeCount":101},[],{"trials":5441,"activeCount":101},[],{"intervention":566,"totalTrials":141,"cells":5443},{"EARLY_PHASE1":5444,"PHASE1":5446,"PHASE2":5448,"PHASE3":5454,"PHASE4":5456,"NA":5458},{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":101},[],{"trials":5449,"activeCount":101},[5450],{"nctId":557,"briefTitle":558,"status":113,"phases":5451,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":5452,"interventions":5453},[90],[564],[566,567,568,467,406,569],{"trials":5455,"activeCount":101},[],{"trials":5457,"activeCount":101},[],{"trials":5459,"activeCount":101},[],{"intervention":567,"totalTrials":141,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5472,"PHASE4":5474,"NA":5476},{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[5468],{"nctId":557,"briefTitle":558,"status":113,"phases":5469,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":5470,"interventions":5471},[90],[564],[566,567,568,467,406,569],{"trials":5473,"activeCount":101},[],{"trials":5475,"activeCount":101},[],{"trials":5477,"activeCount":101},[],{"intervention":568,"totalTrials":141,"cells":5479},{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[5486],{"nctId":557,"briefTitle":558,"status":113,"phases":5487,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":5488,"interventions":5489},[90],[564],[566,567,568,467,406,569],{"trials":5491,"activeCount":101},[],{"trials":5493,"activeCount":101},[],{"trials":5495,"activeCount":101},[],{"intervention":569,"totalTrials":141,"cells":5497},{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5502,"PHASE3":5508,"PHASE4":5510,"NA":5512},{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":101},[],{"trials":5503,"activeCount":101},[5504],{"nctId":557,"briefTitle":558,"status":113,"phases":5505,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":5506,"interventions":5507},[90],[564],[566,567,568,467,406,569],{"trials":5509,"activeCount":101},[],{"trials":5511,"activeCount":101},[],{"trials":5513,"activeCount":101},[],{"intervention":5515,"totalTrials":141,"cells":5516},"Rucaparib",{"EARLY_PHASE1":5517,"PHASE1":5519,"PHASE2":5521,"PHASE3":5536,"PHASE4":5538,"NA":5540},{"trials":5518,"activeCount":101},[],{"trials":5520,"activeCount":101},[],{"trials":5522,"activeCount":101},[5523],{"nctId":5524,"briefTitle":5525,"status":113,"phases":5526,"primaryCompletion":5527,"completion":5528,"start":5529,"enrollment":165,"conditions":5530,"interventions":5533},"NCT03694262","The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)",[90],"2023-03-30","2026-03-10","2019-07-19",[5531,5532],"Endometrial Cancer","Uterine Carcinosarcoma",[5515,5534,5535],"Bevacizumab","Atezolizumab",{"trials":5537,"activeCount":101},[],{"trials":5539,"activeCount":101},[],{"trials":5541,"activeCount":101},[],{"intervention":5534,"totalTrials":141,"cells":5543},{"EARLY_PHASE1":5544,"PHASE1":5546,"PHASE2":5548,"PHASE3":5554,"PHASE4":5556,"NA":5558},{"trials":5545,"activeCount":101},[],{"trials":5547,"activeCount":101},[],{"trials":5549,"activeCount":101},[5550],{"nctId":5524,"briefTitle":5525,"status":113,"phases":5551,"primaryCompletion":5527,"completion":5528,"start":5529,"enrollment":165,"conditions":5552,"interventions":5553},[90],[5531,5532],[5515,5534,5535],{"trials":5555,"activeCount":101},[],{"trials":5557,"activeCount":101},[],{"trials":5559,"activeCount":101},[],{"intervention":5535,"totalTrials":141,"cells":5561},{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5572,"PHASE4":5574,"NA":5576},{"trials":5563,"activeCount":101},[],{"trials":5565,"activeCount":101},[],{"trials":5567,"activeCount":101},[5568],{"nctId":5524,"briefTitle":5525,"status":113,"phases":5569,"primaryCompletion":5527,"completion":5528,"start":5529,"enrollment":165,"conditions":5570,"interventions":5571},[90],[5531,5532],[5515,5534,5535],{"trials":5573,"activeCount":101},[],{"trials":5575,"activeCount":101},[],{"trials":5577,"activeCount":101},[],{"intervention":2047,"totalTrials":141,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5590,"PHASE4":5592,"NA":5594},{"trials":5581,"activeCount":101},[],{"trials":5583,"activeCount":101},[],{"trials":5585,"activeCount":101},[5586],{"nctId":2037,"briefTitle":2038,"status":113,"phases":5587,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":5588,"interventions":5589},[89,90],[2045],[467,2047,2048,2049],{"trials":5591,"activeCount":101},[],{"trials":5593,"activeCount":101},[],{"trials":5595,"activeCount":101},[],{"intervention":2048,"totalTrials":141,"cells":5597},{"EARLY_PHASE1":5598,"PHASE1":5600,"PHASE2":5602,"PHASE3":5608,"PHASE4":5610,"NA":5612},{"trials":5599,"activeCount":101},[],{"trials":5601,"activeCount":101},[],{"trials":5603,"activeCount":101},[5604],{"nctId":2037,"briefTitle":2038,"status":113,"phases":5605,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":5606,"interventions":5607},[89,90],[2045],[467,2047,2048,2049],{"trials":5609,"activeCount":101},[],{"trials":5611,"activeCount":101},[],{"trials":5613,"activeCount":101},[],{"intervention":2049,"totalTrials":141,"cells":5615},{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5626,"PHASE4":5628,"NA":5630},{"trials":5617,"activeCount":101},[],{"trials":5619,"activeCount":101},[],{"trials":5621,"activeCount":101},[5622],{"nctId":2037,"briefTitle":2038,"status":113,"phases":5623,"primaryCompletion":2040,"completion":2041,"start":2042,"enrollment":2043,"conditions":5624,"interventions":5625},[89,90],[2045],[467,2047,2048,2049],{"trials":5627,"activeCount":101},[],{"trials":5629,"activeCount":101},[],{"trials":5631,"activeCount":101},[],{"intervention":5633,"totalTrials":141,"cells":5634},"Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen",{"EARLY_PHASE1":5635,"PHASE1":5637,"PHASE2":5639,"PHASE3":5650,"PHASE4":5652,"NA":5654},{"trials":5636,"activeCount":101},[],{"trials":5638,"activeCount":101},[],{"trials":5640,"activeCount":101},[5641],{"nctId":5642,"briefTitle":5643,"status":533,"phases":5644,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":1833,"conditions":5647,"interventions":5648},"NCT03150004","Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse\u002FRefractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)",[90],"2025-03-14","2017-06-14",[540,585],[5633,5649],"Cladribine and Cytarabine (CLLDAC) Regimen",{"trials":5651,"activeCount":101},[],{"trials":5653,"activeCount":101},[],{"trials":5655,"activeCount":101},[],{"intervention":5649,"totalTrials":141,"cells":5657},{"EARLY_PHASE1":5658,"PHASE1":5660,"PHASE2":5662,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5659,"activeCount":101},[],{"trials":5661,"activeCount":101},[],{"trials":5663,"activeCount":101},[5664],{"nctId":5642,"briefTitle":5643,"status":533,"phases":5665,"primaryCompletion":5645,"completion":5645,"start":5646,"enrollment":1833,"conditions":5666,"interventions":5667},[90],[540,585],[5633,5649],{"trials":5669,"activeCount":101},[],{"trials":5671,"activeCount":101},[],{"trials":5673,"activeCount":101},[],{"intervention":5675,"totalTrials":141,"cells":5676},"AGB101 220 mg",{"EARLY_PHASE1":5677,"PHASE1":5679,"PHASE2":5681,"PHASE3":5692,"PHASE4":5694,"NA":5696},{"trials":5678,"activeCount":101},[],{"trials":5680,"activeCount":101},[],{"trials":5682,"activeCount":101},[5683],{"nctId":5684,"briefTitle":5685,"status":113,"phases":5686,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":1971,"conditions":5689,"interventions":5691},"NCT03461861","Network-Level Mechanisms for Preclinical Alzheimer's Disease Development",[90],"2021-03-31","2019-04-11",[5690],"APOE 4",[5675],{"trials":5693,"activeCount":101},[],{"trials":5695,"activeCount":101},[],{"trials":5697,"activeCount":101},[],{"intervention":3718,"totalTrials":141,"cells":5699},{"EARLY_PHASE1":5700,"PHASE1":5702,"PHASE2":5704,"PHASE3":5710,"PHASE4":5712,"NA":5714},{"trials":5701,"activeCount":101},[],{"trials":5703,"activeCount":101},[],{"trials":5705,"activeCount":101},[5706],{"nctId":3705,"briefTitle":3706,"status":113,"phases":5707,"primaryCompletion":3708,"completion":3709,"start":3710,"enrollment":3711,"conditions":5708,"interventions":5709},[90],[3713,3467,419,3714,3715,3716],[3718,3696],{"trials":5711,"activeCount":101},[],{"trials":5713,"activeCount":101},[],{"trials":5715,"activeCount":101},[],{"intervention":3728,"totalTrials":141,"cells":5717},{"EARLY_PHASE1":5718,"PHASE1":5720,"PHASE2":5722,"PHASE3":5728,"PHASE4":5730,"NA":5732},{"trials":5719,"activeCount":101},[],{"trials":5721,"activeCount":101},[],{"trials":5723,"activeCount":101},[5724],{"nctId":3720,"briefTitle":3721,"status":113,"phases":5725,"primaryCompletion":3723,"completion":3709,"start":3724,"enrollment":3725,"conditions":5726,"interventions":5727},[90],[3713,3467,419,3714,3715,3716],[3728,3696],{"trials":5729,"activeCount":101},[],{"trials":5731,"activeCount":101},[],{"trials":5733,"activeCount":101},[],{"intervention":5735,"totalTrials":141,"cells":5736},"Propranolol",{"EARLY_PHASE1":5737,"PHASE1":5739,"PHASE2":5741,"PHASE3":5751,"PHASE4":5753,"NA":5755},{"trials":5738,"activeCount":101},[],{"trials":5740,"activeCount":101},[],{"trials":5742,"activeCount":101},[5743],{"nctId":5744,"briefTitle":5745,"status":113,"phases":5746,"primaryCompletion":4981,"completion":5747,"start":5748,"enrollment":9,"conditions":5749,"interventions":5750},"NCT02420223","Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients",[90],"2020-02","2015-07-17",[21],[5735],{"trials":5752,"activeCount":101},[],{"trials":5754,"activeCount":101},[],{"trials":5756,"activeCount":101},[],{"intervention":2148,"totalTrials":141,"cells":5758},{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5763,"PHASE3":5769,"PHASE4":5771,"NA":5773},{"trials":5760,"activeCount":101},[],{"trials":5762,"activeCount":101},[],{"trials":5764,"activeCount":101},[5765],{"nctId":2140,"briefTitle":2141,"status":113,"phases":5766,"primaryCompletion":2143,"completion":2144,"start":2145,"enrollment":2019,"conditions":5767,"interventions":5768},[90],[29,24],[2148,66,2000,864],{"trials":5770,"activeCount":101},[],{"trials":5772,"activeCount":101},[],{"trials":5774,"activeCount":101},[],{"intervention":5776,"totalTrials":141,"cells":5777},"Rabeprazole 20 mg twice a day for 90-day period treatment",{"EARLY_PHASE1":5778,"PHASE1":5780,"PHASE2":5782,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5779,"activeCount":101},[],{"trials":5781,"activeCount":101},[],{"trials":5783,"activeCount":101},[5784],{"nctId":5785,"briefTitle":5786,"status":113,"phases":5787,"primaryCompletion":5788,"completion":5788,"start":5789,"enrollment":803,"conditions":5790,"interventions":5792},"NCT00199953","Post-nasal Drainage as an Extraesophageal Manifestation of Reflux",[90],"2007-12","2002-06",[5791],"Postnasal Drainage",[5776],{"trials":5794,"activeCount":101},[],{"trials":5796,"activeCount":101},[],{"trials":5798,"activeCount":101},[],{"intervention":4716,"totalTrials":141,"cells":5800},{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5811,"PHASE4":5813,"NA":5815},{"trials":5802,"activeCount":101},[],{"trials":5804,"activeCount":101},[],{"trials":5806,"activeCount":101},[5807],{"nctId":4703,"briefTitle":4704,"status":617,"phases":5808,"primaryCompletion":4706,"completion":4707,"start":4708,"enrollment":101,"conditions":5809,"interventions":5810},[89,90],[4710,1379,4711,4712,4713,4714],[4716,4717,4718,4683],{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[],{"intervention":4717,"totalTrials":141,"cells":5818},{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5829,"PHASE4":5831,"NA":5833},{"trials":5820,"activeCount":101},[],{"trials":5822,"activeCount":101},[],{"trials":5824,"activeCount":101},[5825],{"nctId":4703,"briefTitle":4704,"status":617,"phases":5826,"primaryCompletion":4706,"completion":4707,"start":4708,"enrollment":101,"conditions":5827,"interventions":5828},[89,90],[4710,1379,4711,4712,4713,4714],[4716,4717,4718,4683],{"trials":5830,"activeCount":101},[],{"trials":5832,"activeCount":101},[],{"trials":5834,"activeCount":101},[],{"intervention":4718,"totalTrials":141,"cells":5836},{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5838,"activeCount":101},[],{"trials":5840,"activeCount":101},[],{"trials":5842,"activeCount":101},[5843],{"nctId":4703,"briefTitle":4704,"status":617,"phases":5844,"primaryCompletion":4706,"completion":4707,"start":4708,"enrollment":101,"conditions":5845,"interventions":5846},[89,90],[4710,1379,4711,4712,4713,4714],[4716,4717,4718,4683],{"trials":5848,"activeCount":101},[],{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"intervention":2121,"totalTrials":97,"cells":5854},{"EARLY_PHASE1":5855,"PHASE1":5857,"PHASE2":5867,"PHASE3":5869,"PHASE4":5871,"NA":5873},{"trials":5856,"activeCount":101},[],{"trials":5858,"activeCount":101},[5859,5863],{"nctId":2105,"briefTitle":2106,"status":617,"phases":5860,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":5861,"interventions":5862},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"nctId":2125,"briefTitle":2126,"status":113,"phases":5864,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1971,"conditions":5865,"interventions":5866},[89],[540],[2132,2121,2000,2122,508],{"trials":5868,"activeCount":101},[],{"trials":5870,"activeCount":101},[],{"trials":5872,"activeCount":101},[],{"trials":5874,"activeCount":101},[],{"intervention":2122,"totalTrials":97,"cells":5876},{"EARLY_PHASE1":5877,"PHASE1":5879,"PHASE2":5889,"PHASE3":5891,"PHASE4":5893,"NA":5895},{"trials":5878,"activeCount":101},[],{"trials":5880,"activeCount":101},[5881,5885],{"nctId":2105,"briefTitle":2106,"status":617,"phases":5882,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":5883,"interventions":5884},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"nctId":2125,"briefTitle":2126,"status":113,"phases":5886,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1971,"conditions":5887,"interventions":5888},[89],[540],[2132,2121,2000,2122,508],{"trials":5890,"activeCount":101},[],{"trials":5892,"activeCount":101},[],{"trials":5894,"activeCount":101},[],{"trials":5896,"activeCount":101},[],{"intervention":5898,"totalTrials":97,"cells":5899},"CAR-20\u002F19-T cells",{"EARLY_PHASE1":5900,"PHASE1":5902,"PHASE2":5929,"PHASE3":5931,"PHASE4":5933,"NA":5935},{"trials":5901,"activeCount":101},[],{"trials":5903,"activeCount":101},[5904,5919],{"nctId":5905,"briefTitle":5906,"status":533,"phases":5907,"primaryCompletion":5908,"completion":5909,"start":5910,"enrollment":912,"conditions":5911,"interventions":5918},"NCT04049383","CAR-20\u002F19-T Cells in Patients With Relapsed\u002FRefractory B Cell ALL",[89],"2025-06-01","2025-09-01","2020-10-16",[5912,5913,5914,5915,5916,5917],"Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Acute Lymphoblastic Leukemia Recurrent","Acute Lymphoblastic Leukemia Not Having Achieved Remission","Acute Lymphoblastic Leukemia, Pediatric","Acute Lymphoblastic Leukemia",[5898,5898,5898,5898],{"nctId":5920,"briefTitle":5921,"status":113,"phases":5922,"primaryCompletion":5923,"completion":5924,"start":3767,"enrollment":1971,"conditions":5925,"interventions":5928},"NCT03019055","Study of CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell",[89],"2019-10-01","2021-08-24",[4674,3714,5926,5927],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[5898,5898,5898,5898],{"trials":5930,"activeCount":101},[],{"trials":5932,"activeCount":101},[],{"trials":5934,"activeCount":101},[],{"trials":5936,"activeCount":101},[],{"intervention":5938,"totalTrials":141,"cells":5939},"Melatonin, Peppermint Oil (mentharil), and Simethicone",{"EARLY_PHASE1":5940,"PHASE1":5942,"PHASE2":5955,"PHASE3":5957,"PHASE4":5959,"NA":5961},{"trials":5941,"activeCount":101},[],{"trials":5943,"activeCount":101},[5944],{"nctId":5945,"briefTitle":5946,"status":617,"phases":5947,"primaryCompletion":934,"completion":5948,"start":5949,"enrollment":101,"conditions":5950,"interventions":5954},"NCT01269671","Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain",[89],"2012-04","2011-01",[5951,5952,5953],"Functional Abdominal Pain","Irritable Bowel Syndrome","Functional Dyspepsia",[5938],{"trials":5956,"activeCount":101},[],{"trials":5958,"activeCount":101},[],{"trials":5960,"activeCount":101},[],{"trials":5962,"activeCount":101},[],{"intervention":627,"totalTrials":141,"cells":5964},{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5973,"PHASE3":5975,"PHASE4":5977,"NA":5979},{"trials":5966,"activeCount":101},[],{"trials":5968,"activeCount":101},[5969],{"nctId":615,"briefTitle":616,"status":617,"phases":5970,"primaryCompletion":619,"completion":620,"start":621,"enrollment":101,"conditions":5971,"interventions":5972},[89],[623,624],[626,495,627,628,629],{"trials":5974,"activeCount":101},[],{"trials":5976,"activeCount":101},[],{"trials":5978,"activeCount":101},[],{"trials":5980,"activeCount":101},[],{"intervention":628,"totalTrials":141,"cells":5982},{"EARLY_PHASE1":5983,"PHASE1":5985,"PHASE2":5991,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5984,"activeCount":101},[],{"trials":5986,"activeCount":101},[5987],{"nctId":615,"briefTitle":616,"status":617,"phases":5988,"primaryCompletion":619,"completion":620,"start":621,"enrollment":101,"conditions":5989,"interventions":5990},[89],[623,624],[626,495,627,628,629],{"trials":5992,"activeCount":101},[],{"trials":5994,"activeCount":101},[],{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":101},[],{"intervention":629,"totalTrials":141,"cells":6000},{"EARLY_PHASE1":6001,"PHASE1":6003,"PHASE2":6009,"PHASE3":6011,"PHASE4":6013,"NA":6015},{"trials":6002,"activeCount":101},[],{"trials":6004,"activeCount":101},[6005],{"nctId":615,"briefTitle":616,"status":617,"phases":6006,"primaryCompletion":619,"completion":620,"start":621,"enrollment":101,"conditions":6007,"interventions":6008},[89],[623,624],[626,495,627,628,629],{"trials":6010,"activeCount":101},[],{"trials":6012,"activeCount":101},[],{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"intervention":6018,"totalTrials":141,"cells":6019},"Antibiotic",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6035,"PHASE3":6037,"PHASE4":6039,"NA":6041},{"trials":6021,"activeCount":101},[],{"trials":6023,"activeCount":101},[6024],{"nctId":6025,"briefTitle":6026,"status":113,"phases":6027,"primaryCompletion":6028,"completion":6028,"start":6029,"enrollment":768,"conditions":6030,"interventions":6034},"NCT05367479","Antibiotics, Gastric Bypass, and the Microbiome",[89],"2020-01-09","2018-07-18",[6031,6032,6033],"Obesity, Morbid","Hypertension","Bariatric Surgery Candidate",[6018],{"trials":6036,"activeCount":101},[],{"trials":6038,"activeCount":101},[],{"trials":6040,"activeCount":101},[],{"trials":6042,"activeCount":101},[],{"intervention":1015,"totalTrials":141,"cells":6044},{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6053,"PHASE3":6055,"PHASE4":6057,"NA":6059},{"trials":6046,"activeCount":101},[],{"trials":6048,"activeCount":101},[6049],{"nctId":1005,"briefTitle":1006,"status":617,"phases":6050,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":6051,"interventions":6052},[89],[1012,1013],[998,1015,1016,1017,1018,1019,1020],{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[],{"trials":6058,"activeCount":101},[],{"trials":6060,"activeCount":101},[],{"intervention":1016,"totalTrials":141,"cells":6062},{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6071,"PHASE3":6073,"PHASE4":6075,"NA":6077},{"trials":6064,"activeCount":101},[],{"trials":6066,"activeCount":101},[6067],{"nctId":1005,"briefTitle":1006,"status":617,"phases":6068,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":6069,"interventions":6070},[89],[1012,1013],[998,1015,1016,1017,1018,1019,1020],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[],{"trials":6076,"activeCount":101},[],{"trials":6078,"activeCount":101},[],{"intervention":1017,"totalTrials":141,"cells":6080},{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6089,"PHASE3":6091,"PHASE4":6093,"NA":6095},{"trials":6082,"activeCount":101},[],{"trials":6084,"activeCount":101},[6085],{"nctId":1005,"briefTitle":1006,"status":617,"phases":6086,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":6087,"interventions":6088},[89],[1012,1013],[998,1015,1016,1017,1018,1019,1020],{"trials":6090,"activeCount":101},[],{"trials":6092,"activeCount":101},[],{"trials":6094,"activeCount":101},[],{"trials":6096,"activeCount":101},[],{"intervention":1019,"totalTrials":141,"cells":6098},{"EARLY_PHASE1":6099,"PHASE1":6101,"PHASE2":6107,"PHASE3":6109,"PHASE4":6111,"NA":6113},{"trials":6100,"activeCount":101},[],{"trials":6102,"activeCount":101},[6103],{"nctId":1005,"briefTitle":1006,"status":617,"phases":6104,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":6105,"interventions":6106},[89],[1012,1013],[998,1015,1016,1017,1018,1019,1020],{"trials":6108,"activeCount":101},[],{"trials":6110,"activeCount":101},[],{"trials":6112,"activeCount":101},[],{"trials":6114,"activeCount":101},[],{"intervention":1020,"totalTrials":141,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6125,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6118,"activeCount":101},[],{"trials":6120,"activeCount":101},[6121],{"nctId":1005,"briefTitle":1006,"status":617,"phases":6122,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":101,"conditions":6123,"interventions":6124},[89],[1012,1013],[998,1015,1016,1017,1018,1019,1020],{"trials":6126,"activeCount":101},[],{"trials":6128,"activeCount":101},[],{"trials":6130,"activeCount":101},[],{"trials":6132,"activeCount":101},[],{"intervention":6134,"totalTrials":141,"cells":6135},"Gemtuzumab Ozogamicin 3 mg\u002Fm^2",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6151,"PHASE3":6153,"PHASE4":6155,"NA":6157},{"trials":6137,"activeCount":101},[],{"trials":6139,"activeCount":101},[6140],{"nctId":6141,"briefTitle":6142,"status":113,"phases":6143,"primaryCompletion":6144,"completion":6144,"start":6145,"enrollment":19,"conditions":6146,"interventions":6147},"NCT03848754","Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[89],"2021-05-05","2019-05-24",[2112],[6134,6148,6149,6150],"Gemtuzumab Ozogamicin 2 mg\u002Fm^2","Pracinostat - 45 mg","Pracinostat - 60 mg",{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[],{"trials":6156,"activeCount":101},[],{"trials":6158,"activeCount":101},[],{"intervention":6148,"totalTrials":141,"cells":6160},{"EARLY_PHASE1":6161,"PHASE1":6163,"PHASE2":6169,"PHASE3":6171,"PHASE4":6173,"NA":6175},{"trials":6162,"activeCount":101},[],{"trials":6164,"activeCount":101},[6165],{"nctId":6141,"briefTitle":6142,"status":113,"phases":6166,"primaryCompletion":6144,"completion":6144,"start":6145,"enrollment":19,"conditions":6167,"interventions":6168},[89],[2112],[6134,6148,6149,6150],{"trials":6170,"activeCount":101},[],{"trials":6172,"activeCount":101},[],{"trials":6174,"activeCount":101},[],{"trials":6176,"activeCount":101},[],{"intervention":6149,"totalTrials":141,"cells":6178},{"EARLY_PHASE1":6179,"PHASE1":6181,"PHASE2":6187,"PHASE3":6189,"PHASE4":6191,"NA":6193},{"trials":6180,"activeCount":101},[],{"trials":6182,"activeCount":101},[6183],{"nctId":6141,"briefTitle":6142,"status":113,"phases":6184,"primaryCompletion":6144,"completion":6144,"start":6145,"enrollment":19,"conditions":6185,"interventions":6186},[89],[2112],[6134,6148,6149,6150],{"trials":6188,"activeCount":101},[],{"trials":6190,"activeCount":101},[],{"trials":6192,"activeCount":101},[],{"trials":6194,"activeCount":101},[],{"intervention":6150,"totalTrials":141,"cells":6196},{"EARLY_PHASE1":6197,"PHASE1":6199,"PHASE2":6205,"PHASE3":6207,"PHASE4":6209,"NA":6211},{"trials":6198,"activeCount":101},[],{"trials":6200,"activeCount":101},[6201],{"nctId":6141,"briefTitle":6142,"status":113,"phases":6202,"primaryCompletion":6144,"completion":6144,"start":6145,"enrollment":19,"conditions":6203,"interventions":6204},[89],[2112],[6134,6148,6149,6150],{"trials":6206,"activeCount":101},[],{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[],{"intervention":840,"totalTrials":141,"cells":6214},{"EARLY_PHASE1":6215,"PHASE1":6217,"PHASE2":6223,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6216,"activeCount":101},[],{"trials":6218,"activeCount":101},[6219],{"nctId":832,"briefTitle":833,"status":617,"phases":6220,"primaryCompletion":835,"completion":835,"start":836,"enrollment":101,"conditions":6221,"interventions":6222},[89],[838],[840,841,480],{"trials":6224,"activeCount":101},[],{"trials":6226,"activeCount":101},[],{"trials":6228,"activeCount":101},[],{"trials":6230,"activeCount":101},[],{"intervention":841,"totalTrials":141,"cells":6232},{"EARLY_PHASE1":6233,"PHASE1":6235,"PHASE2":6241,"PHASE3":6243,"PHASE4":6245,"NA":6247},{"trials":6234,"activeCount":101},[],{"trials":6236,"activeCount":101},[6237],{"nctId":832,"briefTitle":833,"status":617,"phases":6238,"primaryCompletion":835,"completion":835,"start":836,"enrollment":101,"conditions":6239,"interventions":6240},[89],[838],[840,841,480],{"trials":6242,"activeCount":101},[],{"trials":6244,"activeCount":101},[],{"trials":6246,"activeCount":101},[],{"trials":6248,"activeCount":101},[],{"intervention":6250,"totalTrials":141,"cells":6251},"Antithrombin",{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6263,"PHASE3":6265,"PHASE4":6267,"NA":6269},{"trials":6253,"activeCount":101},[],{"trials":6255,"activeCount":101},[6256],{"nctId":6257,"briefTitle":6258,"status":533,"phases":6259,"primaryCompletion":4657,"completion":4657,"start":3196,"enrollment":33,"conditions":6260,"interventions":6262},"NCT01158729","Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates",[89],[6261],"Postoperative Hemorrhage",[6250],{"trials":6264,"activeCount":101},[],{"trials":6266,"activeCount":101},[],{"trials":6268,"activeCount":101},[],{"trials":6270,"activeCount":101},[],{"intervention":6272,"totalTrials":141,"cells":6273},"Selenium",{"EARLY_PHASE1":6274,"PHASE1":6276,"PHASE2":6287,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6275,"activeCount":101},[],{"trials":6277,"activeCount":101},[6278],{"nctId":6279,"briefTitle":6280,"status":533,"phases":6281,"primaryCompletion":3754,"completion":6282,"start":6283,"enrollment":912,"conditions":6284,"interventions":6286},"NCT01212965","Selenium in the Treatment of Complicated Lymphatic Malformations",[89],"2012-11","2010-09",[6285],"Lymphatic Malformations",[6272],{"trials":6288,"activeCount":101},[],{"trials":6290,"activeCount":101},[],{"trials":6292,"activeCount":101},[],{"trials":6294,"activeCount":101},[],{"intervention":6296,"totalTrials":141,"cells":6297},"Sorafenib",{"EARLY_PHASE1":6298,"PHASE1":6300,"PHASE2":6312,"PHASE3":6314,"PHASE4":6316,"NA":6318},{"trials":6299,"activeCount":101},[],{"trials":6301,"activeCount":101},[6302],{"nctId":6303,"briefTitle":6304,"status":617,"phases":6305,"primaryCompletion":6306,"completion":2144,"start":3926,"enrollment":101,"conditions":6307,"interventions":6311},"NCT01618253","Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma",[89],"2015-06",[6308,6309,6310,4863],"Hepatocellular Carcinoma","Hepatocellular Cancer","Hepatoma",[6296],{"trials":6313,"activeCount":101},[],{"trials":6315,"activeCount":101},[],{"trials":6317,"activeCount":101},[],{"trials":6319,"activeCount":101},[],{"intervention":2115,"totalTrials":141,"cells":6321},{"EARLY_PHASE1":6322,"PHASE1":6324,"PHASE2":6330,"PHASE3":6332,"PHASE4":6334,"NA":6336},{"trials":6323,"activeCount":101},[],{"trials":6325,"activeCount":101},[6326],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6327,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6328,"interventions":6329},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6331,"activeCount":101},[],{"trials":6333,"activeCount":101},[],{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"intervention":2116,"totalTrials":141,"cells":6339},{"EARLY_PHASE1":6340,"PHASE1":6342,"PHASE2":6348,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6341,"activeCount":101},[],{"trials":6343,"activeCount":101},[6344],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6345,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6346,"interventions":6347},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6349,"activeCount":101},[],{"trials":6351,"activeCount":101},[],{"trials":6353,"activeCount":101},[],{"trials":6355,"activeCount":101},[],{"intervention":2117,"totalTrials":141,"cells":6357},{"EARLY_PHASE1":6358,"PHASE1":6360,"PHASE2":6366,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6359,"activeCount":101},[],{"trials":6361,"activeCount":101},[6362],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6363,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6364,"interventions":6365},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6367,"activeCount":101},[],{"trials":6369,"activeCount":101},[],{"trials":6371,"activeCount":101},[],{"trials":6373,"activeCount":101},[],{"intervention":2118,"totalTrials":141,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6384,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6377,"activeCount":101},[],{"trials":6379,"activeCount":101},[6380],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6381,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6382,"interventions":6383},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6385,"activeCount":101},[],{"trials":6387,"activeCount":101},[],{"trials":6389,"activeCount":101},[],{"trials":6391,"activeCount":101},[],{"intervention":2119,"totalTrials":141,"cells":6393},{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6402,"PHASE3":6404,"PHASE4":6406,"NA":6408},{"trials":6395,"activeCount":101},[],{"trials":6397,"activeCount":101},[6398],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6399,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6400,"interventions":6401},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6403,"activeCount":101},[],{"trials":6405,"activeCount":101},[],{"trials":6407,"activeCount":101},[],{"trials":6409,"activeCount":101},[],{"intervention":2120,"totalTrials":141,"cells":6411},{"EARLY_PHASE1":6412,"PHASE1":6414,"PHASE2":6420,"PHASE3":6422,"PHASE4":6424,"NA":6426},{"trials":6413,"activeCount":101},[],{"trials":6415,"activeCount":101},[6416],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6417,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6418,"interventions":6419},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6421,"activeCount":101},[],{"trials":6423,"activeCount":101},[],{"trials":6425,"activeCount":101},[],{"trials":6427,"activeCount":101},[],{"intervention":2123,"totalTrials":141,"cells":6429},{"EARLY_PHASE1":6430,"PHASE1":6432,"PHASE2":6438,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6431,"activeCount":101},[],{"trials":6433,"activeCount":101},[6434],{"nctId":2105,"briefTitle":2106,"status":617,"phases":6435,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":101,"conditions":6436,"interventions":6437},[89],[2112,2113],[2115,2116,2117,2118,2119,2120,2121,2000,2000,2122,2123],{"trials":6439,"activeCount":101},[],{"trials":6441,"activeCount":101},[],{"trials":6443,"activeCount":101},[],{"trials":6445,"activeCount":101},[],{"intervention":6447,"totalTrials":141,"cells":6448},"Antitumor B KAC",{"EARLY_PHASE1":6449,"PHASE1":6451,"PHASE2":6461,"PHASE3":6463,"PHASE4":6465,"NA":6467},{"trials":6450,"activeCount":101},[],{"trials":6452,"activeCount":101},[6453],{"nctId":6454,"briefTitle":6455,"status":617,"phases":6456,"primaryCompletion":2928,"completion":2928,"start":6457,"enrollment":101,"conditions":6458,"interventions":6460},"NCT05452408","Antitumor-B KAC PK Study",[89],"2026-12",[6459],"Squamous Cell Carcinoma of the Oral Cavity",[6447],{"trials":6462,"activeCount":101},[],{"trials":6464,"activeCount":101},[],{"trials":6466,"activeCount":101},[],{"trials":6468,"activeCount":101},[],{"intervention":6470,"totalTrials":141,"cells":6471},"gallium nitrate",{"EARLY_PHASE1":6472,"PHASE1":6474,"PHASE2":6487,"PHASE3":6489,"PHASE4":6491,"NA":6493},{"trials":6473,"activeCount":101},[],{"trials":6475,"activeCount":101},[6476],{"nctId":6477,"briefTitle":6478,"status":113,"phases":6479,"completion":6480,"start":6481,"enrollment":654,"conditions":6482,"interventions":6486},"NCT00002543","Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors",[89],"2004-10","1995-02",[6483,29,6484,823,6485],"Brain and Central Nervous System Tumors","Neuroblastoma","Unspecified Childhood Solid Tumor, Protocol Specific",[6470],{"trials":6488,"activeCount":101},[],{"trials":6490,"activeCount":101},[],{"trials":6492,"activeCount":101},[],{"trials":6494,"activeCount":101},[],{"intervention":4531,"totalTrials":141,"cells":6496},{"EARLY_PHASE1":6497,"PHASE1":6499,"PHASE2":6505,"PHASE3":6507,"PHASE4":6509,"NA":6511},{"trials":6498,"activeCount":101},[],{"trials":6500,"activeCount":101},[6501],{"nctId":4523,"briefTitle":4524,"status":533,"phases":6502,"primaryCompletion":4526,"completion":4526,"start":4527,"enrollment":97,"conditions":6503,"interventions":6504},[89],[599,4529,29,905],[4531,876,4531],{"trials":6506,"activeCount":101},[],{"trials":6508,"activeCount":101},[],{"trials":6510,"activeCount":101},[],{"trials":6512,"activeCount":101},[],{"intervention":6514,"totalTrials":141,"cells":6515},"Cytotoxic T Lymphocytes",{"EARLY_PHASE1":6516,"PHASE1":6518,"PHASE2":6531,"PHASE3":6533,"PHASE4":6535,"NA":6537},{"trials":6517,"activeCount":101},[],{"trials":6519,"activeCount":101},[6520],{"nctId":6521,"briefTitle":6522,"status":113,"phases":6523,"primaryCompletion":6524,"completion":6524,"start":6525,"enrollment":9,"conditions":6526,"interventions":6530},"NCT01535885","Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV",[89],"2019-10","2012-02",[6527,6528,6529],"Epstein-Barr Virus Infections","Adenovirus","Cytomegalovirus Infections",[6514],{"trials":6532,"activeCount":101},[],{"trials":6534,"activeCount":101},[],{"trials":6536,"activeCount":101},[],{"trials":6538,"activeCount":101},[],{"intervention":6540,"totalTrials":141,"cells":6541},"Concurrent Atezolizumab",{"EARLY_PHASE1":6542,"PHASE1":6544,"PHASE2":6558,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6543,"activeCount":101},[],{"trials":6545,"activeCount":101},[6546],{"nctId":6547,"briefTitle":6548,"status":113,"phases":6549,"primaryCompletion":6550,"completion":6551,"start":6552,"enrollment":6553,"conditions":6554,"interventions":6556},"NCT04477759","Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer",[89],"2024-04-08","2025-04-14","2021-01-26",18,[6555],"Head and Neck Neoplasm",[6540,6557],"Adjuvant Atezolizumab",{"trials":6559,"activeCount":101},[],{"trials":6561,"activeCount":101},[],{"trials":6563,"activeCount":101},[],{"trials":6565,"activeCount":101},[],{"intervention":6557,"totalTrials":141,"cells":6567},{"EARLY_PHASE1":6568,"PHASE1":6570,"PHASE2":6576,"PHASE3":6578,"PHASE4":6580,"NA":6582},{"trials":6569,"activeCount":101},[],{"trials":6571,"activeCount":101},[6572],{"nctId":6547,"briefTitle":6548,"status":113,"phases":6573,"primaryCompletion":6550,"completion":6551,"start":6552,"enrollment":6553,"conditions":6574,"interventions":6575},[89],[6555],[6540,6557],{"trials":6577,"activeCount":101},[],{"trials":6579,"activeCount":101},[],{"trials":6581,"activeCount":101},[],{"trials":6583,"activeCount":101},[],{"intervention":2132,"totalTrials":141,"cells":6585},{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6594,"PHASE3":6596,"PHASE4":6598,"NA":6600},{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[6590],{"nctId":2125,"briefTitle":2126,"status":113,"phases":6591,"primaryCompletion":2128,"completion":2128,"start":2129,"enrollment":1971,"conditions":6592,"interventions":6593},[89],[540],[2132,2121,2000,2122,508],{"trials":6595,"activeCount":101},[],{"trials":6597,"activeCount":101},[],{"trials":6599,"activeCount":101},[],{"trials":6601,"activeCount":101},[],{"intervention":6603,"totalTrials":141,"cells":6604},"Acetazolamide",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6617,"PHASE3":6619,"PHASE4":6621,"NA":6623},{"trials":6606,"activeCount":101},[],{"trials":6608,"activeCount":101},[6609],{"nctId":6610,"briefTitle":6611,"status":113,"phases":6612,"primaryCompletion":5687,"completion":5687,"start":6613,"enrollment":3490,"conditions":6614,"interventions":6616},"NCT04470843","Impact of Acetazolamide in Reducing Referred Postoperative Pain",[89],"2018-08-22",[35,6615],"Men",[6603],{"trials":6618,"activeCount":101},[],{"trials":6620,"activeCount":101},[],{"trials":6622,"activeCount":101},[],{"trials":6624,"activeCount":101},[],{"intervention":2273,"totalTrials":141,"cells":6626},{"EARLY_PHASE1":6627,"PHASE1":6629,"PHASE2":6635,"PHASE3":6637,"PHASE4":6639,"NA":6641},{"trials":6628,"activeCount":101},[],{"trials":6630,"activeCount":101},[6631],{"nctId":2264,"briefTitle":2265,"status":533,"phases":6632,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":2270,"conditions":6633,"interventions":6634},[89],[582],[2273,1997,2274],{"trials":6636,"activeCount":101},[],{"trials":6638,"activeCount":101},[],{"trials":6640,"activeCount":101},[],{"trials":6642,"activeCount":101},[],{"intervention":2274,"totalTrials":141,"cells":6644},{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6653,"PHASE3":6655,"PHASE4":6657,"NA":6659},{"trials":6646,"activeCount":101},[],{"trials":6648,"activeCount":101},[6649],{"nctId":2264,"briefTitle":2265,"status":533,"phases":6650,"primaryCompletion":2267,"completion":2268,"start":2269,"enrollment":2270,"conditions":6651,"interventions":6652},[89],[582],[2273,1997,2274],{"trials":6654,"activeCount":101},[],{"trials":6656,"activeCount":101},[],{"trials":6658,"activeCount":101},[],{"trials":6660,"activeCount":101},[],{"intervention":6662,"totalTrials":141,"cells":6663},"Rectus sheath block with bupivacaine",{"EARLY_PHASE1":6664,"PHASE1":6666,"PHASE2":6680,"PHASE3":6682,"PHASE4":6684,"NA":6686},{"trials":6665,"activeCount":101},[],{"trials":6667,"activeCount":101},[6668],{"nctId":6669,"briefTitle":6670,"status":113,"phases":6671,"primaryCompletion":6672,"completion":6673,"start":6674,"enrollment":6675,"conditions":6676,"interventions":6679},"NCT04908449","Pectointercostal Fascial Plane Block (PIFB) Alone Versus PIFB With Rectus Sheath Block (RSB) in Cardiac Surgery",[89],"2024-11-08","2024-11-14","2023-06-19",62,[3182,6677,6678],"Postoperative Pain","Respiratory Failure",[6662],{"trials":6681,"activeCount":101},[],{"trials":6683,"activeCount":101},[],{"trials":6685,"activeCount":101},[],{"trials":6687,"activeCount":101},[],{"intervention":4698,"totalTrials":141,"cells":6689},{"EARLY_PHASE1":6690,"PHASE1":6692,"PHASE2":6698,"PHASE3":6700,"PHASE4":6702,"NA":6704},{"trials":6691,"activeCount":101},[],{"trials":6693,"activeCount":101},[6694],{"nctId":4690,"briefTitle":4691,"status":533,"phases":6695,"primaryCompletion":4693,"completion":4693,"start":4694,"enrollment":33,"conditions":6696,"interventions":6697},[89],[4696],[4698,4698,4698,4698,4699,4683],{"trials":6699,"activeCount":101},[],{"trials":6701,"activeCount":101},[],{"trials":6703,"activeCount":101},[],{"trials":6705,"activeCount":101},[],{"intervention":4699,"totalTrials":141,"cells":6707},{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6716,"PHASE3":6718,"PHASE4":6720,"NA":6722},{"trials":6709,"activeCount":101},[],{"trials":6711,"activeCount":101},[6712],{"nctId":4690,"briefTitle":4691,"status":533,"phases":6713,"primaryCompletion":4693,"completion":4693,"start":4694,"enrollment":33,"conditions":6714,"interventions":6715},[89],[4696],[4698,4698,4698,4698,4699,4683],{"trials":6717,"activeCount":101},[],{"trials":6719,"activeCount":101},[],{"trials":6721,"activeCount":101},[],{"trials":6723,"activeCount":101},[],{"intervention":6725,"totalTrials":141,"cells":6726},"verteporfin",{"EARLY_PHASE1":6727,"PHASE1":6729,"PHASE2":6739,"PHASE3":6741,"PHASE4":6743,"NA":6745},{"trials":6728,"activeCount":101},[],{"trials":6730,"activeCount":101},[6731],{"nctId":6732,"briefTitle":6733,"status":546,"phases":6734,"start":6735,"enrollment":2822,"conditions":6736,"interventions":6738},"NCT00002647","Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors",[89],"1994-05",[6483,6737],"Metastatic Cancer",[6725],{"trials":6740,"activeCount":101},[],{"trials":6742,"activeCount":101},[],{"trials":6744,"activeCount":101},[],{"trials":6746,"activeCount":101},[],{"intervention":6748,"totalTrials":141,"cells":6749},"0.75x10^6 cells\u002Fkg CAR20.19.22 cells",{"EARLY_PHASE1":6750,"PHASE1":6752,"PHASE2":6767,"PHASE3":6769,"PHASE4":6771,"NA":6773},{"trials":6751,"activeCount":101},[],{"trials":6753,"activeCount":101},[6754],{"nctId":6755,"briefTitle":6756,"status":533,"phases":6757,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":570,"conditions":6760,"interventions":6762},"NCT05094206","CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies",[89],"2024-01-29","2022-06-30",[2824,6761],"B-cell Chronic Lymphocytic Leukemia",[6748,6763,6764,6765,6766],"1x10^6 cells\u002Fkg CAR20.19.22 cells","2.5x10^6 cells\u002Fkg CAR20.19.22 cells","5x10^6 cells\u002Fkg CAR20.19.22 cells","Dose expansion: The maximum tolerated dose of CAR20.19.22 cells",{"trials":6768,"activeCount":101},[],{"trials":6770,"activeCount":101},[],{"trials":6772,"activeCount":101},[],{"trials":6774,"activeCount":101},[],{"intervention":6763,"totalTrials":141,"cells":6776},{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6785,"PHASE3":6787,"PHASE4":6789,"NA":6791},{"trials":6778,"activeCount":101},[],{"trials":6780,"activeCount":101},[6781],{"nctId":6755,"briefTitle":6756,"status":533,"phases":6782,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":570,"conditions":6783,"interventions":6784},[89],[2824,6761],[6748,6763,6764,6765,6766],{"trials":6786,"activeCount":101},[],{"trials":6788,"activeCount":101},[],{"trials":6790,"activeCount":101},[],{"trials":6792,"activeCount":101},[],{"intervention":6764,"totalTrials":141,"cells":6794},{"EARLY_PHASE1":6795,"PHASE1":6797,"PHASE2":6803,"PHASE3":6805,"PHASE4":6807,"NA":6809},{"trials":6796,"activeCount":101},[],{"trials":6798,"activeCount":101},[6799],{"nctId":6755,"briefTitle":6756,"status":533,"phases":6800,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":570,"conditions":6801,"interventions":6802},[89],[2824,6761],[6748,6763,6764,6765,6766],{"trials":6804,"activeCount":101},[],{"trials":6806,"activeCount":101},[],{"trials":6808,"activeCount":101},[],{"trials":6810,"activeCount":101},[],{"intervention":6765,"totalTrials":141,"cells":6812},{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6821,"PHASE3":6823,"PHASE4":6825,"NA":6827},{"trials":6814,"activeCount":101},[],{"trials":6816,"activeCount":101},[6817],{"nctId":6755,"briefTitle":6756,"status":533,"phases":6818,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":570,"conditions":6819,"interventions":6820},[89],[2824,6761],[6748,6763,6764,6765,6766],{"trials":6822,"activeCount":101},[],{"trials":6824,"activeCount":101},[],{"trials":6826,"activeCount":101},[],{"trials":6828,"activeCount":101},[],{"intervention":6766,"totalTrials":141,"cells":6830},{"EARLY_PHASE1":6831,"PHASE1":6833,"PHASE2":6839,"PHASE3":6841,"PHASE4":6843,"NA":6845},{"trials":6832,"activeCount":101},[],{"trials":6834,"activeCount":101},[6835],{"nctId":6755,"briefTitle":6756,"status":533,"phases":6836,"primaryCompletion":6758,"completion":6758,"start":6759,"enrollment":570,"conditions":6837,"interventions":6838},[89],[2824,6761],[6748,6763,6764,6765,6766],{"trials":6840,"activeCount":101},[],{"trials":6842,"activeCount":101},[],{"trials":6844,"activeCount":101},[],{"trials":6846,"activeCount":101},[],{"intervention":6848,"totalTrials":97,"cells":6849},"Estradiol",{"EARLY_PHASE1":6850,"PHASE1":6872,"PHASE2":6874,"PHASE3":6876,"PHASE4":6878,"NA":6880},{"trials":6851,"activeCount":101},[6852,6861],{"nctId":6853,"briefTitle":6854,"status":113,"phases":6855,"primaryCompletion":6856,"completion":6856,"start":6857,"enrollment":416,"conditions":6858,"interventions":6860},"NCT04036500","Transgender Estradiol",[88],"2020-07-13","2019-09-23",[6859],"Transgender Persons",[6848],{"nctId":6862,"briefTitle":6863,"status":533,"phases":6864,"primaryCompletion":6865,"completion":6865,"start":6866,"enrollment":537,"conditions":6867,"interventions":6870},"NCT05387577","Coagulation and Fibrinolysis of Estradiol in Transwomen",[88],"2022-11-23","2021-12-07",[6868,6869],"Transgenderism","Clotting Disorder",[6848,6871,6848],"Transdermal patch",{"trials":6873,"activeCount":101},[],{"trials":6875,"activeCount":101},[],{"trials":6877,"activeCount":101},[],{"trials":6879,"activeCount":101},[],{"trials":6881,"activeCount":101},[],{"intervention":6883,"totalTrials":141,"cells":6884},"Antitumor B",{"EARLY_PHASE1":6885,"PHASE1":6894,"PHASE2":6896,"PHASE3":6898,"PHASE4":6900,"NA":6902},{"trials":6886,"activeCount":101},[6887],{"nctId":6888,"briefTitle":6889,"status":113,"phases":6890,"primaryCompletion":3489,"completion":6891,"start":5924,"enrollment":537,"conditions":6892,"interventions":6893},"NCT03459729","Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer",[88],"2022-02-16",[6459],[6883],{"trials":6895,"activeCount":101},[],{"trials":6897,"activeCount":101},[],{"trials":6899,"activeCount":101},[],{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[],{"intervention":6905,"totalTrials":141,"cells":6906},"Anti-tumor B",{"EARLY_PHASE1":6907,"PHASE1":6919,"PHASE2":6921,"PHASE3":6923,"PHASE4":6925,"NA":6927},{"trials":6908,"activeCount":101},[6909],{"nctId":6910,"briefTitle":6911,"status":113,"phases":6912,"primaryCompletion":6913,"completion":6914,"start":6915,"enrollment":165,"conditions":6916,"interventions":6918},"NCT04278989","Inhibition of Oral Tumorigenesis by Antitumor B",[88],"2025-05-19","2025-06-05","2022-04-22",[6917],"Squamous Cell Cancer of the Oral Cavity",[6905],{"trials":6920,"activeCount":101},[],{"trials":6922,"activeCount":101},[],{"trials":6924,"activeCount":101},[],{"trials":6926,"activeCount":101},[],{"trials":6928,"activeCount":101},[],{"intervention":3200,"totalTrials":141,"cells":6930},{"EARLY_PHASE1":6931,"PHASE1":6937,"PHASE2":6939,"PHASE3":6941,"PHASE4":6943,"NA":6945},{"trials":6932,"activeCount":101},[6933],{"nctId":3193,"briefTitle":3194,"status":113,"phases":6934,"primaryCompletion":2143,"completion":2143,"start":3196,"enrollment":3197,"conditions":6935,"interventions":6936},[88],[18],[3200,3188],{"trials":6938,"activeCount":101},[],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"trials":6946,"activeCount":101},[],{"intervention":6871,"totalTrials":141,"cells":6948},{"EARLY_PHASE1":6949,"PHASE1":6955,"PHASE2":6957,"PHASE3":6959,"PHASE4":6961,"NA":6963},{"trials":6950,"activeCount":101},[6951],{"nctId":6862,"briefTitle":6863,"status":533,"phases":6952,"primaryCompletion":6865,"completion":6865,"start":6866,"enrollment":537,"conditions":6953,"interventions":6954},[88],[6868,6869],[6848,6871,6848],{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":101},[],{"trials":6960,"activeCount":101},[],{"trials":6962,"activeCount":101},[],{"trials":6964,"activeCount":101},[],{"intervention":6966,"totalTrials":141,"cells":6967},"intravitreous VEGF-inhibitors",{"EARLY_PHASE1":6968,"PHASE1":6978,"PHASE2":6980,"PHASE3":6982,"PHASE4":6984,"NA":6986},{"trials":6969,"activeCount":101},[6970],{"nctId":6971,"briefTitle":6972,"status":113,"phases":6973,"primaryCompletion":6974,"completion":6974,"start":6306,"enrollment":2270,"conditions":6975,"interventions":6977},"NCT02457975","Photobiomodulation for the Treatment of Diabetic Macular Edema",[88],"2019-08-30",[6976],"Diabetic Retinopathy",[6966],{"trials":6979,"activeCount":101},[],{"trials":6981,"activeCount":101},[],{"trials":6983,"activeCount":101},[],{"trials":6985,"activeCount":101},[],{"trials":6987,"activeCount":101},[],{"intervention":4255,"totalTrials":570,"cells":6989},{"EARLY_PHASE1":6990,"PHASE1":6992,"PHASE2":6994,"PHASE3":6996,"PHASE4":7002,"NA":7004},{"trials":6991,"activeCount":101},[],{"trials":6993,"activeCount":101},[],{"trials":6995,"activeCount":101},[],{"trials":6997,"activeCount":101},[6998],{"nctId":4245,"briefTitle":4246,"status":113,"phases":6999,"primaryCompletion":4248,"completion":2904,"start":4249,"enrollment":4250,"conditions":7000,"interventions":7001},[91],[4252,4253],[4234,4255],{"trials":7003,"activeCount":101},[],{"trials":7005,"activeCount":101},[7006,7016,7025],{"nctId":7007,"briefTitle":7008,"status":113,"phases":7009,"primaryCompletion":7010,"completion":7011,"start":3006,"enrollment":7012,"conditions":7013,"interventions":7014},"NCT00726999","Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion",[93],"2008-07","2009-05",63,[6677],[7015,4255],"Gabapentin",{"nctId":7017,"briefTitle":7018,"status":113,"phases":7019,"primaryCompletion":7020,"completion":7020,"start":7021,"enrollment":7022,"conditions":7023,"interventions":7024},"NCT02456909","Patient Controlled Analgesia Pump Cues on Patient Satisfaction",[93],"2019-10-03","2015-04",176,[6677],[4255],{"nctId":7026,"briefTitle":7027,"status":113,"phases":7028,"primaryCompletion":7029,"completion":7029,"start":4141,"enrollment":524,"conditions":7030,"interventions":7033},"NCT01823497","Parent\u002FNurse Controlled Analgesia in the Neonatal Intensive Care Unit",[93],"2019-03",[7031,7032],"Abdominal Surgery","Thoracic Surgery",[4255],{"intervention":3243,"totalTrials":654,"cells":7035},{"EARLY_PHASE1":7036,"PHASE1":7038,"PHASE2":7040,"PHASE3":7042,"PHASE4":7044,"NA":7054},{"trials":7037,"activeCount":101},[],{"trials":7039,"activeCount":101},[],{"trials":7041,"activeCount":101},[],{"trials":7043,"activeCount":101},[],{"trials":7045,"activeCount":101},[7046,7050],{"nctId":3234,"briefTitle":3235,"status":113,"phases":7047,"primaryCompletion":3237,"completion":3237,"start":2040,"enrollment":3238,"conditions":7048,"interventions":7049},[92],[3240,3241],[3243,3221,3244,3245,3246,3247],{"nctId":3249,"briefTitle":3250,"status":617,"phases":7051,"primaryCompletion":3252,"completion":3237,"start":3253,"enrollment":101,"conditions":7052,"interventions":7053},[92],[3255,3256,3257],[3243,3221,3247,3259],{"trials":7055,"activeCount":101},[7056],{"nctId":7057,"briefTitle":7058,"status":113,"phases":7059,"primaryCompletion":7060,"completion":7060,"start":7061,"enrollment":7062,"conditions":7063,"interventions":7066},"NCT04274361","Ketamine for Pain Control After Severe Traumatic Injury",[93],"2025-02-28","2021-01-20",93,[7064,7065],"Hospital Inpatient Trauma Injury","Pain Management",[3243],{"intervention":3244,"totalTrials":97,"cells":7068},{"EARLY_PHASE1":7069,"PHASE1":7071,"PHASE2":7073,"PHASE3":7075,"PHASE4":7077,"NA":7083},{"trials":7070,"activeCount":101},[],{"trials":7072,"activeCount":101},[],{"trials":7074,"activeCount":101},[],{"trials":7076,"activeCount":101},[],{"trials":7078,"activeCount":101},[7079],{"nctId":3234,"briefTitle":3235,"status":113,"phases":7080,"primaryCompletion":3237,"completion":3237,"start":2040,"enrollment":3238,"conditions":7081,"interventions":7082},[92],[3240,3241],[3243,3221,3244,3245,3246,3247],{"trials":7084,"activeCount":101},[7085],{"nctId":7086,"briefTitle":7087,"status":113,"phases":7088,"primaryCompletion":4387,"completion":4387,"start":7089,"enrollment":7090,"conditions":7091,"interventions":7093},"NCT00520442","Acute Pediatric Fracture Analgesia Study",[93],"2003-09",335,[7092],"Fracture",[7094,7095],"ibuprofen","acetamin w codeine",{"intervention":3259,"totalTrials":97,"cells":7097},{"EARLY_PHASE1":7098,"PHASE1":7100,"PHASE2":7102,"PHASE3":7104,"PHASE4":7106,"NA":7112},{"trials":7099,"activeCount":101},[],{"trials":7101,"activeCount":101},[],{"trials":7103,"activeCount":101},[],{"trials":7105,"activeCount":101},[],{"trials":7107,"activeCount":101},[7108],{"nctId":3249,"briefTitle":3250,"status":617,"phases":7109,"primaryCompletion":3252,"completion":3237,"start":3253,"enrollment":101,"conditions":7110,"interventions":7111},[92],[3255,3256,3257],[3243,3221,3247,3259],{"trials":7113,"activeCount":101},[7114],{"nctId":7115,"briefTitle":7116,"status":533,"phases":7117,"primaryCompletion":7118,"completion":7118,"start":4957,"enrollment":25,"conditions":7119,"interventions":7121},"NCT02379858","Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair",[93],"2018-05-31",[7120],"Ventral Hernia",[3259],{"intervention":7123,"totalTrials":141,"cells":7124},"acyanotic erythropoietin",{"EARLY_PHASE1":7125,"PHASE1":7127,"PHASE2":7129,"PHASE3":7131,"PHASE4":7133,"NA":7135},{"trials":7126,"activeCount":101},[],{"trials":7128,"activeCount":101},[],{"trials":7130,"activeCount":101},[],{"trials":7132,"activeCount":101},[],{"trials":7134,"activeCount":101},[],{"trials":7136,"activeCount":101},[7137],{"nctId":7138,"briefTitle":7139,"status":533,"phases":7140,"primaryCompletion":7141,"completion":7141,"start":7142,"enrollment":30,"conditions":7143,"interventions":7145},"NCT00451698","Erythropoietin and Pediatric Cardiac Surgery",[93],"2011-12","2007-10",[7144],"Congenital Heart Defect",[7123,7146],"acyanotic placebo",{"intervention":7146,"totalTrials":141,"cells":7148},{"EARLY_PHASE1":7149,"PHASE1":7151,"PHASE2":7153,"PHASE3":7155,"PHASE4":7157,"NA":7159},{"trials":7150,"activeCount":101},[],{"trials":7152,"activeCount":101},[],{"trials":7154,"activeCount":101},[],{"trials":7156,"activeCount":101},[],{"trials":7158,"activeCount":101},[],{"trials":7160,"activeCount":101},[7161],{"nctId":7138,"briefTitle":7139,"status":533,"phases":7162,"primaryCompletion":7141,"completion":7141,"start":7142,"enrollment":30,"conditions":7163,"interventions":7164},[93],[7144],[7123,7146],{"intervention":7166,"totalTrials":141,"cells":7167},"Heparin, Low-Molecular-Weight, or direct oral anticoagulants",{"EARLY_PHASE1":7168,"PHASE1":7170,"PHASE2":7172,"PHASE3":7174,"PHASE4":7176,"NA":7178},{"trials":7169,"activeCount":101},[],{"trials":7171,"activeCount":101},[],{"trials":7173,"activeCount":101},[],{"trials":7175,"activeCount":101},[],{"trials":7177,"activeCount":101},[],{"trials":7179,"activeCount":101},[7180],{"nctId":7181,"briefTitle":7182,"status":113,"phases":7183,"primaryCompletion":7184,"completion":7185,"start":7186,"enrollment":3197,"conditions":7187,"interventions":7190},"NCT01999179","Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis",[93],"2019-04-02","2022-04-26","2014-06",[7188,7189],"Venous Thrombosis","Neoplasms",[7166],{"intervention":7192,"totalTrials":141,"cells":7193},"Activase",{"EARLY_PHASE1":7194,"PHASE1":7196,"PHASE2":7198,"PHASE3":7200,"PHASE4":7202,"NA":7204},{"trials":7195,"activeCount":101},[],{"trials":7197,"activeCount":101},[],{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"trials":7205,"activeCount":101},[7206],{"nctId":7207,"briefTitle":7208,"status":533,"phases":7209,"primaryCompletion":7210,"completion":7210,"start":7211,"enrollment":7212,"conditions":7213,"interventions":7216},"NCT01870492","Improving Patient Access to Stroke Therapy Study",[],"2015-09-29","2014-01",500,[7214,7215],"Ischemic Stroke","Transient Ischemic Attack",[7192],{"intervention":7015,"totalTrials":141,"cells":7218},{"EARLY_PHASE1":7219,"PHASE1":7221,"PHASE2":7223,"PHASE3":7225,"PHASE4":7227,"NA":7229},{"trials":7220,"activeCount":101},[],{"trials":7222,"activeCount":101},[],{"trials":7224,"activeCount":101},[],{"trials":7226,"activeCount":101},[],{"trials":7228,"activeCount":101},[],{"trials":7230,"activeCount":101},[7231],{"nctId":7007,"briefTitle":7008,"status":113,"phases":7232,"primaryCompletion":7010,"completion":7011,"start":3006,"enrollment":7012,"conditions":7233,"interventions":7234},[93],[6677],[7015,4255],{"intervention":7236,"totalTrials":141,"cells":7237},"1% buffered lidocaine",{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7244,"PHASE4":7246,"NA":7248},{"trials":7239,"activeCount":101},[],{"trials":7241,"activeCount":101},[],{"trials":7243,"activeCount":101},[],{"trials":7245,"activeCount":101},[],{"trials":7247,"activeCount":101},[],{"trials":7249,"activeCount":101},[7250],{"nctId":7251,"briefTitle":7252,"status":113,"phases":7253,"primaryCompletion":7254,"completion":7254,"start":7255,"enrollment":7256,"conditions":7257,"interventions":7258},"NCT01890642","The Use of Jet Injection Lidocaine for Blood Draws in Young Children",[93],"2013-08","2013-07",205,[4253],[7236],{"intervention":7260,"totalTrials":141,"cells":7261},"Bicalutamide",{"EARLY_PHASE1":7262,"PHASE1":7264,"PHASE2":7266,"PHASE3":7268,"PHASE4":7270,"NA":7272},{"trials":7263,"activeCount":101},[],{"trials":7265,"activeCount":101},[],{"trials":7267,"activeCount":101},[],{"trials":7269,"activeCount":101},[],{"trials":7271,"activeCount":101},[],{"trials":7273,"activeCount":101},[7274],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7277,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7280,"interventions":7281},"NCT02366494","Micro RNAs to Predict Response to Androgen Deprivation Therapy",[],"2021-05-11","2015-04-29",[35],[7260,7282,7283,7284,7285,7286,7287,7288],"Leuprolide","Goserelin","Triptorelin","Docetaxel","Abiraterone","Apalutamide","Enzalutamide",{"intervention":7282,"totalTrials":141,"cells":7290},{"EARLY_PHASE1":7291,"PHASE1":7293,"PHASE2":7295,"PHASE3":7297,"PHASE4":7299,"NA":7301},{"trials":7292,"activeCount":101},[],{"trials":7294,"activeCount":101},[],{"trials":7296,"activeCount":101},[],{"trials":7298,"activeCount":101},[],{"trials":7300,"activeCount":101},[],{"trials":7302,"activeCount":101},[7303],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7304,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7305,"interventions":7306},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7283,"totalTrials":141,"cells":7308},{"EARLY_PHASE1":7309,"PHASE1":7311,"PHASE2":7313,"PHASE3":7315,"PHASE4":7317,"NA":7319},{"trials":7310,"activeCount":101},[],{"trials":7312,"activeCount":101},[],{"trials":7314,"activeCount":101},[],{"trials":7316,"activeCount":101},[],{"trials":7318,"activeCount":101},[],{"trials":7320,"activeCount":101},[7321],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7322,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7323,"interventions":7324},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7284,"totalTrials":141,"cells":7326},{"EARLY_PHASE1":7327,"PHASE1":7329,"PHASE2":7331,"PHASE3":7333,"PHASE4":7335,"NA":7337},{"trials":7328,"activeCount":101},[],{"trials":7330,"activeCount":101},[],{"trials":7332,"activeCount":101},[],{"trials":7334,"activeCount":101},[],{"trials":7336,"activeCount":101},[],{"trials":7338,"activeCount":101},[7339],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7340,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7341,"interventions":7342},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7285,"totalTrials":141,"cells":7344},{"EARLY_PHASE1":7345,"PHASE1":7347,"PHASE2":7349,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7346,"activeCount":101},[],{"trials":7348,"activeCount":101},[],{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[],{"trials":7356,"activeCount":101},[7357],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7358,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7359,"interventions":7360},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7286,"totalTrials":141,"cells":7362},{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7367,"PHASE3":7369,"PHASE4":7371,"NA":7373},{"trials":7364,"activeCount":101},[],{"trials":7366,"activeCount":101},[],{"trials":7368,"activeCount":101},[],{"trials":7370,"activeCount":101},[],{"trials":7372,"activeCount":101},[],{"trials":7374,"activeCount":101},[7375],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7376,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7377,"interventions":7378},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7287,"totalTrials":141,"cells":7380},{"EARLY_PHASE1":7381,"PHASE1":7383,"PHASE2":7385,"PHASE3":7387,"PHASE4":7389,"NA":7391},{"trials":7382,"activeCount":101},[],{"trials":7384,"activeCount":101},[],{"trials":7386,"activeCount":101},[],{"trials":7388,"activeCount":101},[],{"trials":7390,"activeCount":101},[],{"trials":7392,"activeCount":101},[7393],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7394,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7395,"interventions":7396},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7288,"totalTrials":141,"cells":7398},{"EARLY_PHASE1":7399,"PHASE1":7401,"PHASE2":7403,"PHASE3":7405,"PHASE4":7407,"NA":7409},{"trials":7400,"activeCount":101},[],{"trials":7402,"activeCount":101},[],{"trials":7404,"activeCount":101},[],{"trials":7406,"activeCount":101},[],{"trials":7408,"activeCount":101},[],{"trials":7410,"activeCount":101},[7411],{"nctId":7275,"briefTitle":7276,"status":113,"phases":7412,"primaryCompletion":7278,"completion":7278,"start":7279,"enrollment":2406,"conditions":7413,"interventions":7414},[],[35],[7260,7282,7283,7284,7285,7286,7287,7288],{"intervention":7416,"totalTrials":141,"cells":7417},"Adenosine arm",{"EARLY_PHASE1":7418,"PHASE1":7420,"PHASE2":7422,"PHASE3":7424,"PHASE4":7426,"NA":7428},{"trials":7419,"activeCount":101},[],{"trials":7421,"activeCount":101},[],{"trials":7423,"activeCount":101},[],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[7430],{"nctId":7431,"briefTitle":7432,"status":113,"phases":7433,"primaryCompletion":6306,"completion":6306,"start":7434,"enrollment":434,"conditions":7435,"interventions":7437},"NCT01590875","Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation",[93],"2012-05",[7436],"Atrial Fibrillation",[7416],{"intervention":7439,"totalTrials":141,"cells":7440},"Vitamin D",{"EARLY_PHASE1":7441,"PHASE1":7443,"PHASE2":7445,"PHASE3":7447,"PHASE4":7449,"NA":7451},{"trials":7442,"activeCount":101},[],{"trials":7444,"activeCount":101},[],{"trials":7446,"activeCount":101},[],{"trials":7448,"activeCount":101},[],{"trials":7450,"activeCount":101},[],{"trials":7452,"activeCount":101},[7453],{"nctId":7454,"briefTitle":7455,"status":533,"phases":7456,"primaryCompletion":733,"completion":4141,"start":7457,"enrollment":3154,"conditions":7458,"interventions":7461},"NCT01337635","Vitamin D Deficiency and Atopic Dermatitis",[93],"2010-11",[7459,7460],"Atopic Dermatitis","Vitamin D Deficiency",[7439],{"intervention":7463,"totalTrials":141,"cells":7464},"simvastatin or ezetimibe",{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7471,"PHASE4":7473,"NA":7475},{"trials":7466,"activeCount":101},[],{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[],{"trials":7472,"activeCount":101},[],{"trials":7474,"activeCount":101},[],{"trials":7476,"activeCount":101},[7477],{"nctId":7478,"briefTitle":7479,"status":113,"phases":7480,"primaryCompletion":7255,"completion":7255,"start":4959,"enrollment":7481,"conditions":7482,"interventions":7486},"NCT00879710","Effect of Diabetes Mellitus on Cholesterol Metabolism",[93],57,[7483,7484,7485],"Type 1 Diabetes Mellitus","Type 2 Diabetes Mellitus","Hypercholesterolemia",[7463],{"intervention":7488,"totalTrials":141,"cells":7489},"Cheek cell samples or blood sample",{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7494,"PHASE3":7496,"PHASE4":7498,"NA":7500},{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"trials":7495,"activeCount":101},[],{"trials":7497,"activeCount":101},[],{"trials":7499,"activeCount":101},[],{"trials":7501,"activeCount":101},[7502],{"nctId":7503,"briefTitle":7504,"status":533,"phases":7505,"primaryCompletion":4671,"completion":7506,"start":3513,"enrollment":396,"conditions":7507,"interventions":7509},"NCT00466375","Genetic Basis of Hemangiomas",[],"2016-05",[7508],"Hemangioma, Vascular Anomalies",[7488,7510],"Cheek cell sample or blood sample",{"intervention":7510,"totalTrials":141,"cells":7512},{"EARLY_PHASE1":7513,"PHASE1":7515,"PHASE2":7517,"PHASE3":7519,"PHASE4":7521,"NA":7523},{"trials":7514,"activeCount":101},[],{"trials":7516,"activeCount":101},[],{"trials":7518,"activeCount":101},[],{"trials":7520,"activeCount":101},[],{"trials":7522,"activeCount":101},[],{"trials":7524,"activeCount":101},[7525],{"nctId":7503,"briefTitle":7504,"status":533,"phases":7526,"primaryCompletion":4671,"completion":7506,"start":3513,"enrollment":396,"conditions":7527,"interventions":7528},[],[7508],[7488,7510],{"intervention":7530,"totalTrials":141,"cells":7531},"Everolimus, Myfortic and Tacrolimus",{"EARLY_PHASE1":7532,"PHASE1":7534,"PHASE2":7536,"PHASE3":7538,"PHASE4":7540,"NA":7542},{"trials":7533,"activeCount":101},[],{"trials":7535,"activeCount":101},[],{"trials":7537,"activeCount":101},[],{"trials":7539,"activeCount":101},[],{"trials":7541,"activeCount":101},[],{"trials":7543,"activeCount":101},[7544],{"nctId":7545,"briefTitle":7546,"status":617,"phases":7547,"primaryCompletion":4957,"completion":4858,"start":5023,"enrollment":101,"conditions":7548,"interventions":7550},"NCT01807767","Myfortic in High MELD Liver Transplantation",[93],[7549],"High Model for End-Stage Liver Disease (MELD) Score",[7530,7551],"Myfortic and Tacrolimus",{"intervention":7551,"totalTrials":141,"cells":7553},{"EARLY_PHASE1":7554,"PHASE1":7556,"PHASE2":7558,"PHASE3":7560,"PHASE4":7562,"NA":7564},{"trials":7555,"activeCount":101},[],{"trials":7557,"activeCount":101},[],{"trials":7559,"activeCount":101},[],{"trials":7561,"activeCount":101},[],{"trials":7563,"activeCount":101},[],{"trials":7565,"activeCount":101},[7566],{"nctId":7545,"briefTitle":7546,"status":617,"phases":7567,"primaryCompletion":4957,"completion":4858,"start":5023,"enrollment":101,"conditions":7568,"interventions":7569},[93],[7549],[7530,7551],{"intervention":7571,"totalTrials":141,"cells":7572},"montelukast sodium",{"EARLY_PHASE1":7573,"PHASE1":7575,"PHASE2":7577,"PHASE3":7579,"PHASE4":7581,"NA":7583},{"trials":7574,"activeCount":101},[],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"trials":7582,"activeCount":101},[],{"trials":7584,"activeCount":101},[7585],{"nctId":7586,"briefTitle":7587,"status":113,"phases":7588,"primaryCompletion":7589,"completion":7589,"start":3724,"enrollment":7590,"conditions":7591,"interventions":7593},"NCT00863317","Trial of Montelukast for Treatment of Acute Bronchiolitis",[93],"2011-07",141,[7592],"Bronchiolitis",[7571],{"intervention":7595,"totalTrials":141,"cells":7596},"Septra",{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7601,"PHASE3":7603,"PHASE4":7605,"NA":7607},{"trials":7598,"activeCount":101},[],{"trials":7600,"activeCount":101},[],{"trials":7602,"activeCount":101},[],{"trials":7604,"activeCount":101},[],{"trials":7606,"activeCount":101},[],{"trials":7608,"activeCount":101},[7609],{"nctId":7610,"briefTitle":7611,"status":113,"phases":7612,"primaryCompletion":7613,"completion":7614,"start":7615,"enrollment":7616,"conditions":7617,"interventions":7619},"NCT02593903","Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair",[93],"2017-06-30","2018-04","2014-03-04",67,[7618],"Hypospadias",[7595],{"intervention":7621,"totalTrials":141,"cells":7622},"Prednisolone",{"EARLY_PHASE1":7623,"PHASE1":7625,"PHASE2":7627,"PHASE3":7629,"PHASE4":7631,"NA":7633},{"trials":7624,"activeCount":101},[],{"trials":7626,"activeCount":101},[],{"trials":7628,"activeCount":101},[],{"trials":7630,"activeCount":101},[],{"trials":7632,"activeCount":101},[],{"trials":7634,"activeCount":101},[7635],{"nctId":7636,"briefTitle":7637,"status":113,"phases":7638,"primaryCompletion":7639,"completion":7640,"start":7641,"enrollment":2270,"conditions":7642,"interventions":7643},"NCT00433940","Immune Suppression Of Infants Treated With Steroids",[],"2008-04","2010-07","2006-10",[736],[7621],{"intervention":7645,"totalTrials":141,"cells":7646},"PEG+E",{"EARLY_PHASE1":7647,"PHASE1":7649,"PHASE2":7651,"PHASE3":7653,"PHASE4":7655,"NA":7657},{"trials":7648,"activeCount":101},[],{"trials":7650,"activeCount":101},[],{"trials":7652,"activeCount":101},[],{"trials":7654,"activeCount":101},[],{"trials":7656,"activeCount":101},[],{"trials":7658,"activeCount":101},[7659],{"nctId":7660,"briefTitle":7661,"status":617,"phases":7662,"primaryCompletion":7663,"completion":6306,"start":7186,"enrollment":101,"conditions":7664,"interventions":7666},"NCT02124447","Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy",[93],"2014-08",[7665],"Patients Undergoing Screening or Surveillance Colonoscopy",[7645,7667,7668,7669],"PEG+Asc","P+MC","sulfate",{"intervention":7667,"totalTrials":141,"cells":7671},{"EARLY_PHASE1":7672,"PHASE1":7674,"PHASE2":7676,"PHASE3":7678,"PHASE4":7680,"NA":7682},{"trials":7673,"activeCount":101},[],{"trials":7675,"activeCount":101},[],{"trials":7677,"activeCount":101},[],{"trials":7679,"activeCount":101},[],{"trials":7681,"activeCount":101},[],{"trials":7683,"activeCount":101},[7684],{"nctId":7660,"briefTitle":7661,"status":617,"phases":7685,"primaryCompletion":7663,"completion":6306,"start":7186,"enrollment":101,"conditions":7686,"interventions":7687},[93],[7665],[7645,7667,7668,7669],{"intervention":7668,"totalTrials":141,"cells":7689},{"EARLY_PHASE1":7690,"PHASE1":7692,"PHASE2":7694,"PHASE3":7696,"PHASE4":7698,"NA":7700},{"trials":7691,"activeCount":101},[],{"trials":7693,"activeCount":101},[],{"trials":7695,"activeCount":101},[],{"trials":7697,"activeCount":101},[],{"trials":7699,"activeCount":101},[],{"trials":7701,"activeCount":101},[7702],{"nctId":7660,"briefTitle":7661,"status":617,"phases":7703,"primaryCompletion":7663,"completion":6306,"start":7186,"enrollment":101,"conditions":7704,"interventions":7705},[93],[7665],[7645,7667,7668,7669],{"intervention":7669,"totalTrials":141,"cells":7707},{"EARLY_PHASE1":7708,"PHASE1":7710,"PHASE2":7712,"PHASE3":7714,"PHASE4":7716,"NA":7718},{"trials":7709,"activeCount":101},[],{"trials":7711,"activeCount":101},[],{"trials":7713,"activeCount":101},[],{"trials":7715,"activeCount":101},[],{"trials":7717,"activeCount":101},[],{"trials":7719,"activeCount":101},[7720],{"nctId":7660,"briefTitle":7661,"status":617,"phases":7721,"primaryCompletion":7663,"completion":6306,"start":7186,"enrollment":101,"conditions":7722,"interventions":7723},[93],[7665],[7645,7667,7668,7669],{"intervention":7095,"totalTrials":141,"cells":7725},{"EARLY_PHASE1":7726,"PHASE1":7728,"PHASE2":7730,"PHASE3":7732,"PHASE4":7734,"NA":7736},{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[],{"trials":7731,"activeCount":101},[],{"trials":7733,"activeCount":101},[],{"trials":7735,"activeCount":101},[],{"trials":7737,"activeCount":101},[7738],{"nctId":7086,"briefTitle":7087,"status":113,"phases":7739,"primaryCompletion":4387,"completion":4387,"start":7089,"enrollment":7090,"conditions":7740,"interventions":7741},[93],[7092],[7094,7095],{"intervention":7743,"totalTrials":141,"cells":7744},"Chlorhexidine Gluconate",{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7749,"PHASE3":7751,"PHASE4":7753,"NA":7755},{"trials":7746,"activeCount":101},[],{"trials":7748,"activeCount":101},[],{"trials":7750,"activeCount":101},[],{"trials":7752,"activeCount":101},[],{"trials":7754,"activeCount":101},[],{"trials":7756,"activeCount":101},[7757],{"nctId":7758,"briefTitle":7759,"status":113,"phases":7760,"primaryCompletion":7761,"completion":7762,"start":7763,"enrollment":9,"conditions":7764,"interventions":7766},"NCT04721626","Topical Antisepsis in Head and Neck Cancer Surgery",[],"2021-05-28","2021-10-04","2021-01-06",[7765],"Head and Neck Cancer",[7743,7767,7768],"Povidone-iodine","Tetracycline Ointment",{"intervention":7767,"totalTrials":141,"cells":7770},{"EARLY_PHASE1":7771,"PHASE1":7773,"PHASE2":7775,"PHASE3":7777,"PHASE4":7779,"NA":7781},{"trials":7772,"activeCount":101},[],{"trials":7774,"activeCount":101},[],{"trials":7776,"activeCount":101},[],{"trials":7778,"activeCount":101},[],{"trials":7780,"activeCount":101},[],{"trials":7782,"activeCount":101},[7783],{"nctId":7758,"briefTitle":7759,"status":113,"phases":7784,"primaryCompletion":7761,"completion":7762,"start":7763,"enrollment":9,"conditions":7785,"interventions":7786},[],[7765],[7743,7767,7768],{"intervention":7768,"totalTrials":141,"cells":7788},{"EARLY_PHASE1":7789,"PHASE1":7791,"PHASE2":7793,"PHASE3":7795,"PHASE4":7797,"NA":7799},{"trials":7790,"activeCount":101},[],{"trials":7792,"activeCount":101},[],{"trials":7794,"activeCount":101},[],{"trials":7796,"activeCount":101},[],{"trials":7798,"activeCount":101},[],{"trials":7800,"activeCount":101},[7801],{"nctId":7758,"briefTitle":7759,"status":113,"phases":7802,"primaryCompletion":7761,"completion":7762,"start":7763,"enrollment":9,"conditions":7803,"interventions":7804},[],[7765],[7743,7767,7768]]